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Abstract 
 
Bone is among the most transplanted tissues with more than a million surgical procedures 
annually in Europe, and around two million worldwide. The regeneration of bone defects, 
caused by trauma, congenital deformities, age-related bone loss or bone infections 
represents an urgent challenge for today’s healthcare system. This has fueled the 
demand of more efficient synthetic bone substitutes.   
Due to their similar characteristics to the mineral phase of bone, calcium phosphates 
(CaPs) have raised a lot of interest. Some properties of calcium phosphates, like 
biodegradability, biocompatibility, bioactivity and osteoconduction represent a great 
potential for this application. Among them, calcium phosphate cements (CPCs) have 
additional advantages like injectability and in situ hardening ability. Moreover, the 
possibility to tune the porosity of CaPs in general and of CPCs in particular makes them 
suitable vehicles for local delivery of drugs. Loading CaPs with drugs allows conferring 
additional functionalities to the synthetic bone grafts, which is of great interest.  
The main aim of this thesis is to explore CaP bioceramics as vehicles for local delivery of 
drugs, covering both low temperature biomimetic ceramics, like calcium deficient 
hydroxyapatite (CDHA), and high temperature sintered ceramics, like beta tricalcium 
phosphate (β-TCP), in the form of microporous and macroporous substrates. The physic-
chemical nature of these bioceramics, their porosity and textural properties plays an 
essential role in their drug delivery properties.  
In order to be able to tailor the drug release kinetics of the bioceramics beyond their 
intrinsic properties, plasma polymerization has been investigated. Plasma is a particular 
state of a gas, electrically neutral, which is formed by ions, electrons, radicals, 
metastables, UV and visible radiation and can be employed in different applications. 
Although plasma polymerization has been widely studied for biomedical applications, its 
combination with bioceramics is rather unexplored.  
To select a suitable drug for bone regeneration, an extensive literature review was done 
on statins, and more particularly on simvastatin as a potential osteogenic and angiogenic 
promoter (Chapter 2). This drug was evaluated within macroporous scaffolds of either 
CDHA or β-TCP as drug delivery vehicles. The drug-loaded materials were plasma-coated 
with polycaprolactone:poly ethylene glycol (PCL:PEG) co-polymers. The coating covered 
xviii 
 
the micro and nanopores of the CaPs surface and produced complex geometries 
presenting a nano and micro rough morphology which led to low wettability despite the 
hydrophilicity of the copolymer. Plasma coating with PCL-co-PEG on scaffolds loaded with 
simvastatin acid allowed delaying and modulating the drug release from the bone 
scaffolds depending on the thickness of the layer deposited, which, in turn depended on 
the initial specific surface area of the CaP (Chapter 3).To further investigate the 
fundamentals of plasma polymerization on bioceramics, PEG-like polymer coatings of 
different thickness were deposited on microporous β-TCP loaded with antibiotics. The 
rough β-TCP surface was associated to strong hydrophobic surface properties, which 
nevertheless retained their suitable biological behavior with regard to human osteoblast 
cells. The microbiological activity of the antibiotics was preserved, and the coatings 
reduced the total amount of drug released as a function of the increasing plasma 
treatment time (Chapter 4).   
In another approach, a statin that had never before been employed in combination with 
CaPs, Pitavastatin (PITA), was investigated as potentially osteogenic and angiogenic 
promoter through in vitro studies which revealed dose-dependent enhancement of 
mineralization and vascularization. The incorporation of PITA to the liquid phase of an 
injectable CDHA foam allowed obtaining injectable local drug delivery scaffolds, without 
altering their macroporosity or textural properties. The drug release kinetics was affected 
by the evolving microstructure of the setting of the macroporous cement. Overall the 
results obtained proved that PITA seems to be a suitable novel candidate to enhance the 
osteogenic potential of synthetic bone grafts and identified the required doses to obtain 
the desired biological effects (Chapter 5).  
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Resumen 
Los fosfatos de calcio (CaPs) tienen gran potencial como sustituto óseo por sus 
propiedades como biodegradabilidad, biocompatibilidad, bioactividad y osteoconducción. 
Entre ellos, los cementos de fosfato de calcio (CPC) tienen ventajas adicionales como la 
inyecctabilidad y la capacidad de fraguado a baja temperatura. La posibilidad de modular 
la porosidad de los convierte en vehículos adecuados para la liberación local de fármacos. 
El objetivo principal de esta tesis es explorar las biocerámicas de CaP como vehículos 
para la administración local de fármacos, que abarcan cerámicas biomiméticas de baja 
temperatura, como la hidroxiapatita deficiente en calcio (CDHA) y cerámicas sinterizadas 
a alta temperatura, como el fosfato tricálcico beta (β-TCP) en forma de sustratos micro y 
macroporosos.  
Para modular la cinética de liberación del fármaco de las biocerámicas más allá de sus 
propiedades intrínsecas, se ha investigado la polimerización de plasma. El plasma es un 
estado particular de un gas, eléctricamente neutro, que puede emplearse en diferentes 
aplicaciones. Aunque la polimerización por plasma ha sido ampliamente estudiada para 
aplicaciones biomédicas, su combinación con biocerámicas es muy novedosa.     
Para seleccionar un fármaco adecuado para la regeneración ósea, se realizó una extensa 
revisión de la literatura sobre las estatinas, y más particularmente sobre la simvastatina 
como potencial promotor osteogénico y angiogénico (Capítulo 2). Este fármaco se evaluó 
en andamios macroporosos de CDHA o β-TCP que fueron recubiertos con plasma con 
copolímeros de policaprolactona: polietilenglicol (PCL: PEG). El recubrimiento produjo 
geometrías complejas que presentaban una morfología nano y micro rugosa que condujo 
a una baja mojabilidad a pesar de la hidrofilidad del copolímero. El recubrimiento de 
plasma con PCL-co-PEG permitió retrasar y modular la liberación de simvastatina de los 
andamios óseos dependiendo del espesor de la capa depositada, la cual, a su vez, 
dependía del área superficial específica inicial del CaP (Capítulo 3). Para investigar más a 
fondo los fundamentos de la polimerización por plasma en biocerámica, se depositaron 
capas poliméricas tipo PEG de espesor diferente sobre β-TCP microporoso cargado con 
antibióticos. La elevada rugosidad superficial del β-TCP, una vez recubierto con plasma 
asoció propiedades hidrófobas, que sin embargo conservaron su comportamiento 
biológico adecuado con respecto a las células osteoblásticas humanas. Se conservó la 
actividad microbiológica de los antibióticos y los recubrimientos redujeron la cantidad total 
de fármaco liberado en función del tiempo de tratamiento con plasma (Capítulo 4). 
xx 
 
En otro enfoque, una estatina que nunca antes se había empleado en combinación con 
CaPs, Pitavastatina (PITA), se investigó por su potencial osteogénico y angiogénico. 
Estudios in vitro revelaron un aumento de la mineralización y vascularización dependiente 
de la dosis. La incorporación de PITA a la fase líquida de una espuma inyectable CDHA 
permitió la obtención de andamios, sin alterar su macroporosidad o propiedades 
texturales. La cinética de liberación del fármaco depende de la microestructura en 
evolución derivada del fraguado del cemento macroporoso. En general, los resultados 
muestran que PITA puede ser un candidato adecuado para mejorar el potencial 
osteogenico de los andamios de fosfato de calico (Capítulo 5). 
 
xxi 
 
Objectives and Structure of the thesis 
Objectives 
The main aim of this PhD thesis is to investigate new strategies for controlled drug 
delivery from calcium phosphate (CaP) bone substitutes (sintered CaP ceramic scaffolds 
and injectable calcium phosphate foams), which might contribute to enhanced bone 
regeneration.  
Specifically, the following objectives have been set and constitute the different parts of this 
thesis: 
 To conduct a thorough research on the existing literature on simvastatin, an 
osteogenic and angiogenic promoter, covering both in vitro and in vivo effects, to 
provide a basis for further advancements. 
 
 To evaluate the potential of plasma polymerization in the modulation of drug 
release from CaP scaffolds. The issues tackled here are the design and thorough 
physico-chemical characterization of macroporous calcium deficient 
hydroxyapatite (CDHA) and β-tricalcium phosphate (-TCP) scaffolds, their 
modifications by plasma polymer layers and the evaluation of loading and release 
of simvastatin acid (SVA) from the aforementioned scaffolds.  
 
 To investigate in-depth the surface modification produced by plasma 
polymerization on β-TCP ceramics coated with PEG-like polymers, its effects on 
the biological behavior of the materials, and on the release properties of two 
antibiotics (ampicillin or gentamicin) loaded therein. 
 
 To investigate a novel candidate drug, i.e. Pitavastatin (PITA) as an osteogenic 
and angiogenic promoter, in combination with injectable calcium phosphate foams 
(i-CPFs). This includes the investigation of the effects of PITA in vitro with relevant 
cell lines, the effects of PITA addition on the physical and chemical properties of i-
CPFs, and the drug release patterns.  
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Structure 
The present work involves the investigation of CDHA and β-TCP scaffolds, including 
injectable scaffolds ( i-CPFs) as bone substitutes and drug delivery vehicles. Plasma 
polymerization has been investigated as a novel tool to modulate the drug release from 
the scaffolds. This thesis has been divided into four main parts. The schematic diagram of 
the structure of the present thesis is shown in Figure 1. In the beginning, a general state 
of the art including bone, bone substitutes, drug delivery vehicles and plasma 
polymerization has been discussed (Chapter 1). Chapter 2 presents a literature review for 
simvastatin, as osteogenic and angiogenic promoter. Chapter 3 introduces the 
development of SVA-loaded calcium phosphate scaffolds (CDHA or β-TCP) where 
controlled release was aimed at using plasma polymerization. The findings of the latter led 
to further interest in the effects of plasma polymerization found on the surface properties 
of calcium phosphates. Thus, Chapter 4 focuses upon the fundamentals of plasma 
polymerization on β-TCP loaded with two different antibiotics, Ampicillin and Gentamicin. 
In the end, Chapter 5 introduces i-CPFs as potential drug delivery vehicles for a novel 
drug candidate, Pitavastatin to investigate it as osteogenic and angiogenic promoter.  
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Chapter 1  
State of the art 
 
 
3D SEM image of calcium deficient hydroxyapatite (CDHA) 
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Introduction 
Bone is among the most transplanted tissues with more than a million surgical procedures 
annually in Europe. Bone defects may be due to trauma, congenital deformities, bone loss 
due to ageing and bone infections. Bone replacement materials are currently estimated for 
a worldwide market of € 5 billion, with a 10 % annual growth.  In 2010, estimated costs for 
osteoporotic and fragility fractures were € 37 billion including 66 % of this cost for incident 
fractures, 29% for long term fracture and 5 % for prevention. By 2025, these estimated 
costs are expected to shoot with a 25 % increase [1]. According to the World Health 
organization, musculoskeletal diseases are expected to be the fourth main disability by 
the year 2020 [2]–[4].  
In the following sections, the composition, structure and functions of bone will be 
described. The understanding of the hierarchal structure and processes like modeling and 
remodeling of bone will provide the necessary information that can help designing of the 
biomaterials for the bone regeneration process. Apart from this, bone features like 
osteoinduction, osteoconduction or osteointegration can support the understanding of the 
grafts that have been used and will be used in future. Ultimately, an important facet of this 
thesis being local or controlled delivery of the selected drug by plasma polymerization to 
enhance bone regeneration, angiogenesis or antibiotics for osteomyelitis will be discussed 
in the further sections. 
Bone 
Bones in our body are living tissues. A child is born with about 300 soft bones. During 
childhood and adolescence, the cartilage grows and is slowly replaced by hard bone. 
Some of these bones later fuse together; eventually the adult skeleton has 206 bones. 
This characteristic reflects the capability of bone to grow or repair with help of the bone 
marrow. Bones are vascularized with their own blood vessels and are made of living cells 
in bone marrow. Bones are innervated organs made up of bone tissue, bone marrow, and 
a surrounding connective tissue called periosteum [5]. The skeleton serves as structural 
support while protecting the vital organs. Bones act as the ion, growth factors, nutrients, 
and proteins reservoir and are highly responsible for the calcium/phosphate balance and 
detoxification of the heavy metals [6].Composition of the bone makes them a suitable 
provider for an environment for marrow where blood cells are produced. Due to 
osteogenesis, mineralization and degradation / resorption bone can go through modeling 
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and remodeling [6]. 
Bone Architecture: 
 
Bone is a highly hierarchical structure from the nano to the macro size scale as shown in 
Figure 1-1. A general classification includes two types of bones; compact or cortical bone 
and trabecular or cancellous or spongy bone.  The hard outer layer called cortical 
(compact) bone is strong, dense and tough. The spongy inner layer called trabecular 
(cancellous) bone is lighter and less dense than compact bone.  
Cortical bone comprises 80 % of the total mass of the skeleton and is generally found in 
the shaft of long bones and outer shells. Trabecular bone is located inside the cortical 
tissues, in medullary cavities at the end of long bones and within the interior of short bones 
like spinal vertebrae. One of the major microstructural parameters in cortical bone is its 
porosity around 5-10%. This porosity is contributed by Haversian canals, Volkmann´s 
canal and resorption cavities. Trabecular bone is a three-dimensional structure of 
interconnected plates and rods known as trabeculae of around 200μm thick. The porosity 
of trabecular bone is between 75-95%. The pores in trabecular bone are interconnected 
and filled with bone marrow [7], [8].  
Microscopically, these two structures, cortical or spongy are consequences of a specific 
arrangement of collagen fibers at lower scale: as lamellar bone or as woven bone.  
 Lamellar bone is characterized by a regular parallel alignment of collagen into 
sheets (lamellae) and is mechanically strong. 
 Woven bone is characterized by a haphazard organization of collagen fibers and 
is mechanically weak. 
Woven bone is produced when osteoblasts produce osteoid rapidly. This occurs 
initially in all foetal bones, but the resulting woven bone is replaced by remodeling 
and the deposition of more resilient lamellar bone. In adults, woven bone is formed 
when there is very rapid new bone formation, as occurs in the repair of a fracture. 
Following a fracture, woven bone is remodelled and lamellar bone is deposited. 
Virtually all bone in the healthy mature adult is lamellar bone. 
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Figure 1-1 Hierarchical structure of bone: collagen fibrils, lamellae, osteons and trabecular, cortical 
and trabecular bone [8]. 
Bone Matrix Composition: 
Bone is a composite material formed by an inorganic component (70%) and an organic 
matrix (30%). On the other hand, the inorganic part of bone consists of poorly crystalline 
calcium-deficient hydroxyapatite (95%). The mineral hydroxyapatite phase (calcium 
phosphate crystal) contains multiple ionic substitutions. Hydroxyapatite has an open and 
hospitable structure which allows several ionic substitutions such as sodium, magnesium, 
fluoride or citrate, being the most common carbonate-substituted. On the other hand, the 
remaining organic matrix is constituted by collagen (90%) and non-collagen structural 
proteins such as proteoglycans, sialoproteins, growth factors and cytokines, including 
bone forming cells, such as osteoblasts, osteoclasts and osteocytes [7], [9]. These bone 
forming cells and their biological cascades derived from them will be deeply described in 
the following sections. 
Bone cells 
Bone cells (Figure 1-2) are responsible for bone production, maintenance and modeling: 
 Osteoblasts: These cells are derived from mesenchymal stem cells and are 
responsible for bone matrix synthesis and its subsequent mineralization.  
 Osteocytes: These cells are osteoblasts that become incorporated within the 
newly formed osteoid, which eventually becomes calcified bone. They are thought to be 
ideally situated to respond to changes in physical forces upon bone and to transduce 
messages to cells on the bone surface, directing them to initiate resorption or formation 
responses. 
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 Osteoclasts: These cells are large multinucleated cells, like macrophages, derived 
from the hematopoietic lineage. Osteoclasts function in the resorption of mineralized 
tissue and are found attached to the bone surface at sites of active bone resorption. 
One of their characteristic features is a ruffled edge where active resorption takes place 
with the secretion of bone-resorbing enzymes, which digest bone matrix. 
 
Bone modeling 
Modeling occurs when bone resorption and bone formation occur on separate surfaces 
(i.e. formation and resorption are not coupled). During birth to adulthood, long bone grows 
in length and diameter and is also responsible for gain in skeletal mass and changes in 
skeletal form.  
Bone remodeling 
Replacement of old tissue by new bone tissue is known as bone remodeling process. This 
mainly occurs in the adult skeleton to maintain bone mass. This process consists of five 
phases as shown in Figure 1-2:  
1. Activation: Under the influence of cytokines and growth factors pre-osteoclasts 
are stimulated and differentiate into mature active osteoclasts. 
2. Resorption: Osteoclasts digest mineral matrix (old bone) and produce an acid 
environment. 
Figure 1-2 Bone remodeling process [10]. 
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3. Reversal: Resorption finishes by the osteoclast apoptosis while activation of the 
pre-osteoblast takes place. 
4. Formation: Pre-osteoblasts differentiate to osteoblasts and synthesize new bone 
matrix. 
5. Quiescence: This phase is also called as resting phase because osteoblasts 
become resting bone lining cells on the newly formed bone surface. 
 
Bone Diseases 
As bone is a critical component and being involved in so many functions and processes it 
is highly prone to diseases from osteoporosis to bone infections, ranging through a 
number of bone cancers. One of the reasons known behind bone diseases is imbalance in 
the ions or growth factors or proteins like vascular endothelial growth factor (VEGF) or 
bone morphogenetic protein-2 (BMP-2). Other major issues and pathologies are known to 
be caused by the accidental trauma, infections due to surgery or other causes or age 
related causes. 
Traumatic bone defects 
One of the most frequent musculoskeletal injuries that are recorded is fractures of long 
bone. Fractures, bone dislocations or severe bone damage due to accidental injuries are 
recorded in high numbers worldwide. Fractures are defined as a single or multi-
fragmentary circumferential disruption of a diaphysis or metaphysis or a single disruption 
of an articular surface [11]. Among most common traumatic fractures are long-bone 
fractures, pelvic fracture in pediatric or adult trauma patients, forearm or elbow injuries, 
cranio-maxillofacial trauma, spinal injuries or traumatic brain injuries (TBI) etc. [12], [13]. In 
1986, Schmitz and Hollinger introduced the term of critical size bone defects referring to the 
defects that are unable to heal completely during the lifetime of an animal [14]. To heal 
the critical size defects different grafting options are available. The increasing number of 
trauma has raised the demand of bone grafts.  
Bone infection, Osteomyelitis 
Osteomyelitis (osteo- derived from the Greek word osteon, meaning bone, myelo-
 meaning marrow, and -itis meaning inflammation) is the appellation used for bone 
infection. Osteomyelitis is common bone pathology of bone infection mostly caused by 
bacteria or other germs. Most common bacteria known for the osteomyelitis are S. aureus 
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and S. epidermidis. Infection can be caused by different pathologies as discussed below 
[15]: 
- Devascularization: Originated from trauma, surgical intervention (mechanical 
damage or overheating) and leads to bone necrosis. In the case that necrosis 
exists in both sides of a fracture, an infected non-union is inevitable [15]. 
- General infection: Bacterial infection may come from damaged soft tissues or 
travel through blood stream and spread to the bone. This occurs when the 
patient has an infection elsewhere such as pneumonia etc.   
- Implant associated infection: Any foreign body is capable of retaining bacteria 
on its surface protected by a biofilm [15]. Despite, the sterilization of the implant 
surfaces and proper handling during the surgery, there is still certain 
percentage of infections. 
In 200, Ciampolini and Harding summarized the micro-organisms and pathogenic factors 
behind the chronicity of a bone infection as shown in Figure 1-3 [16]. Axford presented in 
2010 a complete study of joint and bone infections and a special focus on osteomyelitis 
[17].  
 
Figure 1-3  Micro-organisms (left) and pathogenic factors (right) behind the chronicity of a bone 
infection [16]. 
 
Mainly literature shows two routes of administration (oral and intravenous (IV)) among 
others. However, this has different disadvantages, such as side effects or low patient 
compliance. Local drug delivery in musculoskeletal disorder treatments can address some 
of the critical issues more effectively and efficiently than the systemic delivery. It ensures 
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delivery of the drug to the surrounding tissue at the target site, allowing decreasing the 
dosage which reduces associated toxicity to other non-target sites. 
 
In this thesis, two antibiotic drugs will be evaluated: ampicillin (pencillin) and 
gentamicin (aminoglycoside), which will be incorporated to calcium 
phospahte bone grafts to evaluate novel methods to acheieve controlled 
release. 
 
Osteoporosis 
Osteoporosis is known as the major cause for the disability and death in the elderly 
population. It causes an increased risk of fracture, disruption of bone micro architecture 
and reduction in non-collagenous proteins. Osteoporosis is a growing issue in the modern 
world. 30% of Caucasian woman over 50 years old suffer osteoporosis at the hip, spine or 
forearm. An osteoporotic fracture due to a major or minor trauma is due to a bone that has 
lower bone quantity and quality. The major reasons for the bone loss can be hormonal 
changes after menopause, estrogen deprivation, vitamin D or calcium deficiency and many 
other factors as shown in Figure 5. Many comprehensive approaches to the therapy of 
Osteoporosis have been taken. Successful therapy includes mainly aspects like treatment 
of pain, initiation of physical activity, nutrition, Vitamin D or calcium supplements, and 
Hormonal replacement therapy (HRT). List of some most common pharmaceutical 
treatment options is shown in Table 1-1. 
Three major therapies include anti-resorptive therapy, osteoanabolic therapy and other 
medications [19]. Presently these treatments of osteoporosis rely on the systemic 
administration (generally oral) of some drugs from the following families are here as 
examples: 
- Anti-resorptive therapy 
Bisphosphonates: Bisphosphonates present an inhibitory effect on osteoclast-
mediated bone resorption and are widely used to treat increased bone turnover 
such as osteoporosis but also Paget´s disease of bone or metastatic bone 
tumor. 
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Calcitonin and parathyroid hormone: Whereas administration of parathyroid 
hormone stimulates bone formation in fracture healing, calcitonin presents the 
opposite effect by reducing the activity of osteoclasts, i.e. bone resorption, 
modulating the levels of calcium in serum and kidney. 
 
- Osteoanabolic therapy 
Strontium ranelate: Strontium ralenate increases both bone formation by 
promoting differentiation of osteoblast precursors and decreases bone 
resorption limiting the activation of osteoclasts.  
 
 
Figure 1-4 Etiology of osteoporosis and osteoporortic fractures [18]. 
Nevertheless, prevention of osteoporosis by following patient presenting risk factors is the 
approach chosen nowadays to prevent fractures and increase bone density by lifestyle 
advices (balanced diet, adequate calcium and vitamin D intake, mobility) or light drug 
therapies with bisphosphonates or selective estrogen receptor modulator raloxifene, 
particularly in post-menopausal woman [19], [21], [22]. 
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Table 1-1 Various pharmacological interventions that have been involved in the treatments of 
osteoporosis as vertebral, non-vertebral and hip fractures and their associated efficacy [20]. 
 
By understanding the above information it is clearly seen that anti-resorptive drugs are not 
sufficient if osteoporosis is chronic. Thereby, a localized drug delivery system can be more 
suitable for the chronic osteogenesis.  
 
In this PhD thesis, two drugs, simvastatin and Pitavastatin from the family of 
statins, will be loaded with the prepared biomaterials, with the focus on 
traumatic bone injuries or osteoporosis in views of fostering bone 
regeneration. 
Bone Grafts 
A bone graft is the replacement or augmentation of a fracture or diseased part of a bone 
by transplanting a biomaterial substitute. It is a surgical procedure generally done to 
reverse loss or resorption of bone due to trauma or diseases such as osteoporosis or 
Paget’s disease. Surgeons use bone grafts to repair and rebuild diseased bones in 
patient’s hips, knees, spine, and sometimes other bones and joints. Grafts can also repair 
bone loss caused by some types of fractures or cancers. Once your body accepts the 
bone graft, it should provide a framework for growth of new, living bone. Different types of 
bone grafts will be discussed in further section. Before discussing the types of bone grafts, 
it is important to understand the physiology of the bone grafting. 
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The Physiology of Bone-Grafting 
The biology of bone grafts and their substitutes is based on the clear understanding of the 
bone formation processes of osteogenesis, osteoinduction, and osteoconduction. After 
considering these parameters, the success rate of the bone graft can be estimated 
theoretically.  
Graft osteogenesis: The cellular elements within a donor graft, which survive 
transplantation and synthesize new bone at the recipient site. Osteogenesis is highly 
dependent on the osteoinductive properties of the graft or on the site of transplantation 
[23], [24]. 
 
Graft osteoinduction: It is a process to activate osteogenesis. While new bone forms 
through the active recruitment of host mesenchymal stem cells from the surrounding 
tissue, which differentiate into bone-forming cell lineage / osteoblast cells. This process is 
facilitated by the presence of growth factors within the graft, principally bone 
morphogenetic proteins (BMPs). In addition to the differentiated bone cells, some less 
differentiated cells are also present in the bone and adjacent tissues. These 
undifferentiated cells play a very important role in bone healing and anchorage of an 
implant since they can form osteoprogenitor cells as well (Figure 1-5). Later, with the 
correct stimulus from growth factors as already mentioned they can help in bone growth 
through bone forming cells [23], [24]. 
 
Figure 1-5 During injury, adequate cells differentiate for the bone repair [25]. 
 
Graft osteoconduction: The process of bone growth on the surface or down into pores or 
channels of the transplant is known as osteoconductivity. Such thee-dimensional structural 
graft  is conducive for on growth and/or ingrowth of newly formed bone [26]. This behavior 
directs the bone growth to conform to the material´s surface. It involves facilitation of 
blood-vessel incursion and new-bone formation into a defined passive trellis structure. 
Though the bone growth is completely dependent on the action of differentiated bone cells, 
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without a proper blood supply bone growth and bone conduction both are not possible 
[23], [24]. Thus, angiogenesis is of uttermost importance. 
Autogenous bone grafts 
Autogenous grafts are considered “gold standard,” as a solution to the bone tissue 
engineering paradigm. Autografts are sections or fragments of bone removed from one 
site on the patient, typically the iliac crest, and implanted to another site based on need. 
Autografts harvested from the iliac crest are mostly trabecular bone with a thin shell of 
cortical bone. Since autografts originate within the patient, they are readily incorporated at 
the implant site and rarely elicit any immune responses, which allow autografts to have 
excellent wound healing properties [5], [27].  
 
The major advantage of autologous grafts is that only potential progenitor cells transfer to 
the site of transplantation. Other advantages are low rate of transmission diseases and 
excellent success rate. However, autografts have a few drawbacks; there is often donor 
site morbidity indicated by necrosis and infection at the location of autograft harvest that 
may cause the patient more pain from the harvest site than the implant site. Additionally, 
autografts are limited in availability to the amount of tissue that can be harvested from the 
donor site. It is these shortcomings plaguing the autograft that has increased the effort to 
find other bone graft substitutes.  
 
Allogenic bone grafts 
Allogenic grafts are also known as allografts, and this technique is based on the harvesting 
of bone from one organism to another between the same species. In other words, a lack of 
similar genetic is avoided. One of the major advantages of allografts is their availability in 
different shapes and sizes, harvested from the cadavers. This avoids the problems with 
the donor-site morbidity and sacrifice of the host structure. Allogenic bone can be provided 
as demineralized bone matrix, morsellized or cancellous chips, cortical grafts, 
osteochondral and others like whole bone segments. Literature has shown that structural 
allografts are more stable mechanically. The major disadvantage or cause of concern is 
the fact that they are documented for HIV and hepatitis C virus transmissions [27]. 
Xenogenic bone grafts 
As a parallel to the allograft, the xenograft uses harvested bone from other species, 
generally pig or cows. The obvious problem in this case is the huge genetic variation 
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existing between the donor and the patient. Therefore, there is a high probability of 
immune rejection or consequent rejection of the implant.  
Allografts and Xenografts are generally preferred by patients and professionals as it avoids 
a potentially painful harvesting procedure. However, bone regeneration is likely to take 
somewhat longer than in an autografts case due to the lack of osteogenic and 
osteoinductive properties.  
 
 
Synthetic bone grafts 
Current commercial substitute materials to replace or repair teeth and bones include 
metals, polymers (natural or synthetic), corals, and coral derived, synthetic ceramics 
(calcium phosphates, calcium sulphate, calcium carbonate, bioactive glasses), and 
composites [29]. Depending on their ability to stimulate a response from the tissue, 
materials are classified into bio inert (e.g.: metals some polymers, some ceramics) and 
bioactive materials (including natural polymers, calcium phosphates, calcium carbonate, 
calcium sulphate and bioactive glasses).  
Ceramic based bone graft substitutes 
Calcium orthophosphates have been studied as bone repair materials for the last 80 years. 
The first in vivo use of calcium orthophosphates was performed in 1920, when researchers 
Figure 1-6 Different type of grafts that can be possible [28]. 
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implanted tricalcium phosphate (TCP) into animals to test its efficacy as a bone substitute 
[30]. However, in 1951 it was Ray et al., when for the first time hydroxyapatite (HA) was 
implanted in rats and guinea pigs. Those attempts might be characterized as the initial 
medical trials with the first generation of bone substituting biomaterials. In the 1970s other 
calcium orthophosphates were synthesized, characterized, investigated and tried in 
medicine [31], [32]. Nowadays the most commonly used ceramics are hydroxyapatite and 
β-TCP as synthetic bone grafts. These grafts are of importance due to their characteristics 
suc
h 
as solubility shown in Table 1-2.   
In 2008, LeGeros [29] listed some properties of CaPs that are relevant to achieve 
adequate bone regeneration, like interconnecting porosity, biodegradability, bioactivity,  
osteoconductivity and osteoinductivity. The osteoconductive CaP biomaterials allow the 
cell colonization, and the associated cellular events like migration, proliferation, attachment 
and differentiation to bone-forming cells. These bone substitutes have additional 
advantages such as long shelf life, availability and no risk of disease transfer [27], [45].  
Table 1-2 Properties of the biologically relevant calcium phosphates [46], [47]. 
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Calcium phosphate cements  
In 1980s Brown and Chow patented self-setting Calcium phosphate cements (CPC) [33].  
In general, CPC are formed by a combination of one or more calcium phosphate powders 
and an aqueous solution to form a paste that is able to set and harden after being 
implanted within the body. Properties like setting times, compressive strength, porosity, 
solubility or in vivo resorption etc. are affected by processing parameters like liquid to 
powder  (L/P) ratio or particle size [48], [49]. The cement sets as a result of a dissolution 
and precipitation process as shown in Figure 1-7. The entanglement of the precipitated 
crystals is responsible for cement hardening. Based on the initial formulations either single 
or multicomponent, there can be two types of apatitic cements that yield the most stable 
calcium phosphate at pH > 4.2 which is hydroxyapatite and brushite formed at pH < 4.2 
with multicomponent (Figure 1-8) [49], [50]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The relevance of hydroxyapatite as a bone substitute arises from the fact that the mineral 
in bone is a poorly crystalline carbonate- and other substituent-containing analogue of 
apatite. As mentioned in Section 1.1.2, 90% of the inorganic bone matrix is made up of 
hydroxyapatite. Therefore, hydroxyapatite is the synthetic graft closest in chemical 
composition to the natural bone [51], [52]. When set, CPC consist of a network of calcium 
phosphate crystals, which closely resemble the mineral phase of the bone tissue [52]–[56]. 
Plastic paste 
Rigid paste 
Solid body 
Powder Liquid 
Setting 
Hardening 
Dissolution 
+ 
Precipitation 
at 
physiological 
temperature 
  
Figure 1-7 Schematic diagram for the process of formulation of cements. 
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Figure 1-8 Classification of the most common formulations of Calcium Phosphate Cements from 
[49]. 
 
In this PhD Thesis, apatitic cements will be used. The starting material 
selected will be α-Tricalcium Phosphate, which after mixing with water 
hydrolyzes to calcium deficient hydroxyapatite (CDHA), a low temperature 
ceramic and after sintering transforms to beta-tricalcium phosphate (β-TCP). 
The setting reaction that gives rise to the solid cement consists in three stages: dissolution 
of the reactants, nucleation of the new phase (in this case apatite) and crystal growth. 
Therefore, the setting reaction is a dissolution-precipitation process [48]–[50], [57]. During 
dissolution, the raw powders release calcium and phosphate ions, generating a 
supersaturated solution. Once the ionic concentration reaches a critical value, the 
nucleation of the new phase occurs, generally surrounding the powder particles, the latter 
acting as nucleation dots. Afterwards, the new phase keeps growing as the dissolution of 
the reagents goes on. During the first hours the setting process is controlled by the 
dissolution kinetics of the raw materials, but once the new phase surrounds the reactants, 
the process is controlled by diffusion across the new phase [57]. In 2007, Bohner et al 
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explained that by modulating these three stages we can modify the CPC reactivity as listed 
below (Table 1-3.) [58] 
CPCs can be processed using many different approaches to obtain modified porosity and 
textural properties. Total porosity, microporosity and specific surface area (SSA) vary with 
the processing conditions of the cements, such as the liquid to powder (L/P) ratio and the 
particle size of the starting powder, as shown in Figure 1-9. Thus, the total porosity 
increases when the L/P ratio is increased, and otherwise the particle size of the starting 
powder conditions the shape and size of the precipitated crystals. It has been shown that 
HA needle-like crystals are obtained when fine α-TCP powder is used, whereas plate-like 
crystals with leading to materials are obtained using coarser powder [49], [58].It is 
therefore important to stress the need of a thorough characterization of these textural 
features of CPC in order to achieve a precise knowledge  in views of controlling the 
resorption and biological response of calcium phosphate cements.  
 
Apatitic CPCs are intrinsically microporous but display very slow resorption rates in vivo. 
To solve this problem, macroporosity may be introduced in CPCs. Macroporosity is sought 
to enhance the material’s resorbability and the extent of bioactivity by increasing the 
surface area available for reaction, enhancing fluid circulation within the material and 
allowing cell colonization. To introduce macroporosity, different approaches such as 
foaming, leaching, or air entraining agents among others can be used [59]–[62]. 
Different synthetic routes may lead to the obtention of macroporous calcium phosphate 
cements although porosity can be a limitation for the use in high load bearing applications. 
The incorporation of a water soluble porogen (Mannitol) in the calcium phosphate cement 
Table 1-3 Different strategies and approaches to manipulate the setting reactions [58]. 
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is clearly the most used approach [63]–[65]. Porogens are subsequently removed by 
dissolution, degradation or temperature variation to let free space: the macroporosity. Gas 
 
Figure 1-9 Microporosity and microstructure of CPCs can be adjusted by varying some processing 
parameters such as the liquid-to-powder ratio or particle size [49]. 
generating porogen present another alternative to generation of macroporous CPCs. For 
example, a mixture of sodium hydrogen carbonate and acetic acid produces CO2 and thus, 
macropores [63]. A major drawback of using porogens is that relevant interconnectivity 
between pores can be achieved only with high proportion of porogens like 40% mannitol, 
resulting in increase in the setting time [66],  and introduction of macroporosity leads to 
decrease in density, and thus fragility of the material. 
Another option to introduce macroporosity in CPCs is by foaming liquid phase [67]. Adding 
a surfactant at low concentration to the liquid phase of the cement allows the generation of 
stable foam by mechanical agitation. The foam acts as a template and will keep all or part 
of its structure while mixing with the powder phase to lead to CPCs with high 
macroporosity and interconnections [68], [69]. Macroporosity of the material doesn´t just 
replicate the trabecular bone rather it can play role in guiding the tissue growth and vessel 
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colonization. In fact Yin et al has shown the cell growth inside the macropores of the 
structure [70]. 
Considerable effort and large number of studies have been devoted in the last decades in 
order to combine the intrinsic bone regeneration potential of CPC with their ability to 
incorporate drugs or other active molecules which are therapeutically relevant [45], [60], 
[71]–[77]. Other studies have even reported the relevant property of injectability of CPCs 
for in vivo in soft tissue [78], trabecular bone [79], [80]and many more [43], [64], [81]–[84]. 
Many drugs have been combined with Calcium phosphates cements while the interaction 
between drug and material is a topic of interest, but it has not been tackled always. 
The adequate composition of CPCs providing them with important regenerative properties 
once set in parallel with its intrinsic porosity, non-thermal setting reaction and ease of 
preparation make them excellent drug carriers for bone and musculoskeletal regeneration 
[71]. 
Based on the different bone pathologies and muscoskeletal diseases, calcium phosphates 
have been combined with different types of drugs including antibiotics [73], [85]–[87], anti-
osteoporosis [37], [88]–[90], anti-inflammatory[91], [92], growth factors [93]–[96] and anti-
cancer [76], [77], [97] drugs.  
As already mentioned, combination of solid powders of calcium phosphates in an aqueous 
solution leads to setting and hardening of the cements (Figure 1-7). Understanding the 
process of cement formulation can give a clear understanding of possible approaches to 
load the drugs (Figure 1-10). 
Figure 1-10 Schematic diagram of the possible strategies to load drugs in calcium 
phosphate cements [49]. 
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Ginebra et al. [49] explained the loading of drugs in calcium phosphate cements according 
to three possible strategies: i) by adding the drug either in the powder phase, ii) in the 
liquid phase or iii) after preparation of the cements by droplet addition or immersion. The 
choice of strategy depends on different factors like drug-material interaction, solubility of 
drug, stability of drug or whether CPC is already set or not.  
 
In this PhD thesis, different methods of incorporation of drug i.e. either by 
mixing with liquid phase or by adsorption after immersion in a drug solution 
will be investigated. 
 
Plasma Treatment 
The physical definition of a ¨plasma ¨ is a state of mixed ions, free radicals, electrons, 
excited molecules, UV and visible radiation that preserves electrical neutrality. Roughly, 
the three main effects of plasmas on the surface of a material are: i) functionalization or 
grafting (covalent bonding of new chemical species); ii) etching (removal of surface 
material); and iii) thin film deposition (deposition of thin layers). Plasma allows selection of 
the treatment gas and has the advantage of controlled conditions leading to highly 
reproducible results. It is generated with electric discharges on gases. Coating by plasma 
polymerization refers to the deposition of polymer films due to the excitation of an organic 
monomer in the gas state and the subsequent deposition and polymerization of the excited 
species on the surface of a substrate. The deposition of solid polymer coatings under 
plasma conditions has been well studied since the 1960s, with a very wide range of 
materials now accessible [98].  
The working principle for plasma polymerization involves two-step process: activation and 
coating. Before plasma treatments, an activation step by plasma reaction is generally 
carried out to remove contaminants or finishing agents from the surface and to generate 
surface radicals which may then react with the precursor monomers and generate a 
stronger bond on the surface. In the plasma polymerization process, a monomer gas is 
pumped into a vacuum chamber where it is polymerized by plasma to form a thin film on 
the surface. The monomer, which starts out from a liquid fed into an external recipient, is 
converted to a gas in an evaporator or dragged by bubbling with an inert gas, and is 
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pumped into the vacuum chamber. A glow discharge initiates the polymerization. The 
excited electrons created in the glow discharge ionize the monomer molecules. The 
monomer molecules break apart creating free electrons, ions, excited molecules and 
radicals. The radicals absorb or react with the previously activated surface, condense, and 
polymerize on the substrate. The electrons and ions crosslink, or create a chemical bond, 
with the already deposited molecules to form a polymer (Figure 1-11). 
In the past decade, the use of non-thermal plasmas for selective surface modification for 
controlled drug delivery has been a rapidly growing research field. One of the major 
applications of this technique that has been used is for surface modification with plasma 
polymers to act as a barrier for a controlled drug delivery.  Many studies have shown that 
through multilayer coatings, a controlled  drug release can be obtained [99]–[102]. The 
coating can be used either to regulate the incorporation of the active principle, or to act as 
a shield to delay its release. Stability of a polymeric coating (as in this case) is controlled 
by the physic-chemical properties of the polymer such as composition, crosslinking and 
coating thickness. All these variables can be tuned through the initial composition of the 
gas and plasma parameters such power and time of the treatment. In this work, low 
pressure plasma polymerization (hereinafter plasma polymerization) has been 
investigated in two ways: i) in soft conditions (Pulsed Wave (PW) polymerization) in order 
to retain the functionalities of the precursor or ii) in a Continuous Wave (CW mode) to 
Figure 1-11 Scheme of plasma polymerization process. 
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deposit cross linked thicker layers. It is an important parameter involved in the surface 
modification as the prime objective of this thesis. 
To the best of our knowledge, in the field of CaP materials for drug delivery applications, 
plasma polymerization has not been investigated yet. Therefore, in the present work, we 
have investigated the possibility of applying a biocompatible polymer on the surface of 
calcium phosphates (CDHA and β-TCP) to investigate the principles behind surface 
modification using different plasma treatments for a controlled drug delivery system. 
 
In this PhD thesis, plasma polymerization will be investigated for CaPs 
(CDHA and β-TCP) using low pressure plasma to design a tunable drug 
release system. 
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Chapter 2  
Simvastatin as an osteogenic drug: facts and future 
perspectives 
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Abstract 
Simvastatin, a lactone pro-drug is mainly known by its cholesterol-lowering properties, 
through the inhibition of the enzyme 3-hydroxy-3-methylglutaryl of the mevalonate 
pathway. However, this pathway is responsible for a number of biochemical molecules, 
which confers simvastatin pleotropic effects. Particularly, it has been shown that 
simvastatin can interact with the process of bone remodelling and new bone formation. 
Several studies including in vitro and in vivo have been conducted to evaluate its benefits 
in enhancement of bone formation and inhibiting bone resorption. In this Chapter an 
overview of the main advances regarding the use of simvastatin in bone regeneration 
applications is provided, covering both in vitro and in vivo studies, through local injection or 
in combination with implantable biomaterials. Overall, the vast amount of research has 
shown beneficial effects of simvastatin for inducing osteoinduction with increase in number 
and function of osteoblasts as well as inhibition of osteoclasts activity.  
 
Introduction 
Bone defects are a major health issue, result of pathologies like osteoporosis, or incidents 
such as traumatic accidents or surgical removal. Every year in Europe, one million bone 
reconstruction surgeries are performed [1]. In 2010, the International Osteoporosis 
Foundation (IOF) estimated more than 22 million women and 5.5 million men suffering from 
osteoporosis in the European Union (EU)[2]. This report estimated that approximately one 
in three women in Europe have excessive bone loss with additional factors leading to 
osteoporosis. In addition, EU healthcare carries a burden of €37 million derived from 
fragile fractures due to osteoporosis. These numbers are expected to increase in 23% 
from 2010 to 2025 with the ageing o f  population.  
Even though bone is a self-repairing tissue, its capacity to self-repair can be affected by the 
health or disease condition of the bone tissue, but also by extrinsic parameters like the 
size of the defects. In 1986, Schmitz and Hollinger introduced the term of critical size bone 
defects referring to the defects that are unable to heal completely during the lifetime of 
an animal [3]. To heal the critical size defects different options are available: 
autologous bone grafts, allografts, xenografts or synthetic bone grafts. To further improve 
the performance of bone grafts, t hey  c an  b e  c om b i ned  w i t h  bioactive molecules or 
drugs, which can stimulate bone formation and/or inhibit bone resorption. For instance, 
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Bone morphogenetic protein (BMP-2) or Fibroblast growth factors (FGFs) have been 
evaluated because of their potent role as bone stimulating agents. However, these 
agents have important drawbacks such as tissue inflammation or initiation of the host 
immune system, as well as tumorigenic effects [4]–[6]. As an alternative strategy, 
Bisphosphonates (BPs) have been also employed, based on the finding that BPs prevent 
osteoclasts activation and survival through inhibition of mevalonate pathway related to 
osteoclast activity, [7] which inhibits bone resorption.  
In the early 90´s, statins, a family of drugs was identified as a potent inhibitor of the 
mevalonate pathway by its inhibiting action over an enzyme, the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG -CoA) reductase, which is responsible in this cholesterol 
production pathway [8]. Statins thus have the ability of reducing serum cholesterol 
concentrations, which is their main current therapeutic use. However, the mevalonate 
pathway affects the synthesis of a variety of molecules, which are implicated in the 
endothelial function, oxidative stress and inflammation and immune system and bone 
metabolism, among others [9]. Many of these effects have been related to different 
biological mechanisms including the promotion of osteogenesis and the inhibition of bone 
resorption.  
These findings were confirmed by Mundy et al., who reported new bone formation in vitro 
as well as in rodents by enhancing BMP-2 expression in vitro and producing a 50% 
increase in new bone formation in calvaria defects [10]. After these findings, the interest in 
SIM for bone regenerative therapies was highly raised. Over the last decade, many studies 
have been conducted to evaluate the impact of SIM in bone formation, including in vitro 
and in vivo studies [11]–[13]. Thereby, this Chapter focuses on the current state of 
applications of SIM for bone regeneration majorly in osteoporosis and fracture healing 
among others, summarizing the main findings of in vitro and in vivo studies. 
Mechanism of action of simvastatin and pleiotropic effects 
As shown in Figure 1, the molecular structure of SIM has hexahydronaphtalene rings 
(lactone rings) which are hydrophobic in nature[14] and the metabolism of SIM involves 
lactone/acid inter-conversion [15]–[17].  SIM is readily distributed in the peripheral tissues 
and gastrointestinal tract through passive membrane permeability which has been explained 
by lipophilic factor in other works (Table 1) [18]–[20]. Generally, SIM is metabolized in two 
ways: a) hydrolysis through Carboxyl esterase to simvastatin acid (SVA),  b) oxidation by 
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P450 isoenzymes into regio- and stereo-selectively metabolized products [21], [22]. The 
major metabolized product is SVA which inhibits the 3-hydroxy-3-methylglutaryl reductase 
(HMGR) enzyme by tight binding to it. As this enzyme is responsible for one of the steps of 
conversion to mevalonate, blocking of this enzyme results in the inhibition of the 
mevalonate pathway [23], [24]. The mevalonate pathway is involved in many biological 
pathways (Figure 2-1) other than bone regeneration, so this has led to explore further the 
pleotropic effects of the SIM overviewed in further sections. 
 
Figure 2-1 Graphic representation of the conversion of simvastatin (SIM) to simvastatin acid  (SVA) 
[16], [17]. 
As a consequence of its mechanism of action, based in its interference in the synthesis of 
mevalonic acid (Figure 2-2), SIM has several pleotropic effects. The mevalonate pathway 
has many intermediates being involved with inhibition of Guanosine triphosphate (GTP) 
proteins and isoprenylation. These intermediates and further processes lead to a huge 
number of pleiotropic effects such as: anti-inflammation, anti-oxidative, angiogenesis or 
osteogenesis with respective role in bone generating proteins (Figure 2-2) [23], [25]–[28]. It 
has been seen that inhibition of the mevalonate pathway by statins results in the increase in 
the endothelial nitric oxide synthase (eNOS) enzyme [29], [30]. While it has been shown 
that vascular endothelial nitric oxide (NO) plays a major role in the mediation of the anti-
inflammatory effects explaining indirect impact of statins[26], [31]–[34][9], [35], [36]. Some 
other effects of statins have been reported such as enhanced endothelial nitric oxide 
synthase (eNOS), inhibited apoptosis and accelerated vascular structure formation, in vitro 
and angiogenesis, in vivo [37]. Other studies have reported similar findings with increase 
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in the vascular endothelial growth factor (VEGF) production due to administration of SIM 
[38]. To summarize, SIM effects on angiogenesis and vascularization have been reported 
along with osteogenesis among many studies [39]–[41].  
 
Figure 2-2 Role of Simvastatin (SIM) in the bone regeneration. 
Role of simvastatin in bone metabolism and bone regeneration 
As mentioned in previous sections, in the last two decades SIM has arisen as a potential 
alternative drug for enhancing bone regeneration. The research undertaken covers a wide 
spectrum of approaches, including in vitro and in vivo studies and different administration 
routes. This work reviews the most recent publications about the application of SIM in the 
field of bone regeneration, covering both in vitro and in vivo models, and the including the 
administration of SIM either systemically or locally.  These are summarized in the following 
sections focusing in parameters such as drug delivery route, effective drug dosage or 
selection of animal model among others. 
Effects of simvastatin in the cell fate in vitro: cell culture studies 
In vitro studies provided the first data on the impact of SIM on the bone regeneration. The 
majority of the works focus on the effects of SIM on pre-osteoblasts (e.g. MC3T3-E1) or 
osteoblasts (OBs) (Table 2-2), although other cell lines or primary cells have been 
investigated including osteosarcoma cells (MG 63), murine (2T3), human osteosarcoma 
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(hOS), Mesenchymal stem cells (MSCs), human adipose-derived stromal (hADSCs), 
embryonic cells (mESCs) (Table 2-2). In most cases the administration of SIM in in vitro 
was performed directly in solution in the cell culture medium and only two studies loaded 
SIM in carriers for further in vitro evaluation. The dosage of SIM investigated covered a 
wide range of concentrations, from 0.1 nM to 1mM and low concentrations of 0.1 and 1 
μM were found to be the most effective.  
Table 2-1 Comparison of the lipophilicity of statins, simvastatin being among the most lipophilic. 
[19], [20]. 
STATIN LIPOPHICILITY 
Lovastatin 1.70 
Cerivastatin 1.69 
Simvastatin 1.60 
Pitavastatin 1.49 
Fluvastatin 1.27 
Atorvastatin 1.11 
Rosuvastatin -0.33 
Pravastatin -0.84 
 
The first in vitro study was conducted on human osteoblast-like osteosarcoma (MG63) and 
murine osteoblast cells (2T3) [10]. The study reported the stimulation of BMP-2 gene 
expression in both types of cells. It was found that in MG63 cells, addition of SIM (2.5µM) 
resulted in an increase of 2.7 fold in the gene expression of BMP-2. Later, Frick et al. 
found that SIM (1–10 µM) increased VEGF gene expression in human umbilical vein 
endothelial cells. In contrast, they also reported decreased VEGF production for human 
vascular smooth muscle cells and microvascular endothelial cells [42]. These differences 
point out the importance of the cell model chosen, at which we will pay attention in the 
coming paragraphs.   
Zhou et al. administering SIM (0.1 μM) to human adipose-derived stromal cells (hADSCs) 
showed enhancement of Alkaline phosphatase (ALP) activity at day 14. Alongside, 
Osteocalcin (OCN) secretion at 24h & 72h, and matrix calcification were significantly 
increased [43]. Zhang et al. reported a significant increase in the proliferation rate, 
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migration and angiogenesis with mesenchymal stem cells due to SIM [44]. Later, in 2010 
Chen et al. conducted a study on osteoblast like cells from mice calvaria reporting higher 
viability in 10
−6
M SIM-treated cells. BMP-2 and ALP mRNA gene expression increased in 
the early phase of osteoblast culture at 3 days while SIM-treated group displayed even 
higher expression indicating increased differentiation [45].  
Many studies with pre-osteoblast cells (MC3T3-E1) with SIM observed increase in gene 
expressions such as BMP-2, ALP, VEGF, OCN, collagen type 1 (COL1) or osteopectin 
(OP). In 2001, Maeda et al., reported maximal anabolic (bone forming) effects of SIM (10-7 
M) in mouse osteoblast cells (MC3T3-E1) derived from mouse calvaria. This [46] and 
other works [47] reported stimulation of BMP-2 which triggered osteoblastic cell 
differentiation and production of ALP which is responsible for the mineralization process. 
Apart from direct administration of SIM in cell culture medium of MC3T3-E1, a couple of 
studies investigated with different drug carriers.  A study with SIM-gelatin-polymer 
scaffolds reported osteogenic differentiation and mineralization with increase in OC gene 
expression [48]. SIM-PLGA microspheres incorporated in CaP macroporous scaffolds 
study found higher cell attachment and proliferation with increase in COL-1, OP and OC 
gene expression [49].  In pre-osteoblast cells, MC3T3-E1, mineralization has been 
observed in all the studies with increase in gene expressions related to bone 
regeneration, namely BMP-2 as well as ALP. 
In 2013, Montazerolghaem et al. loaded β-hydroxy simvastatin acid (0.25, 0.5 & 1mg 
SVA/g cement) in premixed brushitic calcium phosphate cements observing a diffusion 
controlled release for over a week. SaOS-2, sarcoma osteogenic cells (human 
osteoblast like cells) were cultured with extracts from the loaded cements where the 
highest dose of 1 mg SVA/g employed showed lowest proliferation rate. On the other 
hand, 0.5 and 0.25 SVA/g cement showed significantly higher ALP activity and 
mineralization but no significant difference in proliferation [50].  
In summary, SIM administration through either cell culture medium or delivered through 
carrier vehicles has reported efficacy in bone regeneration 
Effects of simvastatin in vivo 
The effects of SIM have also been evaluated in vivo, in models which include heterotopic 
and orthotopic sites. Heterotopic models avoid a direct contact with the bone tissue to 
show the osteoinductive properties of the drug. Thereby, subcutaneous (SC) injection or 
38 
 
surgical implantation, intravenous (IV), intraperitoneal (IP) or intramuscular (IM) routes of 
administration are commonly used in heterotopic models. On the other hand, orthotopic 
models are used in intraosseous defects evaluating implants and include bone defects 
such as calvarial, mandibular or trabecular, among others. The models evaluated include 
bone fractures in either healthy animals or osteoporotic ones.  
SIM has been extensively studied in a number of animal models via different routes of 
administration. In the in vivo studies reviewed below, the systemic route is the most 
studied, mainly by oral (P.O.) or subcutaneous (SC) administration to deliver SIM. A 
minority of these studies used intravenous (IV), intraperitoneal (IP) and intramuscular (IM) 
route of administration. On the other hand, local delivery of SIM was performed with either 
local injections or implantable bone grafts. Thereby, the following sections will review the 
findings about the effects of SIM, on the basis of route of administration via systemic or 
local delivery, focusing on osteoporosis or bone defect healing. 
Systemic administration 
Most of the studies assessed the effect of SIM in osteoporotic animals, ovariectomized 
(OVX) rats, the most common model for postmenopausal osteoporosis and fracture 
healing in healthy rats. Most of these studies employed rodents as animal models (rats or 
mice) and only a few employed medium-sized animals such as rabbits or dogs for 
particular pathologies. SIM was administered orally, among a range of suitable 
concentrations generally around 5 - 50 mg kg-1 day-1. Though, in case of  spinal fusion 
model, positive effects were observed with higher SIM concentrations of 120 mg kg-1 day-1 
while lower concentrations (20 mg kg-1 day-1) had no effect (Table 2-3). [51], [52].  
Osteoporotic animal model 
In OVX animal models, the most significant results for bone regeneration were reported at 
low concentrations of 5, 10 and 20 mg kg-1 day-1.  
Junquiera et al. reported new bone formation with SIM (20 mg kg-1 day-1) in a mandibular 
defect in OVX rats at 15 days without any further change [53]. In agreement with these 
findings, Oxlund et al. also reported similar results for the new bone formation in OVX rats 
[54]. Later, Pytlik et al. also reported similar findings for OVX rats with increased bone 
formation and reduced bone resorption by SIM (3 and 6 mg kg-1 day-1) [55]. In parallel, Ho 
et al. also found that SIM (administered orally at 10–20 mg kg-1 day-1) to OVX rats 
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improved their trabecular bone volume/total volume in distal femurs (~25 %) and proximal 
tibiae (~ 20%) which were significantly higher than OVX- group whereas SIM showed no 
significant increase in bone volume in SHAM rats [56]. In the same line, Ito et al. reported 
that micelle of deoxycholate containing SIM coated by calcium phosphate (CaP) via IM 
injection improved bone mineral density and mechanical properties with suppression of 
inflammation in OVX mice [57].  
In contradiction to previous findings, a few studies have reported that SIM has no 
significant effect on bone healing, new bone formation or bone resorption due to critical 
dose dependent behavior [58]–[62]. For instance, Maritz et al. (2001) reported SIM effect 
on OVX rats with different dosage of 1, 5, 10 and 20 mg kg-1 day-1 via oral administration 
(P.O.). Interestingly SIM (20 mg kg-1 day-1) showed increase in both bone formation 
(osteoid volumes, osteoid surfaces, and osteoblast number) and bone resorption (eroded 
surfaces occupied by the Osteoclasts). Thereby, globally no net effect was seen neither in 
bone formation nor in bone resorption [63]. 
Healthy - fracture animal model 
Regarding the effect of SIM in healthy animals, Skoglund et al. reported an in vivo study in 
mice with bone fractures where oral administration of SIM accelerated new bone 
formation [64]. Later on, Saraf et al. conducted an experimental study to investigate the 
bone healing process by administering SIM orally (120 mg kg-1 of body weight) to rabbits 
with femur fracture. Bone healing was hastened during the initial 4 to 8 weeks following 
administration of SIM and the average bending fracture strength and average three point 
bending stiffness significantly improved at 4 and 8 weeks, in comparison to the control 
group [51].The effect of SIM on bone strength in  healthy rats was analyzed by Garip et 
al., who showed a dose dependent effect of SIM (20 & 50 mg kg-1 day-1) in tibiae bone with 
improved bone strength at the lower dosage [65].  Another study by Oxlund et al. (2001), 
reported that SIM (10 mg kg-1) increased cancellous bone volume by 23%, and this was 
associated to a 24% increase in its compressive strength in healthy rats [66]. It is 
important to take into account that an optimum dosage for each animal model is a key 
point. As reported earlier in fracture healing model for rabbits, bone resportion behavior 
was observed with SIM (30 mg kg-1 day-1, P.O.) while lower dosage (10 mg kg-1 day-1) did 
not have any significant effect [67]. 
Overall, systemic delivery of SIM has been reported as having significant efficacy in 
osteoporotic models (i.e. OVX). The majority of studies conducted on OVX rats with SIM 
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reported significant increase in bone formation and inhibition of bone resorption 
consistently. Moreover, SIM has also been found to be beneficial in other bone 
pathologies including fracture healing, spinal fusion, osteonecrosis or bone strength in 
healthy rats. To treat femur fractures and for spinal fusion higher SIM dosages were found 
to be the most suitable. 
Local administration 
As discussed in earlier sections, SIM has a very low bioavailability due to high elimination 
when administered systemically. SIM is known to enhance bone formation through 
inhibition of mevalonate pathway alone.  However, after conversion of SIM to SVA, 20 – 
90 % of the hydrophilic SVA is predominantly eliminated by the human bile [68]. Due to 
such an extensive pre-systemic (first pass) metabolism, SIM has a very low oral 
bioavailability (≤5%) and this justifies the interest for delivering SIM locally to the 
therapeutic site. In order to maximize the efficiency and have sustained drug release and 
minimize its side effects, local delivery is a suitable method. 
In the following sections, the most relevant results reported in the literature on the effect of 
locally administered SIM in bone regeneration are discussed, covering both  the 
administration through local injections or by using a biomaterial as a drug delivery vehicle. 
-Local injections 
Local injections in the overlying tissue of the defect can be applied subcutaneously, 
intramuscularly or intravenously. The most effective range of dosage to have maximum 
benefits of SIM has been found to be between 7 and 20 mg kg-1 day-1 for different bone 
defect models (Table 2-4) which have all been conducted in rodents.  
Different studies where SIM was administered subcutaneously in the tissue overlying 
calvaria defects reported enhanced 50 % increase in new bone formation in OVX rats [10] 
or increase in bone thickness [69] respectively. 
For load bearing locations, bone defects were generated in tibiae and femur. For femoral 
defect, Skoglung & Aspenberg et al., administered SIM subcutaneously or locally through 
an osmotic pump. While there was no significant effect with subcutaneous injection, local 
administration with an osmotic pump resulted in higher force at the fracture site [70]. 
Another study also reported enhancement of ALP, OCN with local injections of SIM at the 
surgical site [71]. Similar findings were reported for tibiae defect, with an increase in BMP-
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2 and ALP with reduction of osteoclasts via transdermal injections of SIM [72]. 
Over all, local injections either in calvaria defect or in defects in load bearing locations, 
both reported significant enhancement in bone regeneration. Even osteoporotic animal 
models with bone defects reported increase in bone volume. It can be said that SIM 
efficacy is proven throughout the variation of bone defect models among osteoporotic as 
well as healthy animal models.  
-Administration of SIM using biomaterial carriers 
The main body of research dealing with local delivery of SIM has been done with 
implantable grafts. The major advantage of employing implants for local drug delivery is to 
allow lower dosage if sustained and controlled, increasing the bioavailability at the 
therapeutic site and overcoming systemic toxicity.  
In the following sections, a summary and brief discussion on the reviewed studies 
evaluating SIM loaded carriers (Table 2-5) in the different bone defects is provided 
(calvaria defects, load bearing locations and other models).  
Osteoporotic animal model 
Yang et al., grafted porous titanium implants coated with SIM-HA in tibiae defect of OVX 
rat. They reported enhanced bone formation and osteointegration; increased bone implant 
contact [73]. Similar findings were reported where SIM loaded Biomimetic β-TCP with an 
apatite coating were employed for OVX rats with a tunable SIM release [74]. They 
reported increased bone mineral density from 400 to 600 mg/cm3 from week 0 to week 6 
respectively. These findings in OVX rats are similar as observed in healthy rat model for 
tibiae or femur defect discussed ahead  [75], [76]. 
Healthy animal model 
Polymeric carriers 
Polymer-based drug carriers have been used extensively in last few decades. Major 
advantages of these carriers include characteristics like biodegradability and 
biocompatibility. The most common polymer-based implants evaluated as carriers for SIM 
used polylactic acid (PLA), polyglycolic Acid (PGA) or their co-polymers.  Some studies 
include model of calvaria defect and a majority investigated load bearing location. Among 
the latter, different models such as tibiae, femur and mandibular defects have been 
investigated, usually with very low dosage of SIM (between 5 μg and 1 mg) and reporting 
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significant improvement in treatment of the bone defects.  
For defects in rat calvaria, Pişkin et al., reported increased  osteointegration and bone 
restoration by using SIM loaded electrospun PCL scaffolds implanted into calvaria defect 
[77]. Another study investigated both calvaria and mandibular defects, with SIM loaded 
(0.1-2.2 mg) methylcellulose gel held by polylactic acid (PLA) membranes [78]. In 
calvaria, it was able to stimulate gene expression of pro-collagen, fibronectin and matrix 
metalloproteinase-13 (MMP13) related to collagen synthesis for bone growth. On the 
other hand, for the mandibular defect, bone area increased by 45% in at the 0.5 mg 
dosage with reduced inflammation vs. control. In agreement, another study conducted on 
mandibular defects used SIM-loaded PLA-PGA copolymer [79] and reported improved 
osteoconduction and inhibited bone resorption. 
A few studies employed polymeric grafts combined with hydroxyapatite. For rat calvaria 
defect, Jiang et al., implanted Poly (lactic-co-glycolic acid)/hydroxyapatite nano- fibrous 
scaffolds loaded with SIM. They reported increased ALP activity and decrease in the 
defect size with enhancement of osteoinduction [80]. Another group employed SIM –poly 
(lactic-co-glycolic acid)/hydroxyapatite (SIM/PLGA/HA) microspheres for tibiae fracture 
with a necrotic bone gap. They reported neovascularisation with cell ingrowth in grafted 
bone as well as necrotic bone [81]. 
Overall, significant bone regeneration enhancement has been reported in the literature 
when SIM was incorporated in biodegradable polymeric matrices, either in calvaria, 
mandible or load bearing defects in rodents.  
Another option for the local delivery of SIM is the use of hydrogels. Those based on 
gelatin or collagen are the ones that have been used more often incorporating SIM 
amounts ranging from 25 µg to 10 mg. In rat calvaria defect, Sukul et al. employed a 
SIM loaded hydrogel scaffold constituted by gelatin-nanofibrillar cellulose and β-Tricalcium 
phosphate prepared by freeze drying. They reported an increase in the expression of 
osteoblastic differentiation related genes and showed higher bone formation[82].  
For non-union femur defects in rats, fracture union was reported due to enhanced 
angiogenesis and osteogenesis thanks to SIM-gelatin hydrogel [83]. Moshiri et al. 
employed gelatin cross linked with genipin loaded with SIM in a rabbit femoral bone 
defect. They reported formation of newly woven ectopic bone. Also, bone maturation and 
remodeling into cortical bone were found with higher bone volume, mineralization, elastic 
modulus, and contact hardness indicated osteogenesis, osteoinduction and 
43 
 
osteoconduction [84]. Similarly, another study was conducted on femur cavity with 
absorbable, hydrolyzed and lyophilized collagen sponges soaked with SIM. They reported 
enhanced angiogenesis, bone formation and increased number of osteoblasts with an 
increase in the OCN and VEGF gene expression [85].  
SIM-loaded collagen grafts were implanted in a parietal bone defect in rats, and SIM 
loaded photocured hyaluronic acid hydrogels were used in the same defect in rabbits. 
SIM-collagen grafts reported a significant increase in new bone formation in comparison 
to unloaded collagen grafts [86]. Similar findings were reported in a rabbit animal model 
with new bone formation and enhanced osteogenesis [87]. 
Tibiae defects were investigated with SIM loaded hydroxypropyl methyl cellulose granules 
by Rushinek et al. They reported increase in osteoid thickness, volume, mineral apposition 
rate and calcein labeling though trabecular surface had no significant effect on osteoblasts 
in static histomorphometric analysis  [88]. Whether rat calvaria defect or load bearing 
location defect, different hydrogels and animal model have reported significant bone 
formation thanks to the presence of SIM. 
Inorganic carriers 
Inorganic grafts, such as apatites and salts of calcium phosphates with similar 
composition to bone are increasingly studied as carriers for SIM. Calcium Phosphates are 
considered excellent bone substitutes due to their bioactivity, osteoconductive behavior, 
biocompatibility, direct bonding with the bone and resorbability [89], [90]. Although the 
range of SIM concentrations vary depending on the material used as carrier, a range from 
0.1 to 5 mg was incorporated per scaffold or per defect depending on the defect model.  
Most studies are conducted with particles of α-TCP, β-TCP or hydroxyapatite, alone or 
combined with hydrogels, as described in the previous section.  
For rat calvaria defect, Nyan et al. implanted calcium sulphate powder loaded with SIM 
showing evident bone formation in 8 weeks, although the early resorption of calcium 
sulphate resulted in burst release of SIM followed by intense soft tissue inflammation. For 
the first 5 weeks, inflammation hindered bone formation which improved significantly by 8 
weeks [91]. Later, Nyan et al. conducted another study with a similar model with SIM 
loaded in α-TCP particles. They reported soft tissue inflammation at 0.25 and 0.5 mg 
dosage. Conversely, 0.1 mg of SIM resulted in maximum bone regeneration with higher 
bone volume over 8 weeks without any sign of inflammation. Gap bridging was seen 
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between the defect border and the inserted α-TCP particles, so histological imaging 
suggested this SIM dosage led to maximum stimulation of local cells [92]. 
Some studies employed different grafts of inorganic bovine bone graft (BOS), combined 
with calcium sulphate (HACS), and collagen sponge (COS) [75]. They reported an 
increase in new bone formation which was significant higher at 8 weeks with HACS-SIM 
(44.31 ± 9.89 mm2) vs. other grafts. On the other hand,  at 4 weeks BOS-SIM 
(43.22 ± 8.82 mm2) showed higher values than other grafts [75].  
Calcium Phosphate Cements (CPCs) are considered excellent bone substitutes due to 
their injectability, ability to harden in-vivo and close composition to the bone’s inorganic 
phase [93]. In addition, CPCs  are considered excellent vehicles for delivery of drugs [94], 
so in the past years progress has been made towards combining SIM with CPCs.  
 In 2012, Yin et al. conducted studies with CPC scaffolds implanted intramuscularly 
(into back muscles) or endosteally (in the femoral condyle) rabbits. They prepared 
macroporous apatitic CPCs with SIM (1, 5 and 10 wt %) blended to its solid phase. The 
highest SIM concentration (10 wt %) resulted into inflammation, muscular necrosis and 
lowered compressive strength of the graft. Whereas, lowest concentration of 1 wt% was 
found to prove the osteogenic potential of macroporous CPCs without any inflammation 
[95].  
To modulate the release of SIM from macroporous scaffolds (either from hydroxyapatite or 
β-TCP), Polycaprolactone – Polyethylene glycol like (PCL-co-PEG) dry coatings were 
produced by cold plasma [96]. The thickness of the coatings essentially depended on the 
specific surface area and on the plasma treatment conditions and allowed blocking, 
delaying or reducing the release rate depending on the with varying thickness of the 
polymer coatings and treatment conditions [96].  
To summarize, different grafts from polymers to inorganic such as CaP or CPCs, SIM has 
consistently proven its anabolic effects. 
Conclusions 
Simvastatin is known for its beneficial effects on bone metabolism through a) 
enhancement of bone formation by fostering osteoinduction and osteoblastic activity and 
b) inhibition of bone resorption through reduced osteoclastogenesis and osteoclastic 
activity.  
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SIM effects have been widely investigated both in vitro and in vivo, using different 
administration routes. In vivo studies have provided evidence of the effect of SIM on the 
gene expression of bone formation related proteins: BMP-2 or ALP. On the other hand, in 
vivo studies have demonstrated the effectiveness of SIM, especially in two major bone 
pathologies: osteoporosis and bone fractures. The local delivery route has been found to 
maximize its efficiency.  
Local drug delivery carriers evaluated in combination with SIM include polymers and 
inorganic matrices, such as CaPs. Despite the variety of grafts evaluated in literature, SIM 
consistently proved its anabolic effects. Bone regeneration was reported throughout the 
reviewed studies with new bone formation or increase in bone volume in vivo, associated 
to the over-expression of some genes relevant for bone regeneration such as BMP-2, ALP 
or OCN, as well as suppression of osteoclasts in vitro.  
To conclude, SIM has proven to be beneficial for bone regeneration from a wide spectrum 
of investigations, including in vitro and in vivo, being the choice of the most suitable 
concentration a critical parameter. Moreover, there is a need to extend the studies to big 
animal models to gather more conclusive information before going to clinical trials.  
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Table 2-2 In vitro studies conducted to study the effect of the simvastatin on bone formation. 
 
Year & Author 
 
Study 
 
Dosage of SIM 
 
Main Findings 
Via Cell culture medium 
Mundy et al., 
1999 [97] 
Human (MG63), Murine (2T3) bone 
cells 
1 -5 µM 2.7 fold  BMP-2 with SIM at 2.5µM 
Ruiz-Gaspa et al. 
2007 [98] 
Primary human osteoblast (hOB) and  
MG-63 
10−6 M to 10−9 M 
In hOB, a significant  in COL1A1, OCN, and BMP-2 gene 
expression and slightly lower values in MG-63 with arrest of 
proliferation. 
Chen et al., 2010 
[45] 
Osteoblast-like cells from calvaria bone, 
mice 
10
−3 - 10
−9
M 
 
At 10
−6
M SIM showed the highest cell viability; 3days:  BMP-2 
and ALP gene expression indicating enhancement of 
differentiation. 
Sugiyama et al., 
2000 [99] 
Human osteosarcoma (HOS) cells 0.1-10 µM 
BMP-2 RNA expression with10 µM of SIM showed ~4.5 fold 
induction in luciferase activity compared with solvent control. 
Maeda et al. 
2003 
[100] 
MC3T3-E1 cells, mouse stromal cells 
(ST2), and rat osteosarcoma cells 
(UMR-106) 
1 nM - 100 
µM 
At 10-6 M  x2 of VEGF expression in MC3T3-E1,  x7 in ST2 
cells at 3h by 7 fold and  in UMR-106 at short times (<12h). 
Maeda et al. 
2001 [46] 
MC3T3-E1 and rat bone marrow cells 10-7 - 10-8 M 
MC3T3-E1 showed increased ALP activity and mineralization vs. 
control at 10-7 M. 
Rat bone marrow cells showed significant  in mineralization 
(10-6 to 10-8 M) vs. control. 
Montazerolghaem 
et al., 2015 [47] 
MC3T3-E1 pre-osteoblasts and 
Primary human monocytes 
Zn (10 and 25 
μM) and SVA 
(0.25 and 0.4 
μM) 
Zn (10 μM) and SVA (0.25 μM) resulted in significant  cell 
differentiation and mineralization without impeding proliferation 
rate. SVA indicated mineralization with higher ALP activity & 
secretion of Ca deposits at 22 days. 
Ahn KS et al., 
2008 [101] 
RAW 264.7 
(mouse macrophage), MCF-7 (human 
breast adenocarcinoma) 
& U266 (multiple myeloma) Cells 
0.1, 0.5 & 1 µM 
Pretreated cells with SIM (1 µM) for 6 hr suppressed the 
activation of NF-кB, IкBa kinase, IкBa phosphorylation and IкBa 
degradation induced by RANKL & suppression of 
osteoclastogenesis. 
Yamashita et al., 
2008 [102] 
C2C12 mouse myoblast cells 1-100 μM 
SIM alone has no effect on Runx2 expression or ALP activity but 
24h pretreatment of cells with SIM reverses the effect of TNF-α 
suppression of BMP-induced Runx2 expression & ALP activity 
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significantly at 30 µM. 
Zhou et al., 
2010[43] 
human adipose- derived stromal cells 
(hADSCs) 
0.01 μM-1 μM 
At 0.1 μM SIM,  ALP activity at day 14, at  OCN secretion, and 
matrix calcification at 24h & 72h. 
Pagkalos et al., 
2010 [103] 
Murine embryonic stem cells (mESCs) 0.1nM - 100nM 
At 0.1 nM, SIM can cause differentiation into osteogenic cells 
even without osteoinductive supplements.  OCN and osetrix 
gene expression. 
Carrier 
Valles et al., 2012 
[34] 
Saos-2cells; human osteoblasts 
(hOBs); 
SIM in the cell culture medium with or 
without Ti particles 
1µM 
In Saos-2 cells & hOBs, SIM significantly decreased the Ti 
particle-induced relative IL-6 secretion for both. These results 
showed cytokine-lowering property of SIM. 
Montazerolghaem 
et al., 2013 [50] 
 
Saos-2 cells; 
Premixed brushite CPCs 
0.25-1 SVA/g 
cement 
4X mineralization at lower SVA dosage (0.5 & 0.25mg. 
Significant increase in ALP for 10-6 M and cell viability for 10-7 M, 
10-8 M SVA vs. control. 
Park et al., 2012 
[48] 
MC3T3-E1 pre-osteoblast cells; 
Gelatin–poly(ethylene glycol)–
tyramine(GPT) hydrogel 
1 and 3 mg/ml 
Osteogenic differentiation observed with increase in matrix 
metalloproteinase-13, OC expression levels, and mineralization 
in 14 days. 
Nath et al., 2013 
[104] 
MC3T3-E1 pre-osteoblast cells; SIM 
loaded PLGA microspheres into 
hydrogel loaded biphasic CaP spongy 
scaffold 
0.2 gm 
Biocompatible scaffold resulted in significantly higher cell 
attachment and proliferation with increase in collagen I (Col-I), 
OP and OC gene expression. 
Jeon et al., 2007 
[105] 
MC3T3-E1 cells; 
Cellulose acetate phthalate/ Pluronic F 
127 (PF-127) Microspheres 
0-1µM (SVA) 
Intermittent release (100 pM - 10 nM) of SIM OCN, ALP and 
cell number depending on the [SIM]. 
Bae et al., 
2011[87] 
MC3T3-E1 cells; 
Photo-cured hyaluronic acid hydrogels 
0.1 and 1 mg 
At 1mg, cell proliferation and mineralization were significantly 
higher than control. 
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Table 2-3 In vivo systemic administration of simvastatin to study the effect on bone formation. (P.O: Oral administration, IM: Intramuscular, IP: 
intraperitoneal) 
 
Year & Author 
 
Study 
 
Dosage of 
SIM 
 
Main Findings 
Osteoporotic / Ovariectomized (OVX) rats or mice 
Maritz et al. 2001 
[63] 
Rats (P.O.) 
1, 5, 10 & 
20 mg kg -1 
day-1 
SIM (20 mg kg-1 day-1) decreased BMD,  1) bone formation ( osteoid 
volumes, osteoid surfaces, and osteoblast numbers) and 2) bone resorption 
(eroded surfaces with osteoclasts) 
= globally no significant difference found. 
Junqueira et al., 
2002 [53] 
Rats with mandibular defect 
(P.O.) 
20 mg kg -1 
day-1 
Significant  new bone formation in mandibles. 
Pytlik et al., 2003 
[55] 
Rats (P.O.) 
3 and 6 mg 
kg -1 day-1 
At higher dosage, strong bone formation and inhibition of bone resorption 
was observed. 
Oxlund & 
Andreassen et al.,  
2004 [66] 
Rats (P.O.) 
20 mg kg -1 
day-1 
SIM reduced cancellous bone loss due to OVX and new cortical bone 
formation. 
Ho et al., 2009[56] Rats (P.O.) 
10–20 mg. 
kg -1 .day-1 
In OVX+20 SIM: ~10 % Traebacular bone volume/ total volume  ~15% of 
distal femurs, and  ~15% in proximal tibiae. 
SHAM rats: No increase in Bone volume. 
Yao et al.,  2006 
[59] 
Rats (P.O.) 
0.3 to 10 mg 
kg -1 day-1 
No significant changes in bone resorption or new bone formation. 
Anbinder et al.,  
2007 [58] 
Rats (P.O.) 
25 mg kg -1 
day-1 
No significant change on bone healing. 
Zhibin Du et al., 
2008 [106] 
Rats with Ti implants in 
cancellous bone (P.O.) 
5 mg kg -1 
day-1 
OVX +SIM vs. OVX showed improved osteointegration of implants in BIC: 
56.06 ± 17.31 vs. 34.92 ± 12.63, BA: 27.03 ± 8.06 vs. 14.45 ± 4.44 and BD: 
19.63 ± 7.01 vs. 9.81 ± 4.18 in cancellous region (zone B) with no change in 
cortical region (zone A) 
Du et al.,  2013 
[107] 
 
Rats with Ti implants in tibiae 
(P.O.) 
5 mg kg -1 
day-1 
Improved osteointegration & serum had higher bone formations markers 
such as bone-specific alkaline phosphatase (BALP) and bone Gla protein 
(BGP) levels. 
Von Stechow et Mice (P.O.) 20 mg kg -1 No significant change in bone formation. 
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al.,  2003 [60] day-1 
Issa et al., 2015 
[108] 
OVX and (SHAM) rats with 
fractured femur (P.O.) 
5 & 20 mg 
week-
1
 
Higher dose of 20 mg showed stronger effects with significant bone repair. 
Healthy animal model 
Femur Fracture 
Skoglund et al. 
2002  [64] 
Mice (P.O.) 
~120 mg kg 
-1 day-1 
At 14 days SIM group 53% larger transverse area than controls, 63% 
greater force required to break the bone, and 150%  energy uptake. 
 
Saraf et al., 2007 
[109] 
Rabbits  (P.O.) 
120 mg kg -1 
day-1 
Bone healing process was hastened during the initial 4 to 8 weeks.  
Bending strength,  three point bending stiffness. 
Spinal Fusion 
Bostan et al., 
2011 [52] 
Rats (P.O.) 
120 mg kg -1 
day-1 
SIM group showed no signs of Psuedoarthrosis. Three point bending force 
showed promotion of fusion in SIM-SF 148.80±39.403 Newtons vs. 
123.80±28.479 Newtons in SF. 
Yee et al., 2006 
[61] 
Rats (P.O.) 
20 mg kg -1 
day-1 
No significant effect of SIM on spinal fusion. 
Other models 
Chissas et al., 
2010 [110] 
Rabbits with ulnar osteotomy 
(fracture healing) (P.O.) 
10 & 30 mg 
kg -1 day-1 
Higher dosage leads to significant reduction in BMD, stiffness and after 15 
days callus formation whereas lower dosage had no effect even at early 
stage of fracture remodelling. 
Bowers et al., 
2004 [111] 
 
Osteonecrosis in Femoral 
head of dog (P.O.) 
40 mg kg -1 
day-1 
Significant increase in Bone mineral density and volume yet lower values on 
comparing to alendronate. 
Oxlund et al. 2001 
[66] 
Cortical shell of 5th lumbar 
vertebra in rats (P.O.) 
10 mg kg -1 
day-1 
23%  in cancellous bone volume (52.7 ± 1.6%) against placebo group (42.8 
± 1.7%) and 24%  in compressive strength (31.8 ± 2.7 MPa) compared with 
the placebo group (24.1 ± 1.9 MPa). 
Nakashima & 
Haneji, 2013 [112] 
Female mice (IP) 
10 mg kg -1 
day-1 
Reduced osteoclast numbers and reduced bone loss. SIM blocks RANKL 
induced IRF4 expression involved in osteoclastogenesis. 
Ito et al., 2013 
[57] 
Deoxycholic acid/SIM in 
calcium phosphate (CaP-
DeCA/SIM) nanocapsules (IM) 
150 μg 
Reduced cytotoxicity, anti-inflammatory and increase in BMD and bone 
strength was seen with mechanical testing. 
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Table 2-4 Local delivery of simvastatin through local injections (INJ) (Subcutaneous (SC), Intradermal (ID) or Intramuscular (IM)) at defect site. 
 
Year & Author Design Dosage Main Findings 
Osteoporotic model 
Mundy et al. 
1999  [10] 
Murine calvaria; OVX Rats (SC 
INJ) 
5 or 10 mg kg -1 39-94% in trabecular bone volume in Rats. 
Wang JW et al., 
2007 [113] 
Tibiae fracture, OVX rats (SC) 
10 mg kg -1 day-1 
 
 Callus cross-section area: 21.3%  (1 week; 20.22±3.42 mm2 vs. 
16.67±4.02 mm2) and new woven bone was functional and 
arranged more tightly and regularly at 2 and 4 weeks; 57.5%  
maximal load. 
Funk et al., 2008 
[114] 
Induced rheumatoid arthritis, 
Osteoporotic rats via 
Streptococcal cell well (SCW ); 
(SC INJ) 
20 mg kg -1 day-1 
(SVA) 
 
SIM after SCW injection suppressed periarticular bone destruction 
& osteoclasts, cells/mm2 33.6 ± 2.4 vs.  43.3 ± 1.9 in SCW alone 
and SIM reduced the joint inflammation as well. 
Healthy animal model 
Thylin et al., 
2002 [69] 
Murine calvaria; 1) 
methylcellulose gel (GEL) vs 
(GEL-SIM) 3) polylactide 
membrane (MEM-SIM) (SC INJ) 
2.2 mg SIM per 50 µl 
gel and 50 µl of SIM-
GEL for injections 
MEM-SIM caused a highly significant increase in bone thickness 
(159% to 172%) and BA (144% to 180%) vs. gel controls. GEL-
SIM resulted in more bone (58% to 83%) vs. gel controls. 
Anbinder et al., 
2006 [115] 
Tibiae defect, rat (SC) 7 mg kg -1 day-1 Subcutaneously either way no significant bone repair was seen. 
Ayukawa et al., 
2009 [72] 
Tibiae defect, rat  (Transdermal 
INJ) 
0.1 mg mL-1 
Local application resulted in bone formation in bone defects with 
increase in BMP-2 and ALP at the early stage with no effect of 
OCN. SIM also suppressed osteoclasts with diminution of the 
RANKL gene expression. 
Koçer et al.,  
2014 [71] 
Femoral defect, mice (SC INJ) 
10 mg kg -1 day-1 
 
Significant increase in ALP, OCN and radiological features of new 
bone at defect site. 
Skoglund & 
Aspenberg et 
al., 2007 [116] 
Femoral fracture, mice a) SC INJ 
b) Systematic (implanted in 
scruff)or local deliverywith 
osmotic mini pump 
10 & 20 mg kg -1 day-1 
or 0.1 mg with osmotic 
mini-pump 
 
SC INJ showed no effects. Systematic delivery resulted with 
160% large force and local delivery with 170% large force at 
fracture site. 
Killeen et al., Fenestration defects in Molar 0.5 mg SIM + ALN after SIM-EtOH injections showed 2-3 fold  in bone width 
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2012) [117] roots, rats (SC) Alendronate (ALN, N-
BP; systemically) 
around the defect (0.93± 0.12 and 0.78 ± 0.11mm with early and 
late systemic ALN, respectively) vs. local SIM/ALN-CD 
preparations (0.32±0.10mm) or short-term SIM-EtOH injections 
(0.35 ± 0.10 mm). 
 
Table 2-5 Local delivery of simvastatin by incorporating in implantable biomaterial carriers. 
 
Year & Author Material Design Dosage Main Findings 
Osteoporotic model 
Yang et al.,  2012 
[73] 
Porous titanium implants 
coated with SIM-HA 
Tibiae defect, OVX 
Rat 
 
10
−6 & 10
−7
M 
 
Enhanced bone formation and osteointegration with 
improved bone-implant contact but no significant 
changes in between dosage. 
Chou et al., 2016 
[74] 
SIM -Biomimetic β-TCP 
with apatite coating 
Femoral bone, OVX 
Mice 
20mg in 4 mL of 
ethanol in 
scaffold 
Significant increase in new bone formation and 
mechanical strength for SIM- β-TCP-Apatite. 
Yang et al., 2014 
[118] 
Bovine serum albumin 
Femur and caudal 
vertebrae, OVX Rat 
5 or 10 mg 
In femur, significantly increased BMD, bone volume 
fraction (BV/TV), improved bone microstructural 
parameters and bone strength. In caudal vertebrae, 
significant increase in BV/TV, bone microstructures, 
and bone strength. 
Healthy animal model 
Polymer-based (Calvaria & load bearing: Mandibular, Tibiae & Femur) 
Pişkin et al., 2008 
[77] 
SIM-containing 
electrospun spiral-wound 
PCL scaffolds 
Rat calvaria defect 
20 μg 
SIM/scaffold 
Implant showed osseous tissue integration and 
significant mineralized bone restoration in calvaria 
defect. 
Stein et al., 2006 
[78] 
Methylcellulose 
gel/polylactic acid (PLA) 
membrane 
Rat Calvaria & 
Mandible defect 
0.1, 0.5, 1, 1.5 & 
2.2 mg day-1 
In calvaria, stimulated gene expression of pro-
collagen, fibronectin and matrix metalloproteinase-
13 (MMP13) related to collagen synthesis. In 
mandibular, 0.5 & 2.2 mg SIM  45%  BA vs. 
control gel. 0.5 mg ↓ inflammation as compared to 
2.2 mg SIM. 
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Wu et al., 2008 
[79] 
SIM loaded Polylactic 
acid/polyglycolic acid 
(PLA/PGA) copolymer 
carriers 
Sockets of right 
mandibular incisors 
1 mg 
SIM treated showed osteoinductive and anti-
resorption properties. At 12 weeks, Control and SIM 
treated both healed completely. 
Pauly et al., 
2009[119] 
Titanium wires coated with 
or without PLA with SIM 
Tibiae fracture, Rat 
3 μg/ implant & 
50 μg/implant 
Study showed osteoconductive behaviour of SIM 
while high dosage resulted in fracture healing with 
significant increase in torsional stiffness & maximum 
load. 
Pauly et al., 2012 
[120] 
SIM- polymer-only 
(poly(D,L-lactide)) coatings 
on the Ti implant 
Femur defect, Rat 5.5 & 90 μg 
No positive effects rather impaired the 
osteointegration between implant and defect after 8 
weeks. 
Zhu et al., 2010 
[121] 
SIM loaded PLA scaffold 
Radial defect, 
Rabbit 
50, 100 & 200 
mg per scaffold 
100 mg dosage showed best results with significant 
bone healing. 
Polymer-hydroxyapatite (HA) (Calvaria & Tibiae) 
Jiang et al., 2013 
[80] 
poly(lactic-co-glycolic 
acid)/hydroxyapatite nano-
ﬁbrous scaffold 
Poly(lactic-co-glycolic 
acid)/hydroxyapatite nano- 
fibrous scaffold 
Calvaria defect, Rat 8µg per defect 
Over 8 weeks ∼23.2% i.e. ∼116 µg of total loading 
(500 µg) was released. In PLGA/HA/SIM group, ALP 
activity was significantly higher and Bone defect was 
reduced by 10% vs. PLGA/HA group. 
Tai et al., 2013 
[81] 
SIM –poly(lactic-co-
glycolic 
acid)/hydroxyapatite 
(SIM/PLGA/HA) 
microspheres 
Tibiae fracture-
necrotic bone gap, 
Mice 
3 & 5 mg 
Low dosage showed callus formation, 
52eovascularisation and cell ingrowth in the grafted 
bone while high dosage resulted in cell growth in 
necrotic bone as well. 
Hydrogels (Calvaria & load bearing: Tibae, femur, parietal etc.) 
Zhou et al., 
2010[43] 
Injectable tissue- 
engineered bone (ITB) 
containing hADSCs and 
platelet-rich plasma gel 
(hPRP) 
Calvaria defect, 
Mice 
0.01,0.1, and 1 
μM 
SIM group induced bone formation 50% at 4 weeks 
higher than that of blank control  (negative), i.e. no 
implantation 
Sukul et al., 
2015[82] 
SIM-Gelatin nanofibrillar 
cellulose-β TCP scaffolds 
Calvaria defect, Rat 
0.25, 0.5 and 1 
µM 
In vitro, GNTS.5 (0.5 µM) showed the highest cell 
differentiation and maximum amount of bone 
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formation. In vivo, release pattern induced 
osteogenesis at the maximum level and enhanced 
bone formation. 
Rushinek et al., 
2014 [88] 
SIM - hydroxypropyl 
methylcellulose granules 
Tibiae defect, Rat 
70% w/w SIM per 
granule (49.4 ± 
17.7 mg per 
defect) 
Osteoid thickness, volume, mineral apposition rate 
and calcein labelling had significant increase yet 
trabecular bone had no significant effect on 
osteoblasts. 
Fukui et al., 2012 
[83] 
SIM-Gelatin hydrogel 
Femoral fracture, 
Rat 
25 μg 
Significant increase in angiogenesis and 
osteogenesis leads to bone healing. 
Rosselli et al., 
2014 [85] 
SIM - hydroxypropyl 
methylcellulose (HPMC) 
gel - Collagen sponge 
Femur cavity, Rat 
0.5 ml of SIM gel 
(SIM 1 mg / 
HPMC 0.5 ml) 
Significant increase in osteoblasts and fibroblast 
proliferation and marked bone formation. 
Moshiri et al., 
2015 [84] 
a) SIM powder b) Gelapin-
SIM 3D scaffold 
Femur cavity (2 
holes), Rabbit 
5mg per hole for 
powder and  
169.6mg per 
scaffold 
At 30 days, SIM powder and Gel-SIM scaffold 
resulted in newly woven ectopic bone. Gel-SIM: 
maturation and remodelling of new bone into cortical 
bone with higher bone volume, mineralization, 
elastic modulus, and contact hardness indicating 
osteogenesis, osteoinduction and osteoconduction. 
Oka et al., 
2013[122] 
SIM-Gelatin hydrogel 
Anterior cruciate 
ligament (ACL) 
reconstruction with 
tendon graft, Rabbit 
125µg SIM 
loaded in 250µg 
gelatin  hydrogel 
Aligned and layered cartilage in area of tendon-bone 
integration, Neovascularization was significantly 
increased (capillary density SIM, 112.0±6.9 vs. 
control, 72.0±5.8/mm2). Osteogenesis assessed by 
osteoblast density was significantly enhanced (SIM, 
495.3–32.9 vs. control, 272.0–28.3/mm2. 
Wong et al.,2003  
[86] 
Fibrillar Collagen sponge Parietal defect, Rat 
10 mg 
SIM/collagen 
sponge) 
308%  new bone growth with 1.68±0.48 mm2 of 
area vs. 0.4±0.28 mm2 in the control group. 
Bae et al., 
2011[87] 
Photo-cured hya- luronic 
acid hydrogels 
Parietal defect, 
Rabbit 
0.1 and 1 mg 
SIM 
Induced osteogenesis with new bone formation. 
Inorganic (Calcium sulphate and calcium phosphates) (Calvaria & load bearing: tibiae, femur etc.) 
Nyan et al., 2007 
[91] 
Calcium Sulphate (CS) Calvaria defect, Rat 
1 mg SIM: 60 mg 
CS 
After 8 weeks, significant increase in bone growth 
was seen in BA 1.15 ± 0.01 cm2 and BMC 79.48 ± 
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3.23 mg with intense soft tissue inflammation for first 
5 weeks. 
Nyan et al., 2009 
[92] 
α-TCP particles Calvaria defect, Rat 
0.01, 0.1, 0.25 & 
0.5 mg / 14 mg of 
α-TCP 
0.1 mg dosage stimulates bone regeneration (266% 
in 8 weeks).  At 8 weeks, defect closure 97.86 ± 
1.49 %, BMC 29.07 ± 1.11 mg and BMD 88.07 ± 
3.35 mg/cm2 were significantly. 
Nyan et al., 2010 
[123] 
α-TCP particles Calvaria defect, Rat 
0.1 mg / 14 mg of 
α-TCP 
In SIM group,  proliferation and migration of 
osteoprogenitor cells from the dura mater, new bone 
formation,  BMP-2 expression and upregulation of 
TGF-β1 was also observed on day 7-14. 
Rojbani et al., 
2011 [124] 
Particles of α-TCP, β-TCP, 
and HA 
Calvaria defect, Rat 0.1 mg per defect 
α-TCP showed a significant more bone formation 
and higher rate of degradation than β-TCP and HA. 
Ma et al., 2008 
[76] 
β-TCP collar Tibiae defect, Rat 
0.1, 0.9 or 1.7 mg 
per scaffold 
At 6 weeks: decrease in mineral apposition 
At 26 weeks: increase in fibrous tissue area fraction 
and higher bone area fraction though changes 
weren’t significant. 
Papadimitriou et 
al., 2015 [75] 
Inorganic bovine bone 
graft (BOS), & 
hydroxyapatite combined 
with calcium sulfate 
(HACS) 
Femur defect, 
Rabbit 
2mg 
BOS + SIM:  At 4 weeks, new bone formation, 
HACS + SIM: At 8 weeks higher rate of new bone 
formation 
Huang et al., 2014 
[125] 
Calcium Sulphate 
Ulnar bone defect, 
Rabbit 
0.5 mg per 
scaffold 
Significant new bone formation in ulnar defect due 
to SIM was comparable to BMP-2. 
Calcium Phosphate cements (CPCs) 
Yin et al., 2012 
[95] 
Hydroxyapatite (HA) 
macroporous CPCs 
Back muscles & 
trabecular bone, 
Rabbit 
1, 5 & 10 wt% 
At the defect site, new bone formation (1 wt %) with 
more area (7.4% ± 3.3%) vs. control (3.6% ± 1.4 
%;). BIC was higher (78.4% ± 23.5%) vs. control 
(54.3% ± 14.6%). 
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Chapter 3  
Design of calcium phosphate scaffolds with controlled 
simvastatin release by plasma polymerization 
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Abstract 
Calcium Phosphates (CaPs) have excellent bone regeneration capacity, and their 
combination with specific drugs is of interest because it allows adding new functionalities. In 
CaPs, drug release is mainly driven by diffusion, which is strongly affected by the porosity of 
the matrix and the drug-material interaction. Therefore, it is very difficult to tune their drug 
release properties beyond their intrinsic properties. Furthermore, when the CaPs are 
designed as scaffolds, the increased complexity of the macrostructure further complicates 
the issue.  
In this chapter we investigate the use of biocompatible plasma-polymers to provide a tool to 
control drug release from drug-loaded CaP scaffolds with complex surfaces and intricate 3D 
structure. Two different CaPs were selected displaying great differences in microstructure: 
low-temperature CaPs (Calcium-deficient hydroxyapatite cements, CDHA) and sintered CaP 
ceramics (β-Tricalcium Phosphate, β-TCP). The deposition of PCL-co-PEG (1:4) 
copolymers on CaPs was achieved by a low pressure plasma process, which allowed 
coating the inner regions of the scaffolds up to a certain depth. The coating covered the 
micro and nanopores of the CaPs surface and produced complex geometries presenting a 
nano and micro rough morphology which lead to low wettability despite the hydrophilicity of 
the copolymer.  Plasma coating with PCL-co-PEG on scaffolds loaded with Simvastatin acid 
(potentially osteogenic and angiogenic) allowed delaying and modulating the drug release 
from the bone scaffolds depending on the thickness of the layer deposited, which, in turn 
depends on the initial specific surface area of the CaP.  
 
Introduction 
Calcium Phosphates (CaP) are excellent candidates in bone replacement due to their 
similarity to the mineral phase of bone and potential resorbability [1, 2]. Their combination 
with different types of drugs allows providing them with additional functionalities, in addition 
to their excellent osteoconductivity and osteogenicity.  However, in CaPs a part of the 
loaded drug often remains trapped in the matrix [3, 4]. This could be partly solved by 
introduction of macroporosity to the material, by production of different kinds of scaffolds [5, 
6]. In any case – both in bulk materials as in scaffolds - the performance of these ceramic 
matrices as drug delivery systems is tightly linked to their inherent porosity and pore size 
distribution features, which is dependent on the fabrication method followed [3]. Thus, 
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whereas biomimetic calcium phosphate cements exhibit a high porosity, ranging from the 
nanometric to the micrometric scale, the porosity in sintered CaP ceramics tends to be 
micrometric in size.  
Thus, a common problem is that drug release cannot be tuned beyond their intrinsic 
capacity, which is related with their porosity. Therein, adapting the release profile to specific 
pathologies requiring a certain rate of delivery poses a problem. Coating of the material’s 
surface could be a solution. However, once the ceramic matrices are loaded with drugs, 
coating by conventional wet methods can lead to loss of drug from the material to the 
coating media.  
In those cases, a promising novel approach to tune the drug release kinetics can be found 
in low temperature plasma technologies. Low temperature plasma, herein plasma, can be 
defined as a particular state of a gas or mixture of gases containing a mixture of ions, free 
radicals, electrons, excited molecules, UV and visible radiation that preserves electrical 
neutrality. This reactive medium can modify the first nanometers of the surface of the 
material without altering its bulk properties. Roughly, the three main effects of plasmas on 
the surface of a material are: i) functionalization or grafting (covalent bonding of new 
chemical species); ii) etching (removal of surface material); and iii) thin film deposition 
(deposition of thin layers).  
These effects may be employed to tailor drug release; Recent works [7,8] have shown that 
surface functionalization of polyamide 6.6 fibers can improve the amount of anti-
inflammatories and lipolithic agents released due to improved interaction of the materials 
with the surrounding media.  
Another approach which can be used to slow down the drug release profile is by creation of 
thin films by plasma polymerisation on the surface of the materials, acting as barrier for its 
release. Coating by plasma polymerization refers to the deposition of polymer films due to 
the excitation of an organic monomer in the gas state and subsequent deposition and 
polymerization of the excited species on the surface of a substrate [9]. 
Few works have investigated plasma polymerization to produce an overlayer to control the 
release kinetics of drugs placed on the surface of solid carrier surfaces. Vasilev et al. have 
coated Vancomycin contained in nanoporous anodic aluminium oxide with allyllamine 
plasma layers [10]. In another work, quartz surfaces were employed as supports for a first n-
heptylamine plasma polymer layer, to allow suitable wettability of Levofloxacin which was 
subsequently coated with a second n-heptylamine layer [11]. Similarly, quartz surfaces were 
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employed as supports for model dye molecules (Methylene Blue) or anticancer agents 
(Cisplatin) and were plasma coated with multilayered biodegradable Poly caprolactone-co-
polyethyleneglycol (PCL-co-PEG) coatings [12]. Both authors have shown that by gradually 
increasing the barrier layer thickness with plasma polymerization deposition time, the 
amount of drug released diminished. In all cases, simple model surfaces have been 
employed.  
However, coating of complex surfaces in 3D scaffold structures and being able to fine tune 
drug release from them is far from being obvious. Therefore, it is the main aim of this 
chapter to show the potential of plasma polymerization in drug modulation from complex 
ceramic scaffolds for bone regenerative applications. These scaffolds were obtained by 
foaming of a calcium phosphate cement, and contained different levels of micro and 
nanoporosity, depending on the subsequent treatment applied, namely low-temperature 
setting to yield Calcium Deficient Hydroxyapatite (CDHA) or high-temperature sintering to 
produce β-Tricalcium Phosphate (β-TCP). Given the great differences on the surface texture 
of both ceramic materials, in the first stage, we investigated the deposition of biocompatible 
PCL-co-PEG polymer layers on 2D discs. Subsequently, the level of complexity was 
increased introducing 3D scaffolds, and the coating of the surface and the penetration of the 
plasma-polymers within the scaffolds was ascertained. To evaluate the possibilities of these 
layers on drug release, Simvastatin acid (SVA), was incorporated to the CaP scaffolds. In 
local drug delivery to the bone site from CaPs, different drugs are of interest [3]. SVA has 
shown potential action on bone and blood vessel formation [13-14], which is of clear interest 
in views of improving bone healing. Thus, to tailor the SVA release from the scaffolds 
plasma polymerisation of a biocompatible and biodegradable copolymer of PCL-co-PEG 
was evaluated as barrier layer in different conditions, and its potential effect on modulating 
the drug release kinetics was assessed.    
Experimental 
Materials 
ε-Caprolactone (ε-CL, Purity: 97%, MW: 114, Empirical formula: C6H10O2), and the cyclic 
esther monomer Diethylene glycol dimethyl ether (DEGME, Purity: 99.5%, MW: 134.17, 
linear formula: (CH3OCH2CH2)2O) were purchased from Sigma Aldrich, France and used in 
this study without further purifications. Simvastatin (≥97%, MW: 418.57, Sigma-Aldrich) was 
used as the precursor of Simvastatin acid (SVA) (1), which was prepared according to [15]. 
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α-TCP was used as starting material for the preparation of the powder phase of the cement, 
and was obtained by heating in a furnace (Hobersal CNR-58) in air, an appropriate mixture 
of calcium hydrogen phosphate (CaHPO4, Sigma Aldrich) and calcium carbonate (CaCO3, 
Sigma-Aldrich) at 1400ºC for 15 h followed by quenching in air. α-TCP powder was milled in 
an agate ball mill (Pulverisette 6, Fritsch GmbH) with 10 balls (d=30mm) for 15 min at 450 
rpm and blended with 2%wt of precipitated hydroxyapatite (PHA) (HA; BP-E341, Merck, 
Germany), which was added as a seed. The liquid phase employed in the preparation of 
cements consisted of a 2.5% solution of Na2HPO4 (Panreac) in MilliQ water, while the liquid 
phase used to prepare scaffolds was a solution of 1 wt% of Polysorbate 80, herein Tween80 
(Polysorbate 80, Sigma Aldrich, USA) in distilled water. 10 wt% Pluronic F-127 (Sigma 
Aldrich, USA) was blended with the solid phase in the preparation of the scaffolds.   
 
 Preparation of low temperature and sintered CaP ceramic discs and scaffolds 
CaP discs were used for the characterization of the polymer layer obtained. In the first 
place, CaP cements were prepared with a liquid-to-powder (L/P) ratio of 0.35 mL/g. The 
powder phase was mixed with the liquid phase in a mortar for about 1 min and then 
transferred into disc moulds of 2 x 15 mm. Samples were allowed to set in Ringer’s solution 
(0.9 % NaCl) for 7 days to obtain Calcium-Deficient Hydroxyapatite (CDHA) discs.  
To obtain β-Tricalcium Phosphate (β-TCP) ceramic discs, the CDHA samples were sintered 
in an oven (Hobersal), in air, by heating for 2.5 h up to 400ºC, and then for 2.20h up to 
110ºC where samples were maintained for 9 h. Cooling was achieved naturally.  
Calcium phosphate scaffolds were prepared by foaming, using a L/P ratio of 0.55 mL/g. The 
powder phase was a mixture of α-TCP containing 2 wt% of PHA and 10 wt% Pluronic F-
127. The liquid phase was a solution of 1%wt of Tween80 in water. The foams were injected 
into moulds (6 mm diameter x 12 mm height) and allowed to set as described. To obtain β-
TCP scaffolds, the CDHA scaffolds were sintered applying the same protocol used for the β-
TCP ceramic discs. 
(1) 
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Methods 
Plasma polymerization of PCL-co-PEG coatings 
PCL-co-PEG coatings were fabricated in a low pressure inductively excited radio frequency-
tubular quartz plasma reactor system (5 cm diameter, 40 cm length, base pressure of 3x10-
2 mbar). The schematics of plasma deposition setup and technical details of the process 
have been provided in earlier works [12, 16 - 17]. Briefly, the partial pressure ratio of the two 
monomers fed in the reactor was controlled by the flow rate of carrier gas (i.e. Ar, Air liquide, 
France), which was regulated and measured by electronic mass flow controllers (MKS 
instruments). The partial pressure in the reactor of ε-CL and DEGME exhibited linear 
correlations with the flow rate of argon gas and were comparable with each other [12]. 
Plasma co-polymerization of organic monomers was carried out on CDHA and β-TCP discs 
for the preliminary study on the layer characteristics, as well as on SVA-loaded 
macroporous CDHA and β-TCP scaffolds. For the current study, the total flow rate was 
varied from 20 to 25 standard cubic centimeter per minute (SCCM) by keeping the operating 
pressure constant at 0.5 mbar. Two operating modes were investigated to deposit the 
plasma coatings: Continuous Wave (CW) or Pulse Wave (PW).  
Copolymer coatings were deposited at 20W CW plasma for 20 min or 90 min followed by 
deposition of a copolymer at 1W PW plasma for 5 min to improve the surface wettability. 
The pulsed plasma discharge coatings were performed for 20 min, the peak power (Ppk) 
was 25W and the duty cycle (DC = (ton / (ton+toff), where ton and toff were the ‘plasma ON’ 
and ‘plasma OFF’ times respectively) was 4% to obtain the effective plasma power (Peff) 
which was 1W PW (ton = 4 ms and toff = 96 ms). After polymer deposition, the reactor was 
again evacuated to base pressure before the plasma polymerization system was vented to 
atmospheric pressure with air. 
 
Characterization of Plasma Polymerized Coatings 
X-ray Photoelectron Spectroscopy 
The chemical composition was analyzed by XPS with a SPECS (Germany) using an Al non 
monocromatic source XR50 (200W and 14 kV) with an analyzer Phoibos 150 MCD-9 with 
pass energy of 25eV, high resolution steps of 0.1eV, chamber pressure of 5.109 mbar and 
using a Flood gun FG15/40. Peak deconvolution was performed with CasaXPS software.  
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Surface Wettability Measurements 
Sessile drop contact angle values were measured using a video capture apparatus 
(Digidrop GBX-3S system, France). For each measurement, 6 μL of DI water droplets were 
dispensed onto the coated surfaces. Four measurements were carried out on each coating 
and resulting values were averaged.  
Scanning Electron Microscopy 
Surface topography of CDHA and β-TCP discs was studied by Field-Emission Scanning 
Electron Microscopy using a Jeol JSM-5000/5610 SEM. Samples were Pd-Pt-coated before 
SEM observation. Observations were carried out at 10 kV working voltage. 
Focus Ion Beam 
To ascertain the thickness of the plasma polymer layer deposited on the CDHA and β-TCP 
surface, Focus Ion Beam tomography (FIB, Zeiss Neon40) was performed. A 30 x 30 x 25 
µm parallelepiped was coated with Pt, cut in slices and FE-SEM pictures were taken.  
BET 
The Specific Surface Area (SSA) of the CaPs was measured by Nitrogen adsorption 
according to the Brunauer-Emmet-Teller (BET) method, (BET) in an ASAP 2020 
(Micromeritics). 
Mercury intrusion porosimetry 
Mercury Intrusion Porosimetry (MIP, AutoPore IV, Micromeritics, USA) was performed to 
determine the porosity and pore entrance size distribution within the materials. 
Drug incorporation 
CaP scaffolds were loaded with SVA by immersion in 200 μg SVA/ml solution (1 
mL/cylinder) during 2 h in the case of CDHA or 24 h in the case of β-TCP to achieve 
equilibration maximum impregnation. The CaP scaffolds were subsequently freeze-dried.  
Drug release experiments 
CDHA and β-TCP scaffolds loaded with SVA and plasma-coated as described were 
immersed in 3 ml of Phosphate Buffer Saline (PBS, pH=7.4) at 37ºC with continuous 
stirring. 350 μL of sample was withdrawn at different time points and replaced by 350 μL of 
fresh PBS. 
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The amount of drug released was obtained by measuring the release media collected at 
each time point by High performance liquid chromatography (HPLC) in a Shimadzu HPLC 
system. A mobile phase of Acetonitrile: 0.1% Phosphoric acid at a ratio of 50:50 (v/v), at a 
flow rate of 0.8 ml/min was passed through a C8 column (Shim-pack, Shimadzu). An 
injection volume of 10 μl of the release sample was measured by photodiode array (PDA) at 
λmax = 238 nm.  
Results 
Characterization of the plasma polymer layer 
In this work two CaP materials were employed: CDHA obtained by low-temperature setting 
of a calcium phosphate cement, and β-TCP ceramic, obtained by sintering the former at high 
temperature. Both kinds of materials were subjected to low temperature plasma 
polymerization of a biocompatible and biodegradable copolymer mixture of PCL-co-PEG 1:4. 
As shown in Figure 3-1 a) and b) the microstructure of the two substrates was significantly 
different, just as the SSA, which was much higher for CDHA (SSACDHA = 20m2/g) than for β-
TCP (SSAβ-TCP= 0.60m2/g). The scanning electron micrographs obtained on the surface of 
the materials (Figure 3-1) revealed the typical microporous structure of β-TCP with its 
sintering grains, while CDHA consisted of entangled platelet-like crystals derived from the 
dissolution-precipitation responsible for cement hardening.   
In the first place it was of interest to characterize the plasma polymer layer deposited with 
CW discharge on the two materials at the longest time evaluated of 90 min.  
FTIR measurements were performed on material obtained from the top surface of the CaPs. 
All materials tested display phosphate vibrations (Supplementary material 1), where the 
wide, strong bands correspond to ʋ3 stretching (944–1122 cm-1) and ʋ4 bending (545–640 
cm-1) typical of calcium phosphates or apatites [18, 19]. On the plasma coated materials, β-
TCP-90CW and CDHA-90CW, different bands indicated the presence of the coating, which 
were more evident in β-TCP-90CW. In particular, bands were recorded at 1716 cm-1, which 
were attributed to the C=O stretching vibrations of the ester carbonyl group from PCL; C-H 
stretching bonds were centered at 2950 and 2870 cm-1. The C-H bending was observed at 
1380 and 1460 cm-1. The weak absorption band at 3430 cm-1 was assigned to terminal -OH 
groups in the coatings which indicated the presence of polar groups incorporated into the 
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copolymer structures [12], as -OH groups from hydroxyapatite usually appear at higher 
bending energies 3567 cm-1 [20].  
 
Figure 3-1 SEM images of the different materials before (top images) and after plasma polymerization 
with PCL-PEG (4:1). β-TCP (a), CDHA (b), β-TCP-90CW (c), and CDHA-90CW (d). FIB-SEM cross-
section of the surface of both polymerized materials β-TCP-90CW (e) and CDHA-90CW (f). 
Modifications on the surface energy and surface chemistry were recorded by means of static 
contact angle and XPS measurements, respectively (Table 3-1). Both untreated materials 
were very hydrophilic and due to their inherent porosity absorbed water very fast, not 
allowing contact angle measurement. However, after plasma polymerization water was no 
longer absorbed and the contact angle rose to hydrophobic values above 110° in both 
materials, showing the highest values for β-TCP-90CW. 
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The surface chemistry of the untreated CaPs as measured by XPS correlated adequately 
with their nominal composition. The polymerization treatment with PCL-co-PEG led to a 
decrease in the O/C ratio, showing the presence of polymer on the surface. The layer 
deposited in the case of β-TCP-90CW was thicker than the detection limit of the XPS (10 
nm), as Ca and P species were no longer detected by the technique. In the case of CDHA-
90CW both Ca and P were detected but in very small quantities which could indicate that the 
CDHA is not completely covered by the plasma polymer. However, such low values 
measured can be also ascribed to background noise, so these particular Ca and P values 
presented in Table 3-1 should be taken with precaution.  
Table 3-1 Static contact angle and X-ray photoelectron spectroscopy (atomic concentration and 
atomic ratio) of the different CaP discs either untreated of after plasma polymerization. 
  
θs (º) 
Atomic concentration % Atomic ratio 
  C1s O1s Ca2p P2p O/C Ca/P 
β-TCP * 14.83 53.61 19.54 11.98 3.61 1.63 
β-TCP-90CW 121 ± 2 76.99 23.01 -- -- 0.29 -- 
CDHA * 10.51 57.81 19.05 12.62 5.50 1.51 
CDHA-90CW 115 ± 1 76.09 23.75 0.12** 0.04** 0.30 --** 
*Not possible to measure contact angle due to too fast water absorption.  
** Too small quantities to be taken with precaution. 
Decomposition of C1s core level spectra of the plasma polymerized samples (Table 3-2, 
Figure 3-2) showed a profile clearly including 3 peaks corresponding to: C-C and/or C-H 
285.00 eV, which were the most abundant groups, followed by C-O at 286.63 eV (in ether  
groups) and C=O 288.63 eV (probably carboxylic/ester groups). The presence of these 
bonds reflected the presence of the copolymer PCL: PEG 1:4. The contribution of the C=O 
peaks was slightly lower in β-TCP than in CDHA, in both cases up to around 6%.   
Table 3-2 C1s peak deconvolution. 
 Atomic percentage 
 C1s 
 285.00  eV 
C-C,C-H 
286.63 eV 
C-O 
288.64 eV 
C=O 
β-TCP-90CW 55.7 37.9 6.4 
CDHA-90CW 51.5 42.4 6.1 
 75 
 
 
 
As displayed in the SEM images (Figure 3-1), after plasma polymerization with PCL-co-PEG 
the structure of the CaPs was covered by a layer following the original patterns of the 
materials, forming bush-like structures on β-TCP-90CW and worm-like structures for CDHA-
90CW.  
Transversal sections obtained by FIB revealed that, as anticipated by XPS measurements, 
the plasma polymer deposited on β-TCP-90CW was thicker (1496 ± 162nm) than that 
deposited on CDHA-90CW (628 ± 61 nm), in the same experimental conditions. 
Once demonstrated that it was possible to produce PCL-co-PEG coatings on the surface of 
flat CDHA and β-TCP discs, the possibility to obtain polymer layers on the surface of 3D 
macroporous samples, herein designated as CaP scaffolds, was assessed. As shown in the 
transversal section of a CaP scaffold (Figure 3-3 left), both β-TCP and CDHA scaffolds 
contained macropores of 80 μm of pore entrance size (Figure 3-4), with a smaller volume of 
pores around 2 μm corresponding to the distance between sintering necks / crystal 
aggregates.  
Figure 3-2 X-ray Photoelectron Spectroscopy C1s peak deconvolution, of (a) β-TCP and (b) 
CDHA with PCL-co-PEG (1:4) plasma coating 90CW. 
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Figure 3-3 Scanning electron micrographs of transversal sections of β-TCP and CDHA scaffolds after 
90 min CW plasma polymerization at different depths. Views of the surface of pores found on the top 
surface layer (top image), at a depth of 550 mm, and at 1500 mm (lower image). 
 
The plateau at the nanoscale range is only present in CDHA scaffolds and corresponds to 
intercrystal distance. The total porosity was of 81.5% for β-TCP and of 82.2% for CDHA. 
Plasma polymerization for 90CW min showed the same bush-like and worm-like structures 
in the pores located at the top surface of the samples (Figure 3-3, right). In addition, it was 
observed that for β-TCP, the plasma process evaluated here was capable of depositing 
PCL-co-PEG coatings up to a depth of 550 mm by diffusion through the interconnected 
macropores of the material. This was not visible for CDHA samples, where the coating was 
restricted to the outer surface. 
Drug loading and release 
CaP Scaffolds were drug-loaded by immersion in a solution containing SVA. SVA showed 
high affinity for CDHA as high loadings of 168 μg/scaffold were obtained in only two hours  
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 (Table 3-3), which accounts for 84 ± 6% loading efficiency. As β-TCP scaffolds displayed 
lower affinity they were allowed 24 h to equilibrate in the SVA solutions. Anyhow, the 
loading efficiency was much lower (9 ± 2 %) so the quantity of drug loaded in β-TCP was of 
18.78 μg.  
  
 
Table 3-3 Simvastatin acid loaded and final amount released (11 days) from CDHA and b-TCP 
scaffolds with different plasma polymerization times. 
 
Samples Qloaded (μg) Qreleased (μg) 
β-TCP-SVA 18.8 ± 3.7 18.4 ± 0.4 
β -TCP-SVA-20CW 18.8 ± 3.7 0.0 ± 0.0 
β -TCP-SVA-90CW 18.8 ± 3.7 0.1 ± 0.1 
β -TCP-SVA-20PW 18.8 ± 3.7 1.3 ± 0.1 
CDHA-SVA 168.1 ± 12.9 27.6 ± 11.7 
CDHA-SVA-20CW 168.1 ± 12.9 2.5 ± 2.5 
CDHA-SVA-90CW 168.1 ± 12.9 4.7 ± 0.7 
CDHA-SVA-20PW 168.1 ± 12.9 2.6 ± 2.6 
Figure 3-4 Pore entrance size distribution of β-TCP and CDHA obtained by Mercury 
Intrusion Porosimetry. 
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The drug release pattern for the SVA-loaded β-TCP and CDHA either untreated or after 90 
min of CW plasma coating is shown in Figure 3-5. Despite these loading diferences, the 
amount of drug released was very similar between the untreated β-TCP and CDHA 
scaffolds.  Over nearly 2 weeks (284 h) both untreated materials showed a progressive 
release, while the coated samples dislayed different behavior: β-TCP-SVA-90CW did not 
show any drug release along 2 weeks of experiment, while in the case of CDHA release 
was initially blocked, delayed for the first 2 h, and release progressed slowly afterwards.  
 
Once it was established that the plasma coatings were effective in blocking drug release, shorter 
treatment times and pulsed mode depositions were evaluated. All conditions evaluated completely 
blocked SVA release from β-TCP scaffolds. On the contrary, CDHA scaffolds coated with shorter 
Figure 3-5 Cumulative release of SVA in (%) from β-TCP (a) or CDHA (b) scaffolds either untreated 
of after 90 min coating in continuous wave mode with hypothesis on the possible phenomena taking 
place (below). 
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polymerization times of 20 min in continuous wave mode (Figure 3-6 a) displayed controlled release 
properties over the course of the experiment. Plasma polymers produced in pulsed wave mode 
showed to be more efficiently blocking the surface in 20 min than CW polymers (Figure 3-6 b), as 
release was delayed for 5 h and progressed slowly afterwards.  
 
Figure 3-6 Release pattern for SVA from CDHA scaffolds at (a) different treatment times with 
continuous wave mode (CW) or (b) different power supply mode being either continuous (CW) or 
pulsed (PW). 
Discussion 
To overcome the intrinsic limitations of CaPs to regulate drug release, this paper focuses on 
the use of biocompatible plasma-polymers to provide a tool to control drug release from 
drug-loaded CaP scaffolds with very complex surfaces and intricate 3D structures. One 
advantage of using a dry method such as plasma lies in avoiding, for instance, any ion 
dissolution of the calcium phosphates and thus conserving intact their initial properties. If the 
material has already been loaded with drugs, coating them is a complicated issue, as any 
contact with processing solutions would lead to dissolution/diffusion of the drugs and thus 
loss active principle from the biomaterial.  
In this work, it has been shown that plasma polymers (PCL-co-PEG) can be deposited on 
the surface of CaP cements and ceramics with very different surface features. As shown by 
the IR spectra (Figure 3-1), the bands corresponding to C-H, C-O and OH confirm the 
formation of a polymer layer on the surface of the ceramics. The thickness of this polymer 
layer is variable depending on the material used, i.e.  β-TCP ceramics or CDHA cements 
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which have different morphologies and specific surface area (SSA). This was confirmed 
both by XPS (Table 3-1), in which the Ca and P species were not detecTable – or hardly -  
after the CW plasma polymerization treatment for 90 min, and also by SEM-FIB (Figure 3-
2), which allowed measuring the thickness of the layers. Thus, β-TCP showed a layer which 
was two times thicker than the one deposited on CDHA in the same conditions. This can be 
attributed to the great differences in SSA between both materials (CDHA has 33 times 
higher SSA than β-TCP), which is related to their structure, consisting in CDHA platelet-like 
crystals in one case, and flat porous structures typical of sintered materials in β-TCP.  The 
thickness of the layer obtained by CW plasma discharge for 90 min was much larger than 
that recorded in previous works [12], mainly due to the longer treatment times employed. 
The thickness of the coating (1.49 ± 0.16 and 0.63± 0.06 μm on β-TCP and CDHA 
respectively) led to important changes in the surface topography of the CaP materials, 
leading to the formation of bush or worm-like structures. This change in surface morphology, 
together with the change in the chemical nature of the surface is expected to result in 
significant changes in the in vitro and in vivo biological performance of the material [9], 
which will have to be further investigated.  
The chemical structure of β-TCP and CDHA is Ca3(PO4)2, and Ca9(HPO4)(PO4)5(OH)2 
respectively, with a theoretical Ca/P ratio of 1.5 for both compounds [21]. None of the 
materials itself contains carbon, so its presence on the surface of the samples (Table 3-1) 
indicates an alteration of the surface chemistry, which could be ascribed to contamination by 
adsorbed hydrocarbons. The PCL-co- PEG 1:4 plasma coatings (90 CW) deposited on the 
surface had a 0.3 O/C ratio in both β-TCP and CDHA, which was close to that of Bhatt et al. 
[102] (0.36 O/C), who employed different deposition conditions (mainly treatment time and 
substrates employed) (Table 3-1). Moreover, the coatings led to a significant change in the 
wetting properties of the materials; both CaPs were initially hydrophilic, with fast water 
absorption through the pores of the materials. After plasma polymerization these relatively 
low O/C ratios, together with blocking of the surface porosity, raised the surface 
hydrophobicity of the materials, which displayed contact angles between 115° and 121°. 
The high roughness of the materials, generated in the growth of the plasma polymer on the 
intricate crystalline structures of the CaPs must also be related to these considerable 
differences in the wettability measurements. 
In the second part of the work, 3D CaP scaffolds made of β-TCP or CDHA were studied. 
These are the macroporous counterparts of the β-TCP and CDHA evaluated in the first part 
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of the work, thus preserving their microstructure (Figure 3-1a and b) but with additional 
interconnected macroporosity (Figure 3-3 left). The advantage of introducing macroporosity 
to CaPs is envisaged as a method to facilitate bone ingrowth not only from the external 
surface but throughout the bulk of the material [22]. This would accelerate its resorption and 
transformation into newly formed bone tissue [23]. It has also been shown that 
macroporosity is relevant for drug delivery, as it allows improving fluid flow throughout the 
material [5]. 
In the 3D treatment of the macroporous CaP scaffolds it was shown here that the plasma 
polymer coating can be performed successfully on the materials, and that the 
interconnections between the macropores allow the penetration of the plasma polymer 
inside the scaffold (Figure 3-3). This is particularly evident in the case of β-TCP, where the 
characteristic bush-like structures can be observed both on the surface, and inside pores of 
the scaffold down to a depth of 550 μm (Figure 3-3).  The higher SSA of CDHA was 
probably related to the fact that the coating layer was restricted to the top surface of the 
CaP scaffolds, and no penetration was observed by SEM, as possibly all available monomer 
was already consumed in the coating of the wider surface. 
In the subsequent steps, the drug release of the plasma-coated scaffolds was evaluated. 
Simvastatin acid (SVA) was incorporated to the CaP scaffolds. Simvastatin is a commonly 
used cholesterol-lowering drug which has been shown to stimulate osteogenesis locally 
through an up-regulation of BMP-2 expression [24] and it has also been related to dose-
dependent improved angiogenesis [25]. Enhancing blood vessel growth within the scaffolds 
is of interest with views on promoting scaffold resorption and bone regeneration. 
The adsorption of SVA, which is a hydrophilic drug (eq. 1), was much favoured in CDHA 
scaffolds than in β-TCP (Table 3-3). This is reflected in drug loading of β-TCP being only 
11% of that of CDHA – even after β-TCP samples allowed to equilibrate with the loading 
solution for 24 h in comparison to 2 h for CDHA scaffolds. As both kinds of scaffolds have 
very close porosity around 82%, this difference can probably be attributed to the higher SSA 
of CDHA but also to its different chemistry, which can probably allow for the creation of 
hydrogen bonds with SVA.  
Drug release patterns were significantly modified by the PCL-co-PEG plasma coatings 
deposited (Figures 3-5 and 3-6). On the one hand, uncoated β-TCP scaffolds showed a 
continuous progressive release for the first 5 h where 98% of the initial drug loads was 
released. After 3 days the drug in the media started degrading (shown by a decrease of the 
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measured drug in the media) (Figure 3-5a). None of the β-TCP scaffolds plasma coated 
with the PCL-co-PEG in different conditions showed any SVA release in the evaluated 
timeframe of 11 days (Data not shown - Scheme shown in Figure 3-5a). This is indicative of 
the lack of diffusion of SVA through the thick plasma layer deposited on the β-TCP, shown 
to be much thicker than that of CDHA in the 90 CW coated samples. It is important to recall 
that the amount of SVA loaded into β-TCP is an order of magnitude lower than that of 
CDHA, so even thinner coatings of 20CW (Supplementary material 2) are able to block 
release from β-TCP.  
In contrast, untreated CDHA scaffolds showed continuous release for more than 10 days, 
although the amount released was only around 16 % of the initial SVA loading (Figure 3-5b). 
The 90 CW PCL-co-PEG layer on the drug-loaded CDHA scaffolds was three times thinner 
than that of β-TCP. Initially (first 1.5h) it blocked SVA release and subsequently allowed its 
slow diffusion along the timeframe of the experiment. Shorter treatment times of 20 min 
(CDHA-SVA-20CW) presented the same profile (Figure 3-6a), and though release started 
from the beginning of the experiment, the rate of release was slowed down with respect to 
the untreated CDHA scaffolds. This is in agreement with a previous work, where Bhatt et al. 
[12] showed that by gradually increasing the barrier layer thickness with longer plasma 
deposition times, the amount of a dye released was reduced.  
In parallel, the mode of deposition clearly affected the drug release, as only 20 min of 
treatment in pulsed mode (CDHA-SVA-20PW) were able to block the release for the initial 5 
h, allowing afterwards for sustained release (Figure 3-6b).  This is most probably related to 
a lower extent of monomer fragmentation achieved by pulsed discharges, with higher 
retention of ether functional groups [26, 27]. Plasma phase fragmentation plays an important 
role in determining the deposition rate and surface chemistry of the deposited film and 
depends on the kind of monomer [28].  
The drug delivery matrices developed in this work constitute complex structures, which 
combine: i) a highly porous (macro, micro and nanoporous) non-degrading bulk [3] which 
was shown to release drugs (i.e. antibiotics) through complex mechanisms following non-
Fickian diffusion [5] with ii) a biodegradable plasma polymer coating. The mechanisms 
involved in drug release from this kind of coatings on flat surfaces were shown to range from 
zero-order to non-Fickian diffusion as the coating thickness increased [12].  Thus, the drug 
release in the developed dosage forms is expected to be ruled by the coating until it is 
completely degraded, followed by diffusion from the CaP matrix afterwards.  
 83 
 
Conclusions 
This work has allowed demonstrating that it is possible to fine-tune drug release from 3D 
ceramic scaffolds (CDHA & β-TCP) with different and very complex surface textures by a 
dry plasma polymerization process by employing biocompatible plasma polymers, 
depending on the treatment conditions. The thickness and structure of the PCL-co-PEG 
(1:4) polymer layer obtained is highly dependent on the texture of the materials, in particular 
on its SSA.  Thicknesses of up to 1.4 μm were obtained on β-TCP, and the plasma 
polymers were able to penetrate the macroporous structure of 3D calcium phosphate foams, 
up to a certain depth. The topography and chemistry of the materials were significantly 
modified by the coatings which led to nano-rough structures which could explain the low 
wettability measured on the materials.   
Simvastatin acid (SVA) was incorporated to the calcium phosphate scaffolds of β-TCP and 
CDHA as osteogenic and angiogenic drug, and the plasma coatings were useful to 
modulate the drug release: thicker PCL-co-PEG layers acted as barriers on β-TCP foams 
impairing SVA release throughout the whole release experiment (11 days), while on CDHA 
the presence of thinner polymer layers – due to its much higher SSA - allowed for the 
diffusion of the drug, leading to progressive and controlled drug release with respect to the 
uncoated biomaterial. On CDHA, longer treatment times (90 min in continuous wave plasma 
discharges) implied initially blocking of release followed by a slow release pattern, while 
shorter times (20 min) allowed a slow, controlled release. Pulsed wave plasma discharges 
allowed efficiently depositing plasma polymer layers which could initially block the release, 
in shorter times (20 min). Thus, the plasma coatings evaluated have shown to be useful 
tools for the tuning of drug release from bone biomaterials, allowing to produce ceramic 
dosage forms combining delayed release, followed by controlled delivery of drugs.  
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Supplementary material 1 
 
Figure 3-S1. IR-ATR spectra of the CaP materials without and with 90CW polymer layer (a) β-TCP 
and (b) CDHA. 
Supplementary material 2 
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Figure 3-S2. FIB-SEM cross-section of the surface of both PCL-co-PEG (4:1) polymerized materials 
(a) β-TCP-20CW and (b) CDHA-20CW, and (c) evolution of the coating thickness in nm depending on 
the polymerization time. 
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Chapter 4  
Effect of plasma polymerization coating of tricalcium 
phosphate ceramics on antibiotic delivery and biological 
performance 
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Abstract 
One of the treatments for recurrent or complicated osteomyelitis is by local antibiotherapy 
mediated by suitable bone grafts. β–Tricalcium Phosphate (β–TCP) bioceramic is a 
resorbable osteogenic bone graft. Its microporosity allows for incorporation of drugs, but a 
too fast release is often obtained. Complex strategies have been explored to obtain 
controlled drug release. In this chapter, plasma polymerization of a biocompatible polymer 
was investigated on -TCP. PEG-like polymer coatings of different thickness were deposited 
on microporous β-TCP loaded with antibiotics. A highly hydrophobic surface was obtained 
despite the hydrophilicity of the PEG-like layer, which was associated to the roughness of 
the β-TCP substrate. The bioceramics nevertheless retained their suitable biological 
behavior with regard to human osteoblast cells. The microbiological activity of the antibiotics 
was preserved, and the coatings reduced the total amount of drug released as a function of 
the increasing plasma treatment time. 
Introduction 
Osteomyelitis is a bone infection. It can spring from different causes: i) from spreading of 
bacteria originating from an infection elsewhere in the body, ii) through an open wound over 
a bone or iii) after the exposure of bone to bacteria during a surgery or an injection around a 
bone. The most usual treatments involve administration of antibiotics, but sometimes 
surgery may be necessary, and whenever bone is damaged it requires removal and 
replacement with a bone graft [1]. Systemic antibiotic regimes are used for four to eight 
weeks depending on the pathogenic bacteria and the response of the patient. But with long 
delays in diagnosis or treatment, significant bone damage, or if the initial treatment is not 
effective, patients are more prone to reoccurrence and the condition can become chronic 
and difficult to eradicate [2], [3].  
The delivery and maintenance of therapeutic levels of antibiotic at the site of infection can 
be achieved by using implants or carriers that release antibiotics locally; these have 
significantly improved the treatment of osteomyelitis [4]. Many local antibiotic releasing 
systems have been developed in recent years, and several are available for clinical use, 
such as polymethylmethacrylate (PMMA) beads, collagen, apatite-wollastonite glass 
ceramic blocks, hydroxyapatite blocks, polylactide/polyglycolide implants, and polylactate 
polymers [3], [5]–[7] Among these PMMA rosary beads impregnated with gentamicin have 
been often employed in the clinics, but they have several disadvantages, especially the 
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need to remove the foreign material surgically under general anesthesia [5], [6], [8]–[10].  
An ideal local carrier should be biocompatible and biodegradable, and in applications 
requiring bone substitution, it should be resorbable and able to promote bone formation. 
Many calcium phosphates (CaPs) have been widely employed as bone grafts and many of 
them are in the market. Among them, β–Tricalcium Phosphate (β–TCP) is an interesting 
bioceramic obtained at high temperatures with higher solubility than i.e. Hydroxyapatite and 
that has been widely employed in reconstructive surgery [11]due to its resorbability and 
ability to promote new bone formation [12]–[14].   
β-TCP has been evaluated as drug delivery system of different drugs. For example in the 
release of gentamicin, fast release was obtained in the first day and different strategies, 
more or less complex were evaluated to control this release [15]. Different works have relied 
in producing composite materials from β-TCP or other CaPs and biocompatible polymers 
(such as chitosan, gelatin, etc.) [16], [17], to improve different features of the material, 
among which to modulate drug release from the matrices. However, this approach usually 
involves complex processing stages. Plasma polymerization is a versatile technique for the 
deposition of films with functional properties suitable for a wide range of applications [18], 
[19]. Although plasma polymerization is a well-studied field, its application to bioceramics is 
rather recent. In a recent work, we proposed plasma polymerization of a hydrophilic PEG-
like layer as a dry method allowing treating -TCP and slowing down the release kinetics of 
an antibiotic [20]. However, the coatings produced by plasma polymerization led to very 
hydrophobic surfaces. This change in wettability could have a critical impact on the 
biological behavior of these bioceramics.  
In this chapter, we aim at investigating in-depth the origins of this unexpected 
hydrophobicity, with a particular focus on its effects on biological behavior. Therein, -TCP 
has been subjected to plasma polymerization to obtain PEG-like coatings, by using single 
and multi-step coatings, and the modified surfaces have been characterized. To ascertain 
the barrier effect of the coatings developed, the release of two different antibiotics 
(gentamicin and ampicillin) has been evaluated from these bioceramics, and their 
microbiological behavior has been studied after the plasma polymerization process 
undergone by the samples. 
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Experimental  
Materials 
Calcium hydrogen phosphate (CaHPO4, Sigma-Aldrich C7263) and calcium carbonate 
(CaCO3, Sigma-Aldrich C4830) were used as raw materials for the synthesis of  β–
Tricalcium Phosphate (β-Ca3(PO4)2, β–TCP). Sodium phosphate dibasic (Na2HPO4, Sigma-
Aldrich) was used in solution as accelerant in the synthesis of calcium deficient 
hydroxyapatite (CDHA) used as a precursor of β–TCP. Ampicillin sodium salt (371.39 g/mol; 
50mg/ml in water), and Gentamicin sulphate (477.6 g/mol, 50mg/ml in water) provided by 
Sigma-Aldrich were selected as antibiotics for loading β–TCP ceramics (Figure 4-1). 
                         
(a)                                                                (b) 
 
Figure 4-1 Chemical structure of ampicillin sodium salt (a) and gentamicin sulphate (b). 
 
Diethylene glycol dimethyl ether (Diglyme, anhydrous, 99.5%, Sigma Aldrich) 
(CH3OCH2CH2)2O was used as precursor for plasma polymerization. Phosphate buffer 
saline (PBS), pH 7.4, was prepared from PBS Tablets (Gibco, LifetechnologiesTM, UK) and 
Milli-Q® deionized water. Agar bacteriological (Scharlau S.A., Spain) and Brain Heart 
Infusion Broth (BHI Broth) (Scharlau S.A., 02-599, Spain) were used to prepare the 
bacteriological culture media of Staphylococcus aureus (S. aureus), (Culture Collection 
University of Göteborg (CCUG 15915), Sweden). 
 
β-TCP synthesis 
Microporous β–TCP discs were obtained by thermal treatment of calcium deficient 
hydroxyapatite (CDHA), which was in turn obtained through the setting reaction of an α–
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TCP calcium phosphate cement. α–TCP was obtained by solid state reaction of a 1:2 molar 
mixture of calcium hydrogen phosphate and calcium carbonate at 1400 ºC. A cement was 
produced by blending α–TCP with a solution of sodium phosphate dibasic at 2.5% (w:w) at 
liquid to powder ratio of 0.65. The mixture was put in a disc-shaped mold and allowed to set 
immersed in water for 7 days to obtain CDHA, as described in [21].  The former discs were 
sintered at 1100 ºC to obtain microporous β–TCP discs of 2 mm thickness × 12 mm ø. This 
allowed obtaining a 100% -TCP material, according to DRX (not shown). 
Plasma polymerization 
Plasma polymerization of β–TCP discs was performed using low-pressure radio-frequency 
plasma (13.56 MHz) (Standard Femto Plasma System, Diener, Germany) with a cylindrical 
glass chamber. Diethylene glycol dimethyl ether (Diglyme, anhydrous, 99.5%, Sigma 
Aldrich) was used as source of ethylene oxide monomers to obtain a PEG-like coating on 
β–TCP [22]. Unloaded or antibiotic-loaded β -TCP discs were placed in the center of the 
reactor. To enhance the polymerization process a short surface activation step with O2 (5.0 
sccm, 0.40 mbar, 150 W) was performed for 60 s. The subsequent polymerization process 
consists in introducing Diglyme in the plasma reactor by bubbling a carrier gas (Ar) through 
the liquid monomer. The polymerization treatment performed in continuous mode (15 sccm, 
1.70 mbar, 150 W) for 10 min is labeled as single polymerization (SP10). Repetition of the 
polymerization  cycle in the same conditions described, without removing the samples from 
the reactor was named designed double (DP), triple (TP) or quadruple (QP) polymerizations 
were performed on each side of the β–TCP materials, and the corresponding samples were 
referenced as DP10, TP10 and QP10 respectively (Figure 4-2). 
Surface topography 
Topography of untreated and plasma polymerized β–TCP discs were studied by Scanning 
Electron Microscopy using a Zeiss Neon 40 cross-beam workstation with Gemini SEM 
column for sample observation. Samples were C-coated before SEM observation. 
Observations were carried out at 5.0 kV working voltage. Coupled-Energy-Dispersive X-
ray spectroscopy (EDX) equipment (INCAPentaFETx3 detector, 30 mm2, ATW2 window) 
was also used for in situ elemental analysis of the surface of a cross-section of plasma-
polymerized β–TCP to determine the depth of the effects of plasma treatment on the 
surface of the bioceramic materials. 
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Figure 4-2 Scheme of the experimental layout employed to obtain PEG-like coatings on β-TCP discs. 
Low pressure plasma: 1st activation of the surface by O2 plasma and 2nd plasma polymerization Ar as 
carrier with Diglyme monomer, with 10 min sequential treatments named as single polymerization 
(SP10), double polymerization (DP10), triple polymerization (TP10) and quadruple polymerization 
(QP10). 
Wetting properties 
Determination of the wettability of the β–TCP surfaces, to compare the untreated with the 
PEG- coated ceramics by plasma polymerization was done by static and dynamic contact 
angle measurements. A Contact Angle System OCA15 (Dataphysics, Germany) was 
used with the SCA20 Software (Dataphysics, Germany) to analyze the images acquired 
with a CCD. In static, 10 µL water droplet were deposited on the β–TCP surface and in 
dynamic, volume changes continuously. Measurements were carried out on the plasma-
polymerized side of the samples. In this study, a minimum of 5 replicates of each kind of 
treatment were carried out. 
Dynamic contact angles were calculated as follows: Advancing contact angles were 
measured by increasing the volume of the water drop, until the contact angle remained 
constant. Receding contact angles were measured by decreasing the volume of the drop 
until the contact angle value remained constant and the solid/liquid interface started to 
decrease. Values reported result from the average of at least 6 replicates measured in 
independent samples. 
The contact angle hysteresis was calculated as the difference between dynamic advancing 
and receding contact angles, according to eq. 1: 
∆=  adv−  rec       (eq.1)  
Chemical characterization 
To determine the chemical composition of the surface of bare and treated β–TCP samples 
and assess the influence of plasma polymerization, XPS experiments were performed with 
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a ESCALab MKII spectrometer by Vacuum Generators using non-monochromatic Al-Kα 
(photon energy 1486.6 eV) in normal emission mode (i.e. photoelectrons were detected 
along the surface normal of the samples). Survey spectra were recorded at reduced energy 
resolution at a pass energy of 50 eV, while the detail spectra of C1s, Ca2p, Ca2s, P2p, P2s and 
O1s were recorded at a pass energy of 10 eV. For estimating the distribution of elements in 
terms of at-% the intensity of the photoemission (as obtained after background correction) 
were weighted with the photoemission cross sections. The relative error associated to the 
XPS measurements is about 0.5%. 
Fourier Transformed Infrared Spectra were recorded using a FTIR Nicolet 6700 in the 
transmittance mode, (128 scans and resolution 1 with data spacing 0.482cm-1). Si wafer 
were used as the substrate instead of β–TCP disc for the FTIR measurement. 
Ampicillin and Gentamicin loading of β–TCP 
Loading of ampicillin and gentamicin was done prior to plasma polymerization, by soaking 
the β–TCP discs in 1.0 mL of 4.0% aqueous drug solution at 100 r.p.m. and 24 - 27 ⁰C during 
30 min, by complete immersion of the sample. Samples were dried at 37 °C for 24 h prior to 
release studies. 
Drug release experiments 
Ampicillin and gentamicin release experiments were performed using untreated and plasma-
polymerized β –TCP discs previously loaded with the 4.0% solution of drugs respectively. 
For the drug release study, an USP equipment (TDT-08L Dissolution Tester (USP), Pharma 
AllianceGroup, U.S.A.) with 8 thermo- jacketed opaque cells of 300 mL was used, each 
one filled with 150 mL of PBS at pH 7.4 as receptor media. Temperature and rotation 
were maintained constant at 37 °C and 100 r.p.m. respectively. 1 mL samples were 
withdrawn from the receptor liquid media for release concentration analysis from the 
untreated and plasma-polymerized β–TCP discs. After each sample withdrawn, the same 
volume of PBS was added to the receptor media. Release experiments were performed with 
four replicates of each plasma polymerization condition. 
For the quantification of the ampicillin release, an UV-visible-NIR spectrophotometer UV-
3600 Shimadzu was used at λ = 204 nm, corresponding to the wavelength of maximum 
absorbance of ampicillin in PBS solution. The concentration of ampicillin was below 10% 
saturation concentration (SINK conditions) in the receptor solution during the experiment. 
Stability of ampicillin after plasma polymerization on the ampicillin-loaded β–TCP was also 
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checked by UV- spectroscopy after release of ampicillin in PBS through comparison of the 
general spectra. The amount of gentamicin released was obtained by measuring the release 
media collected at each time point by High performance liquid chromatography (HPLC) in a 
Shimadzu HPLC system. Mobile phase consisted of methanol–water–ammonium acetate 
buffer (0.02M, adjusted with concentrate ammonia to pH = 9): 35:60:5 (v/v/v), at a flow rate 
of 0.3 ml/min was passed through a C8 column (Shim-pack, Shimadzu). An injection volume 
of 20 μl of the release sample was measured by photodiode array (PDA) at λmax = 238 nm 
corresponding to the wavelength of maximum absorbance of gentamicin in PBS solution. 
Stability of gentamicin after plasma polymerization on the gentamicin-loaded β–TCP was 
also checked by HPLC after release of gentamicin in PBS through comparison of the control 
spectra. 
The kinetic models used were Zero order equation (Qt = Q0 – K0t) and Kopcha kinetics (Qt = 
At1/2 + Bt) [Q0 is the initial amount of drug in the solution Q0= 0, K0 is the zero order release 
constant and Qt is the amount of drug released at time t, A = diffusional constant and B = 
erosion constant].  
Antibacterial assay 
The antibacterial activity of the ampicillin and gentamicin loaded plasma polymerized β-TCP 
discs were tested in suspension against Staphylococcus aureus (S. aureus) in BHI Broth at 
[BHI] = 37.0 g.L-1. After incubation for 24 h at 37 °C, 1 mL of the inoculate media was 
put in each well of a 48-well Falcon™ culture well-plates, previously prepared by 
connecting two adjacent wells. The optical density of bacterial suspension was adjusted to 
0.2 ± 0.01 at 600nm, giving approximately 1 x 108 colony-forming units (CFU)/ml. The assay 
was conducted with samples loaded with drug (D) (ampicillin (AMP) or gentamicin (GENTA): 
UT-D; SP10-D, DP10-D, TP10-D and QP10-D) and samples without antibiotics that were 
treated as controls (untreated β-TCP: UT, untreated β-TCP with 40 min polymerization: 
UT_P40m Samples) apart from controls of S. aureus Ctrl+ (with bacteria) and Ctrl- 
(bacteria growth medium without bacteria). Later, samples were placed in one of the 
connected wells, while the second was employed to measure absorbance and monitoring 
the growth of S. aureus by means of a Synergy HTX Multimode Reader (BioTek 
Instruments, Inc.). The antibacterial growth kinetics was monitored for 48 hours at λ=600 
nm absorbance [23]. Measurements were recorded using Gen. 5 software (BioTek 
Instruments, Inc.) and results are presented in growth curve with standard deviation. 
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Cell Biocompatibility 
The effect of the plasma coating on β-TCP discs on the interaction with osteoblastic cells 
was evaluated using a human osteosarcoma cell line (Saos-2, ATCC, USA), with three 
replicates for each condition. The coated or uncoated β-TCP discs were sterilized by UV 
treatment for 15 min and placed in 24-well tissue polystyrene (TCPS) plates. Saos-2 cells 
(80,000 cells/well) were seeded on the surface of the discs in McCoy’s cell culture medium 
(Invitrogen, Carlsbad, CA, USA) and  incubated at 37 ºC for a week. Cell culture media was 
replaced at every 24 h. At 6 h, 24 h, 3 days and 7 days’ time point, cells were lysed with 300 
µL of M-PER® (Mammalian Protein Extraction Reagent, Thermo Scientific, Waltham, MA, 
USA). The cell number was evaluated using the Cytotoxicity Detection Kit LDH (Roche 
Applied Science, Penzberg, Germany), according to the manufacturer’s instructions. The 
LDH activity was measured spectrophotometrically at 492 nm with PowerWave HT 
microplate reader (Bio-Tek Instruments, Inc.)[24]. The results were expressed as a relative 
fold change compared to the cell number obtained on TCPS at 6 hours (SaOS-2 cells).  The 
cell viability was calculated following Eq. (2), where Abs is the measured absorbance for the 
samples (Abs sample) and the positive (AbsC+) and negative control (AbsC-), all the results 
have been normalized with respect to surface area of TCPS. 
)2 (eq.
(AbsC-) -(AbsC
-AbsC
 -  sample    Abs   viability  ell
)
C
 
Specimens were prepared for SEM observation by fixing the cells with 4% 
paraformaldehyde in PBS, and a sequence for dehydrating the cells was performed by 
immersing the samples in 50%, 70%, 90%, 96%, and 100% (v/v) ethanol during 15 min 
each step. As the final step, samples were immersed in HDMS overnight and carbon 
coated. 
Statistical Analysis 
The data were analyzed using Student’s t-tests and one-way ANOVA Tables with Tukey’s 
multiple comparison tests in order to evaluate statistically significant differences between 
sample groups. The differences were considered to be statistically significant when p<0.05. 
All statistical analysis was performed with Minitab 16TM software (Minitab, Inc., State 
College, PA). 
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Results  
Characterization of the plasma coatings on β-TCP 
Plasma polymer coatings were produced on β-TCP, based on the polymerization of 
Diglyme at low pressure. To assess the kind of polymer produced by the low 
temperature plasma process evaluated, FTIR was performed on a model Si flat surface 
(Figure 4-3). The hamp observed at 3600 cm-1 can be attributed to adsorbed water, the 
other peaks found were characteristic of polymers: Two weak bands at 2952 cm-1 and 
2888 cm-1 which can be attributed to hydrocarbon stretching ʋ(C-H) in alkanes. A 
medium peak at 1655 cm-1  and another at 1533 cm-1 may correspond to ʋ (C=O), and 
the shoulder at 1464 can probably be attributed to ʋ (C-O). The intense bands at 1218 
cm-1 and 1055 cm-1 can probably be assigned to ʋ as(C-O) and ʋ s(C-O), respectively.  
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Figure 4-3 FTIR spectra of the plasma polymer (QP10) obtained on Si wafer as model surface. 
Uncoated β-TCP is a hydrophilic and porous material, and therefore it quickly absorbs 
water, not allowing contact angle measurement (Table 4-1). Furthermore, PEG being a 
hydrophilic polymer, its coatings should display contact angles below 90º, as recorded here 
for some selected plasma treatments on a Silicon water employed as flat model surface 
(Figure 4-3). Surprisingly, this was not the case for the different plasma treatments 
evaluated on β-TCP (Table 4-1) which displayed contact angle values above 120º, except 
for the SP10 sample that still absorbed water (although more slowly than the pristine 
material). It is remarkable that with DP10, TP10 or QP10 the droplet was strongly pinned to 
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the surface, not rolling off even if the sample was held vertical (photographs on Figure 4-4).  
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Figure 4-4 Wettability of two plasma-polymerized substrates: silicon wafer (employed as flat model 
surface) and β-TCP samples (UT and SP10 were not measurable due to hydrophilicity). Images of the 
droplet on the surface of QP10 with the sample lying flat, or held vertical. 
Dynamic contact angles were also measured (Table 4-1), and allowed calculating 
hysteresis, which was high and similar in the three plasma coated samples.   
Table 4-1 Polymerization conditions evaluated on β-TCP, static contact angle and Dynamic advancing 
and receding contact angles and contact angle hysteresis of β-TCP samples untreated (UT) or with 
different plasma treatments. 
* Quick water absorption did not allow static contact angle measurement 
 Description tplasmatot 
(min) 
θs (º) θadv (º) θrec (º) Δθ(º) 
UT -- 0 * * * - 
SP10 Single, 10 min 10 * * * - 
DP 10 Double, 10 min 20 120.03 ± 2.51 128.92 ± 
1.04 
65.61 ± 4.18 63.31 
TP 10 Triple, 10 min 30 123.27 ± 3.76 125.32 ± 
3.42 
59.97 ±  
6.17 
65.35 
QP 10 Quadruple,10min 40 126.20 ± 3.99 119.45 ± 
1.83 
57.08 ± 5.67 62.37 
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The modification in surface chemistry indicated by contact angles was confirmed by 
XPS, by measuring the elemental composition of the untreated and plasma-polymerized 
-TCP (Table 4-2). The composition of untreated -TCP copes very well with its 
theoretical concentration, with a Ca/P ratio of 1.48, and the presence of some C can be 
attributed to adsorbed ambient contamination or surface carbonates. The increase in 
C/O ratio following all plasma polymerization treatments indicates the presence of a 
polymer, and the fact that Ca or P were not detected pointed out thickness of the 
polymer layer above 10 nm (the depth of detection of XPS). Figure 4-5 shows the C1s 
spectra of the QP10 PEG-like coatings, with three peaks corresponding to C-C or C-H, 
C-O , being the latter the most abundant, and C=O. SP10, DP10 and TP10 showed very 
similar C1s spectra.   
Table 4-2 Elemental composition obtained by XPS. β-TCP samples with different plasma treatments 
 
 
 
 
 
 
 
 
Scanning electron micrographs (Figure 4-6, left) reflect the roughness and porosity of -
TCP. Moreover, following plasma polymerization SEM images clearly show that the coating 
itself is very thin, not masking any topographic features of -TCP. At the same time, 
Focused ion beam (FIB-SEM) transversal sections allowed visualizing (Figure 4-6, right) 
and measuring (Figure 4-7) the thickness of the coating as a function of the total treatment 
time of the plasma polymerization process. Thickness ranged between 10 nm for SP10 to 
close to 38 nm for QP10, revealing increasing thickness with longer total plasma treatment 
times but not following a completely linear behavior.  
Codes C1s O1s Ca2p P2p C/O 
UT 12.4 56.1 18.8 12.7 0.22 
SP10 77.5 22.5 - - 3.44 
DP10 77.3 22.7 - - 3.41 
TP10 78.2 21.8 - - 3.59 
QP10 77.7 22.3 - - 3.47 
C-C, C-H C-
O 
C=O 
Figure 4-5 C1s spectra of the PEG-like plasma 
polymer coating on β-TCP for QP10. 
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Figure 4-6 Scanning Electron Micrographs of β-TCP untreated at two different magnifications (top) 
surfaces and of the surface of β-TCP at different polymerization conditions (left) with their 
corresponding transversal sections obtained by FIB. Arrows indicate the polymer coatings. (Other 
plasma polymer coatings: DP10, TP10 not shown). 
Biological response 
The changes in the wettability of the samples might affect the biological response of the 
material. Therefore, the cytocompatibility of the samples was evaluated through 
adhesion and proliferation assays (Figure 4-8). All PEG-like plasma-coated -TCP 
samples displayed the same cell adhesion and proliferation than -TCP for all conditions 
evaluated, with the sole exception of QP10, which showed slightly lower proliferation 
values at 1 and 7 days. 
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Figure 4-7 Thickness of the PEG-like layer obtained by different plasma polymerization treatments on 
the surface of β-TCP as a function of the total treatment time. 
   
 
Figure 4-8  SaOS-2 cells relative fold growth on untreated β-TCP and plasma-polymerized β-TCP at 
different cell culture times. (A indicates significant differences with respect to β-TCP, P >0.05). TCPS 
accounts for “Tissue culture polystyrene” which is taken as a positive control. 
Scanning electron micrographs (Figure 4-9) show cells attached on the surface of β-TCP at 
different time points (6 h & 3 days). The morphology of the cells on all bioceramics showed 
extended cells, with visible fillopodia, disregard of the presence or absence of the coating. 
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Figure 4-9 Scanning electron micrographs of untreated and plasma-coated β-TCP seeded with SaOS-
2 cells for either 6 h (left) or 72 h (right). 
Drug Release  
Two different antibiotics were incorporated to the β-TCP ceramics prior to plasma coating: 
ampicillin (AMP) and gentamicin (GENTA). Their release kinetics was investigated following 
USP pharmacopoeia protocols for 24 h (Figure 4-10) and it can be observed that each drug 
follows a different release profile. On the one hand, ampicillin follows a burst release within 
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the first 2 h in which most of the drug loaded is released (Figure 4-10a). On the other hand, 
gentamicin follows a more progressive release during 24 h (Figure 4-10b). Regarding the 
plasma coatings, it can be underlined that while for GENTA the total amount released 
decreases with the thicker plasma coating, the profile of release remains unaltered, for AMP 
slightly different profile is observed for the samples DP10-D, TP10-D and QP10-D, as 
shown in Figure 4-10c. 
 
The final release percentage of both drugs was close to 100 % for the untreated -TCP 
samples, while as plasma polymerization times were longer, the total release % 
progressively decreased by close to 20% (Table 4-3). The release kinetics were fitted to 
different models, being Kopcha’s model the one showing best fitting. Fitting of the release 
data to Kopcha’s model showed that the release kinetics are governed by diffusion 
phenomena, A/B being >1. 
Figure 4-10 Evaluation of release kinetics of ampicillin and gentamicin (top) for 24 hours, total 
quantity released for both ampicillin and gentamicin (labeled with ¨D¨ for drug) for untreated and 
different treatments (bottom). 
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Table 4-3 Ampicillin or Gentamicin released percentage β-TCP discs after 24 h and kopcha kinetics 
for the release kinetics. 
Antibacterial properties 
The influence of plasma polymerization on the antibacterial activity of ampicillin and 
gentamicin was studied in a kinetic growth assay over 26 hours (Figure 4-11). 
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 Figure 4-11 Continuous monitoring of the optical density of Staphilococcus Aureous bacterial 
suspensions in contact with ampicillin (AMP) and gentamicin (GENTA) loaded β- TCP ceramics either 
untreated (UT) or plasma polymerized (UT_P40m, SP10-D, DP10-D, TP10-D and QP10-D) or the 
suitable controls ( in contact with S. aureus growth activity during 26 hours. 
 
 
Ampicillin Gentamicin 
 
Kopcha´s Kinetics  Kopcha´s Kinetics 
 
AMP 
released (%) 
R2 A B 
A/B 
(>1) 
 
GENTA 
released (%) 
R2 A B 
A/B 
(>1) 
UT 99.6 ± 0.5 0.983 0.736 0.022 32.6 99.3±0.9 0.987 0.540 0.015 35.79 
SP10 99.8 ± 1.7 0.982 0.586 0.010 55.8 98.7 ± 2.1 0.986 0.512 0.015 33.70 
DP10 96.9 ± 1.3 0.994 0.499 0.012 39.0 88.1 ± 4.1 0.975 0.506 0.016 30.53 
TP10 96.2 ± 2.2 0.993 0.559 0.016 34.8 80.9 ± 6.7 0.970 0.475 0.016 29.73 
QP10 80.7 ± 8.0 0.997 0.458 0.011 39.7 78.9 ± 2.8 0.975 0.442 0.015 30.32 
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The growth activity of S. aureus was measured for plasma polymerized β-TCP with 
antibiotics (ampicillin; gentamicin): SP10-D, DP10-D, TP10-D, QP10-D and the bacterial 
growth in BHI medium was used as a control. It was observed that only the samples without 
antibiotic (bacterial suspension used as positive control, untreated β-TCP (UT) and 40 mins 
plasma polymerized β-TCP (UT-P40m) showed bacterial growth. On the contrary, samples 
loaded with antibiotics either untreated or coated with the plasma polymer coating resulted 
in the inhibition of bacterial growth. 
Discussion 
Plasma-polymerization is a versatile technique for the deposition of films with functional 
properties suitable for a wide range of applications [18] and in this work it was employed to 
coat β-TCP bioceramics. These biomaterials are excellent bone substitutes, and their 
instrinsic microporosity allows incorporation of drugs. However, control of drug release is 
complex and a new strategy has been evaluated.  
Plasma polymer coatings deposited on top of polymers have been shown to have excellent 
barrier properties allowing to delay and control drug release [25], [26]. For biomedical 
applications, the polymers selected need to be, of course, non-toxic and biocompatible. 
Conventional polyethylene glycol (PEG) or polyethylene oxide materials (repeating unit: -
CH2CH2O-) are often defined as non-fouling but when they are synthesized by plasma 
processes the chemical structure of the polymer obtained might be very different, with a 
certain degree of cross-linking, and presence of other moieties (i.e. ester, carbonyl, carboxyl 
and hydrocarbon groups)[27].    
The coatings obtained here were produced on -TCP from Diglyme as precursor at low 
pressure in sequential treatments ranging from 10 to 40 min of total treatment time (Figure 
4-2).  The coatings obtained revealed characteristic FTIR peaks of PEG - C-O groups and 
C-H (Figure 4-3). The C/O surface ratio of the coatings was calculated from XPS data 
(Table 4-2), being around 3.5 for the four different coatings evaluated. The stoichiometric 
C/O ratio of Diglyme is of 2, so the values obtained in this work indicate loss of oxygen 
moieties and increased cross-linking due to high fragmentation in the plasma as also found 
by E. Sardella et al. for similar plasma coatings obtained at high power on a polymeric 
substrate [27]. They designated this as “reduced PEG-character” in the plasma coatings 
contributed by cross-linking and oxygen loss from the Diglyme precursor. This is in 
agreement with the peak fitting of C1s XPS spectra of QP10 (Figure 4-4) where the C-C, C-
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H component at 285.0 eV is the most important component (relative fraction ~50%), closely 
followed by C-O (~45%) attesting for the high hydrocarbon nature of PEG-like coatings 
deposited here. Similar results were obtained in [27], [28]  
It is not surprising to find this reduced PEG character, as in general, plasma polymers have 
different properties than those fabricated by conventional polymerization: the plasma-
polymerized films are usually branched, highly cross-linked, insoluble, pinhole-free, and 
adhere well to most substrates [29], [30]. Due to these excellent properties, plasma-
polymerized films have been utilized in a wide range of applications, such as protective 
coatings, biomedical materials, electronic and optical devices, adhesion promoters, etc.    
The thickness of the coatings obtained was above 10 nm in all cases as revealed by the fact 
that Ca and P were not detected by XPS and as confirmed by FIB-SEM cross-section 
imaging (Figure 4-6). The PEG-like layer thickness (Figure 4-7) progressively increased with 
the total plasma treatment time in a nearly linear trend. 
The surface structure of the -TCP bioceramic evaluated in this work is highly complex with 
rough topography (Figure 4-6 top), where crystal grains and sintering necks can be 
observed. The plasma coating did not alter the topography of the surface and the pores 
were not covered with any of the coatings evaluated. The porosity of -TCP and its 
hydrophilic chemistry led to fast water absorption, which did not allow contact angle 
measurement (Table 4-1). For the shortest treatment SP10 the coating was probably 
partially uneven, and some areas remained partially uncoated, still allowing for water 
absorption. Following plasma treatments of a total of 20 min or more (DP10, TP10, QP10), 
the static contact angles of the surface of -TCP raised to values between 120 and 126º as 
observed in Labay et al. [20]. This is shocking, considering that usually PEG-coatings are 
hydrophilic (s < 90º), as confirmed by the contact angle values measured on flat silicon 
surfaces (Figure 4-4) with the same plasma coatings which varied between 74 and 79º.  
Besides, dynamic contact angles were measured, which allowed calculating the contact 
angle hysteresis. The contact angle hysteresis is a measure for how well a drop of liquid 
sticks to the surface [31]. The hysteresis in contact angle obtained (Table 4-1) was rather 
high and very similar for all samples, indicating that the surface was heterogeneous. 
Considering the complex surface topography of -TCP this can be attributed to roughness. 
This high hysteresis values are characteristic of surfaces where the drop does not roll-off 
easily [32], as confirmed by the pictures in Figure 4-4 showing pinning of the drop to the 
 108 
 
surface. 
 
Figure 4-12 Representation of the wetting behaviour of β-TCP bioceramics before and after plasma 
polymerization of PEG-like layers. 
All this was indication of wenzel’s behavior [33] occurring on the surface of plasma coated 
-TCP (depicted in Figure 4-12). The Wenzel relation (cosθ* = r cosθ) predicts that 
roughness enhances wettability which allowed calculating the apparent surface to be of 
roughness (r)= 2.6 ± 0.4 for this bioceramic, and coping well with the SEM images (Figure 
4-6).  
Despite the great changes in surface chemistry altered wettability, the cytocompatibility was 
not compromised (Figure 4-9). Cell adhesion (6h of cell culture) to the surface of PEG-like 
coated -TCP in all conditions evaluated was comparable to that of the UT sample. The 
same occurred for the proliferation of the cells, which was the same to that of naked -TCP 
(except only for QQ10 at 24h and 7 days, where a minor decrease in the number of cells 
was registered).  
Despite PEG being widely acknowledged for its antifouling properties, our polymer layer 
was deposited by plasma in such conditions that lead to rather different chemistry than 
conventional PEG (less amount of C-O groups, more crosslinking, presence of other 
moieties such as C=O) so it has a “reduced” PEG character. Similar results were found 
when seeding 3T3 fibroblasts on flat surfaces plasma coated employing also Diglyme, 
where those conditions leading to reduced PEG character of the coating displayed suitable 
cell morphology, and homogeneous growth of the cells on the substrates with these 
characteristics, while no attachment at all was observed when PEG coatings were produced 
so the PEG character was retained and antifouling properties were ensured [27].  
This is further confirmed by the SEM images on the cells adhered to -TCP (Figure 4-9) at 
different time points, which are very well extended on the surface of  -TCP for all coatings, 
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with visible filopodia which reflect their good attachment to the surface. Many parameters 
influence cell behavior on bioceramics [34], and parameters such as surface roughness, 
chemistry, solubility and crystalinity play a role. It seems clear that the thin layer produced 
here had suitable chemistry allowing, among others the protein adhesion required for further 
cell attachment, and therefore produced the minimum alterations in the biological behavior 
of the samples. 
Two different antibiotics were selected in this work: gentamicin, a wide spectrum antibiotic 
that is widely employed in orthopedics, and ampicillin, which was selected for its wide 
spectrum of action and as reference for comparison with previous works [20], [35]. Both 
antibiotics followed distinct drug release profiles (Figure 4-10): On the one hand, ampicillin 
displayed burst release in the 1st hour of release from UT-D -TCP, and the stationary stage 
was reached after only 7h. On the other hand, gentamicin followed a more progressive 
release from UT-D -TCP, without reaching the stationary stage at least in the 24 h 
timeframe evaluated.  
The recorded differences could be ascribed to the higher molecular weight and steric 
hindrance of gentamicin (Figure 4-1), impairing the diffusion from the -TCP matrix.  
The plasma coatings evaluated here in both cases induced a progressively reduced amount 
of drug released, following this order: UT-D ≥ SP10-D > DP10-D > TP10-D ≥ QP10-D 
This could be explained by two different phenomena: i) etching processes occurring on the 
surface simultaneously to the plasma polymerization during plasma treatment, which might 
have eliminated a certain amount of the most superficial antibiotic adsorbed on the 
bioceramic; and ii) a barrier effect due to the polymer layer created. This copes well with the 
fact that lower amount was released when the plasma coating proceeded on for longer 
times (Figure 4-10d). Fortunately, the reactivity with the plasma phase did not revert in a 
denaturation of the antibiotics, as all samples showed suitable inhibition of the 
Staphilococcus aureus bacterial growth (Figure 4-11). In general after plasma processes 
aimed at modulation of drug release, the drugs keep their activity, as has been shown for 
different drugs (from anticancer to antibiotics), and varied plasma polymerization processes 
works [20], [36]. 
Fitting of the release profiles to the Kopcha model indicates that the release occurring for 
both antibiotics clearly follows a diffusion mechanism (as shown by a A/B ratio >1).  
Of course, to control release from the plasma coating thicker layers need to be produced, as 
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shown for coatings on polymer films by Arefi-Khonsari et al. [37], [38] or in our case in 
bioceramics in Chapter 3. In fact, a certain reduction in the release rate was recorded in the 
release of ampicillin from the coatings obtained at longer plasma treatment times (DP10-D, 
TP10-D and QP10-D) as had also been observed in a previous work of the group evaluating 
the same drug for coatings produced in similar conditions [20]. As observed in that case, it is 
expected that longer treatments produce further reduction in the initial release rate due to 
increased cross-linking of the polymer. 
Conclusions 
This work investigated the effects of plasma polymerization on the modification of surface 
properties of β-TCP bioceramics for bone regeneration. Low pressure plasma 
polymerization of PEG-like polymers on microporous β-Tricalcium Phosphate (β-TCP) 
allowed obtaining coatings with low retention of the PEG character (high C/O ratio, grafting 
of end groups such as C=O and cross-linking of the polymer) which allowed avoiding the 
typical antifouling properties of the coating.   Due to the significant roughness of the surface 
of β-TCP, following plasma coating the bioceramics showed a hydrophobic behavior, 
despite the wettability of the polymer layer produced. This was associated with Wenzel 
behavior, which allowed calculating the roughness ratio of the material, being around 2.6. 
The coating thickness (ranging from 10 nm to 40 nm) was directly dependent on the 
polymerization time, which in turn was related to the total amount of drug released. In 
general, it was observed that the longer the coating, the lesser the amount released (varying 
from close to 100% in the UT bioceramics to 80% in those with the longer (QP10) plasma 
coating. This is probably due to etching of the most superficial drug adsorbed on the surface 
during plasma processes. Moreover, for certain conditions the release profile started to be 
modified.  
The two antibiotics evaluated (ampicillin and gentamicin) retained their antimicrobial activity 
intact after being released from the β-TCP substrates, confirming the suitability of the 
technique for coating the drug-loaded ceramic matrices.  
Despite the great modification in wettability due to the PEG-like coating, the good 
cytocompatibility of β-TCP (adhesion and proliferation of SaOS-2) remained unaltered. The 
research undertaken allowed unraveling the characteristics of plasma coatings on calcium 
phosphate ceramics and advancing towards the design of drug delivery matrices with 
suitable biological and microbiological behavior.  
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Chapter 5  
Injectable Calcium Phosphate Foams for the delivery of 
Pitavastatin as osteogenic and angiogenic agent 
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Abstract 
Apatitic bone cements have been used as a clinical bone substitutes and drug delivery 
vehicle for therapeutic agents in orthopedic applications. This has led to their combination 
with different drugs with known ability to foster bone formation (BMPs, NPs or statins). 
Recent studies have evaluated Simvastatin for its role in enhanced bone regeneration, but 
its lipophilicity hampers incorporation and release to and from the bone graft. 
In the study reported in this Chapter, Injectable calcium phosphate foams (i-CPF) based on 
alpha-tricalcium phosphate were loaded for the first time with Pitavastatin. The stability of 
the drug in different conditions relevant to this study, the effect of the drug on the scaffold’s 
properties, the release proﬁle, and the in vitro biological performance with regards to 
mineralization and vascularization were investigated. Pitavastatin did not cause any 
changes in both the micro and macro structure of the i-CPFs, which retained the biomimetic 
features. PITA-loaded i-CPFs showed a dose-dependent drug release, with early stage 
release kinetics clearly affected by the evolving microstructure due to the setting of cement.  
In vitro studies showed dose-dependent enhancement of mineralization and vascularization. 
Our findings contributes towards a design of controlled and low drug dosing bone grafts; i-
CPFs loaded with PITA as osteogenic and angiogenic agent.  
 
Introduction 
Bone defects represent a major health burden, especially when they are of critical size and 
cannot heal following the usual regeneration mechanisms of bone[1]. In such cases bone 
grafting surgery is required, and in this context synthetic bone biomaterials have an 
increasing demand. Among the different biomaterials available, calcium phosphate cements 
(CPC) present several advantages that have fostered their study and application [2]–[4]. In 
particular, their composition mimicking the bone mineral phase, their ability to strongly bond 
with bone, their injectability and self-setting ability are some of their main assets [5]–[9].   
Moreover, their intrinsic micro-nanoporosity makes them ideal candidates as drug delivery 
vehicles [10], [11], and have thus been studied in combination with different drugs including 
anti-inflammatories, antibiotics or anti-osteoporotic drugs [12]–[15]. 
 Interconnected macroporosity is a key feature of synthetic bone grafts, since it allows 
circulation of nutrients and cell infiltration and enhances resorption and bone ingrowth. 
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Moreover, when injectable CPCs are used as matrices for the delivery of drugs or active 
molecules, the presence of interconnected macropores has been shown to significantly 
increase/modify drug delivery [14]. So far, a number of methods have been investigated to 
obtain macroporous CPCs [16]–[21]. In this work we will focus specifically the addition of 
biocompatible surfactants to obtain injectable calcium phosphate foams (i-CPF), a method 
that has been found adequate for obtaining stable scaffolds with interconnected 
macroporosity[17] . 
Statins are extensively used drugs, employed mainly as inhibitors for the cholesterol 
biosynthesis. Additionally, they are known to present several pleotropic effects, such as 
improving endothelial function, decreasing oxidative stress and inflammation, or inhibiting 
the thrombogenic response, among others [22]. Interestingly, Mundy et al. reported that they 
also played a role in bone formation, through the stimulation of BMP-2 expression [23]. This 
led to a wide investigation, focusing especially on simvastatin (SIM), as a potential drug for 
bone regeneration [23], [24]. However, the hydrophobic nature of SIM results into low oral 
bioavailability (≤5%), due to extensive first-pass metabolism in the gastro-intestinal wall 
and high extraction in the liver [25]. The hydrophobic nature of SIM also hampers its uniform 
incorporation in water-based matrices, as is the case of CPCs, which are formed by a 
combination of powder and aqueous liquid phase.  
With the aim of fostering bioavailability and ease of incorporation in CPCs, a more 
hydrophilic statin, Pitavastatin (PITA) has been investigated for the first time in this work, in 
combination with a foamed CPC. Due to higher oral absorption, oral bioavailability, and  
even solubility, PITA has a higher potency than SIM [26]–[28].  Moreover, although the 
studies on the pleotropic effects of PITA are scarce [29], some findings suggest that it 
enhances bone turnover markers [30];  and gene expressions for mineralization [31]  
The aim of the study that is reported in this Chapter was to explore the feasibility of 
incorporating PITA in i-CPFs as a strategy to foster the bone regenerative process at the 
defect site, using a lower dosage than SIM due to its higher potency. To this end, the effects 
of PITA on mesenchymal stem cells and on endothelial progenitor cells were evaluated, and 
the interactions of PITA with the physic-chemical properties of i-CPFs were assessed. 
Finally, the release kinetics from i-CPFs was evaluated.  
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Materials and methods 
Pitavastatin stability 
Pitavastatin Calcium (C22H23FNO4 * 0.5Ca * 2H2O; Tocris Bioscience, UK) was received in 
powder form and incorporated in the liquid phase with a solubility of 0.426 mg/l in water. The 
molecular structure of PITA; is shown in Figure 5-1. In the evaluation of the PITA’s stability, 
two main factors were taken into account: pH and temperature. The temperature stability 
was evaluated with solutions of PITA prepared in Phosphate Buffer Saline (PBS) at different 
concentrations (5, 50 and 100 μM) and stored at 5 ºC and 37 ºC with a pH of 6.5.  Similarly, 
since during the setting reaction of i-CPF the pH reaches alkaline values of pH 9.5 and 
eventually shifts to neutral pH 7 during initial 24 h [32]. Therefore, PITA’s stability was 
assessed at alkaline pH based on cement setting. PITA was dissolved in water (5, 25, 50, 
75 and 100 μM) and stored at 37 ºC. Subsequently the pH of the PITA solutions (pH 6.5) 
was adjusted to pH 8 and pH 9.5 by addition of 0.01 M NaOH which affected the initial 
concentration for the solutions. The quantification of PITA solutions at various time points 
was carried out with High performance liquid chromatography (HPLC) in a Shimadzu HPLC 
system. A mobile phase of Acetonitrile: 0.1% phosphoric acid at a ratio of 50:50 (v/v), at a 
flow rate of 0.5 ml/min was passed through a C8 column (Shim-pack, Shimadzu). An 
injection volume of 10 μL of the release sample was measured by photodiode array (PDA) 
at λmax = 245 nm. 3 replicates were analyzed for each condition.  
Evaluation of the effects of Pitavastatin on mesenchymal stem cells and endothelial progenitor 
cells in vitro  
 The osteogenic and angiogenic effects of PITA were evaluated in in vitro models with rat 
Mesenchymal stem cells (rMSCs) and endothelial progenitor cells (EPCs) respectively. Both 
cell types were extracted from femurs of young Lewis rats at the Institute for Bioengineering 
of Catalonia (IBEC), as in previous works [33]. Cell phenotypes were previously 
characterized by flow cytometry [34]. rMSCs cells were expanded in Advanced DMEM 
supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES buffer solution, 
penicillin/streptomycin antibiotics (50 U/ml and 50 µg/ml, respectively), and 2 mM L-
glutamine  (all from Invitrogen) at 37 ºC with 5% CO2 and 95% relative humidity. On the 
other hand, supernatant containing EPCs were centrifuged and re-suspended in EBM 
medium (Lonza) supplemented with EGM-2 BulletKit and 5% FBS. Both cell types were 
used from passage 4 for all the experiments. 104 cells/well were seeded in 24 well plates 
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and cultured in their corresponding medium with PITA (0.1, 1 and 10 and μM) and Tissue 
culture polystyrene (TCPS) was used as control. PITA was received in powder form and 
used as received to prepare a stock solution in Milli-Q water, which was further diluted to the 
final concentration of 0.1, 1 and 10 μM in cell culture medium.  
The expression of osteogenic marker genes in rMSCs (BMP-2, Osteocalcin, Collagen-I) and 
vascularization genes in EPCs (VEGFA, VEGFR-1, VEGFR-2) were determined through RT-
qPCR assay at various time points (6 and 24h, 3 and 7 days), Table 5-1. At each culture 
time, total RNA was extracted using RNeasy® Mini Kit (Qiagen, Hilden, Germany) as 
described in the manufacturer’s instructions. Total RNA was quantified using a NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA) and its quality 
was assured by agarose gel electrophoresis. 200 nanograms were retro-transcribed to 
cDNA using the QuantiTect Reverse Transcription Kit (Qiagen). cDNA products were further 
diluted and used as RT-qPCR templates. The RT-qPCR primers were designed, after 
specificity and intron span verification by Blast, using the Primer3 software (http:// 
 rodo.wi.mit.edu/primer3/) to amplify the specific genes for adhesion, ECM synthesis and 
bone remodelling (Table 1). Primers from genes that exhibited more than one transcript were 
selected from common regions. SYBR Green RT-qPCR analyses were carried out using the 
QuantiTect SYBR Green RT-PCR Kit (Qiagen) in an ABIPrism 7700 machine (Applied 
Biosystems, Foster City, CA, USA). Specificity of each RT-qPCR reaction was determined 
by melting curve analysis and by resolving the RT-qPCR products on 2% agarose gels. All 
samples were normalized by the expression levels of β-actin (reference gene) and fold 
changes (FC) were related to TCPS at 6 h of culture as follows: FC = Etarget ΔCq target (TCPS6h – 
Surface)/Ereference ΔCq reference (TCPS4h – Surface) (Pfaffl 2001), where Cq is the median value for the 
quantification cycle for the triplicate of each sample and E is the amplification efficiency, 
determined from the slope of the log-linear portion of the calibration curve, as: E =10 [-1/slope].  
Figure 5-1 Chemical structure of the Pitavastatin used in this study. 
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Preparation of pitavastatin loaded injectable calcium phosphate foams  
α-TCP was used as a solid phase of i-CPFs and was obtained by heating in a furnace 
(CNR-58, Hobersal, Spain) in air a 2:1 molar mixture of calcium hydrogen phosphate 
(CaHPO4; Sigma–Aldrich, USA)  and  calcium  carbonate  (CaCO3;  Sigma–Aldrich,  USA) 
at 1400 ºC for 15 h, followed by quenching in air. The α-TCP obtained was milled in an 
agate ball mill (Pulverisette 6, Fritsch GmbH, Germany) using  10  agate  balls  (d = 30 mm) 
for 15 min at 450 rpm; 2 wt.% of precipitated hydroxyapatite (HA; BP-E341, Merck, 
Germany) was added as a seed in the powder. 10 wt% Pluronic F-127 (Sigma Aldrich, USA) 
was blended with the solid phase for the preparation of the scaffolds. The liquid phase was 
a solution of 1 wt% of Polysorbate 80, herein Tween80 (Polysorbate 80, Sigma Aldrich, 
USA) in distilled water. PITA solutions were prepared at 50, 75, 100 and 200 μM by 
incorporating in the liquid phase.  
Self-setting i-CPFs were foamed by mixing the solid and the liquid phase at 7000 rpm for 30 
s using a domestic hand mixer. The foams were injected in Teflon cylindrical moulds of 6 
mm x 12 mm and left to consolidate in 100 % relative humidity at 37 ºC, followed by 
immersion in water at 37ºC for 7 days to allow for complete reaction, prior to physic-
chemical characterization.  
Physic-chemical characterization of i-CPFs 
The microstructure of the i-CPFs was characterized by field emission scanning electron 
microscopy (FESEM) (Neon 40, Zeiss, Germany). A fracture region was observed at 10 kV 
working voltage. Prior to observation, samples were Au-sputter coated (K950X, Emitech, 
US).  
The Specific Surface Area (SSA) of i-CPFs was measured by Nitrogen adsorption in an 
ASAP 2020 (Micromeritics) with 6 cylindrical samples, using the Brunauer-Emmet-Teller 
(BET) method.  
Helium pycnometry (AccuPyc 1330, Micromeritics, USA) was used to measure the skeletal 
density of i-CPFs and i-CPFs with 100 μM PITA.  
Mercury intrusion porosimetry (MIP, AutoPore IV, Micrometrics, USA) was performed to 
determine the pore entrance size distribution (PESD) within the materials. Four cylindrical 
samples were introduced in the sample holder for the measurement, and a single 
measurement was performed for each composition. 
 123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1 Table 1: DNA sequences of forward (fw) and reverse (rv) primers for the selected genes used for real – time qPCR. 
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Micro-computed tomography, a 3-dimensional micro-computed (3D micro-CT) system 
used was TOMOLIBRIR and was developed at the Fraunhofer IZFP Saarbrucken, 
Germany to evaluate the three-dimensional (3-D) morphology of CPFs. The scanner was 
operated to obtain a voxel size of 4³ µm³, at 100 kV and 9 W X-ray power with a data 
acquisition and reconstruction software, Volex.  The samples employed were cylinders 
with 6 mm in diameter and 12 mm high. The 3-D volume was then reconstructed using 
Amira network (version 5.4.3). 
Evaluation of Pitavastatin release 
For drug release studies, i-CPFs were prepared with the liquid phase containing PITA at 
different concentrations (50, 75, 100 and 200 μM) as described in Sections 2.1 and 2.2. 
They were injected in 2 mm x 6 mm teflon moulds adapted from the USP ointment cell 
with only one open side allowing contact with the release medium. Prior to release, they 
were kept for 5 h in 100% relative humidity to have sufficient cohesion. The total amount 
of PITA loaded per sample was measured by weighing samples before release and 
calculating with respective concentration of PITA in the liquid phase using eq 1. (where, 
Wt. refers to weight) 
1) (eq.  scaffold per 
PITA
Wt 
scaffold loadedPITA 
Wt 
phase. liquidWt phase. solid Wtphase liquid
PITA
Wt
phase liquid
PITA
Wt












 
Then release was conducted for 6 days by immersing the i-CPFs moulds in 5 ml of 
Phosphate Buffer Saline (PBS, pH=7.4) at 37ºC with continuous stirring of 100 rpm, 
release was conducted for 6 days. At each time point 350 μL of release medium was 
withdrawn and replaced with 350 μL of fresh PBS. The amount of drug released was 
quantified by measuring the concentration of PITA in the release media collected at each 
time point with HPLC following the protocol described in the previous section. The 
cumulative release was plotted as a function of time after correcting the data for 
evaporation of PBS during 6 days. Additionally, the data for total percentage of PITA 
released was corrected for degradation occurred during setting, as detailed in section 3.1. 
Modeling was performed using the Korsmeyer Peppas (KP) model. The variable fitted is 
the quantity released Mt, normalized by the maximum quantity released M∞ (eq. 2): 
Mt = M∞. k. tn  (eq. 2) 
where k is a constant that accounts for structural parameters of the material and 
characteristics of the active principle such as the effective coefficient of diffusion. The 
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exponent n allows the identification of the mechanism controlling the release. Specifically, 
for a given geometry of the sample it allows discerning between a release con- trolled by 
Fickian diffusion, swelling/case II transport or an Intermediate situation. The KP model is 
applicable only up to 60% of the quantity released. The exponent n describes the shape of 
the curve. The quantity released as a function of time was thus fitted with the KP equation, 
and both the value of the exponent n and the correlation coefficient R2 were reported. 
Statistics  
Statistical differences were determined using one-way ANOVA with Tukey’s post hoc tests 
using minitab software. Statistical significance was considered when P < 0.05. Data are 
presented as mean ± standard deviation. 
 
Results 
 Evaluation of PITA stability 
The stability of PITA under the influence of temperature and pH as a function of time for 
216 h (9 days) is reported in Figure 5-2. It was found that PITA in PBS was stable at both 
the temperatures of 5 and 37 ºC (Figure 5-2, top), as no degradation was detected (P 
>0.05), allowing to perform the drug release assays at 37ºC without risk of degradation of 
PITA, and if required, samples could be stored in the fridge. In contrast, it was observed 
that PITA was degraded at basic pH (Figure 5-2, bottom), particularly at high 
concentrations of 50, 75 and 100 μM. The degradation was found to be similar at pH 8 or 
9.5, and the amount degraded in the solutions corresponds to ~8% in initial 24 h 
calculated with equation given below. The degradation of PITA was calculated with 
following reaction, further explained in discussion section (eq. 3): 
3) (eq.  CPFs-i  h) (24 ndegradatioPITA h 9
h 24
8) (pH nDegradatio
 h 15
h 24
9.5) (pH nDegradatio
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

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The degradation of PITA at pH 8 and pH 9.5 has been calculated as a function of time for 
initial 24 h (Table 5-2).  
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Table 5-2 Degradation of PITA at pH 8 and pH 9.5 with the function of time (t = 24 h) and total 
degradation when loaded in i-CPFs 24 h, calculated according to eq. (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Degradation 
(%) 
(t = 24h) 
PITA degradation 
in i-CPFs setting reaction (%) 
(t = 24h) 
 pH 8 pH 9.5 pH 9.5  pH 7 
5 μM 0 0 0 
25  μM 0 0 0 
50 μM 8.29 7.84 8.00 
75 μM 7.26 6.59 6.83 
100 μM 8.19 8.17 8.17 
Figure 5-2 Influence of temperature (5 & 37 ºC) (top) and pH (8 & 9.5) (37 ºC) 
on the stability of PITA solutions at different concentrations (Standard 
deviation was calculated with three replicates, error bars are really small to be 
seen clearly). 
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Effects of Pitavastatin on mesenchymal stem cells and endothelial progenitor cells in vitro 
The potential effects of PITA on the expression of some genes involved in bone 
regeneration were evaluated through RT-qPCR studies. The relative fold change in the 
expression by rMSCs of some osteogenic marker genes, namely OCN, collagen type 1 
and BMP-2 is shown in Figure 5-3, left column. An over-expression of OCN was observed 
in presence of PITA at 72h, which was more marked for the 0.1 μM dose. This 
concentration led also to an over-expression of OCN at early time points (6 and 24h) and 
to a significant increase in both Col type 1 gene expression at 72h compared to control, 
whereas no significant effect was observed for 1 μM PITA. On the other hand BMP-2 
gene expression was observed to be decreasing with progressing time yet it was 
significantly higher for both 0.1 μM and 1 μM PITA compared to the control at 72 h. 
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Figure 5-3 Influence of PITA on the gene expression of OCN, Col Type1, BMP-2 by rMSCs and 
VEGFR1, VEGFR2, VEGFA by EPCs and at 6, 24, 48 and 72 h. The statistical difference with 
TCPS and 0.1 μM are represented as A and B respectively for each time point. 
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Concerning EPCs, the gene expression of VEGFA, VEGFR1, and VEGFR2 were studied, 
as an indication of the effect of PITA on vascularization, and the results are shown in the 
right column of Figure 5-3. For the initial hours of 6, 24 and 48 h, PITA showed lower 
expression for vascularization factors though it was more significant in case of VEGFA. 
Later on, presence of PITA at 0.1μM induced an over-expression of VEGFR1, VEGFR2 
and VEGFA at 72h compared to control. In contrast, PITA at 1 μM produced a statistical 
significant decrease on VEGFA, VEGFR1 and VEGFR2 gene expressions at 72h. 
Synthesis and characterization of PITA loaded i-CPFs 
PITA loaded i-CPFs were synthesized and their physic-chemical properties were 
evaluated as shown in Figure 5-4 and Table 5-3.  The characterization of the 
microstructure was conducted with control i-CPF and PITA loaded i-CPF (100 μM), 
highest concentration evaluated for degradation studies. The microstructure of the 
materials with and without PITA (100 μM) in the bulk of i-CPFs, both displayed similar 
features. Entangled plate-like crystals derived from the dissolution-precipitation of α-TCP 
responsible for cement hardening were observed in the control and PITA loaded i-CPFs. 
The drug was completely solubilized in the liquid phase and CDHA was formed as a result 
of the hydrolysis of starting solid phase α-TCP in i-CPFs. The reconstruction of the μCT 
scans allowed visualizing homogeneously distributed and interconnected porosity in i-
CPFs with or without PITA as shown in Figure 5-4 (bottom). Additionally, Specific surface 
area (SSA), skeletal density and total porosity measured through MIP showed no 
significant differences due to the presence of the drug, as reflected in Table 5-3 and 
Figure 5-5. 
 
Table 5-3 Specific surface area (SSA), skeletal density and Porosity of i-CPFS with and without 
PITA at 100 μM, each measurement was conducted with 4 cylinders. 
 
 
Materials Specific surface area 
(m2/g) 
Skeletal Density (g/cm3) Total Porosity (%) 
Control 7.89 2.34 74.39 ± 3.2 
100-PITA 7.98 2.07 78.01 ± 2.8 
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Figure 5-4 FESEM images of i-CPF of control and Pitavastatin loaded i-CPF with 100 μM h (top). 
μCT images of control i-CPF and Pitavastatin loaded i-CPF at 100 μM (bottom). 
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Figure 5-5 MIP pore size entry distribution (n=4) of i-CPF and PITA loaded i-CPF. 
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Pitavastatin release  
The evaluation of the PITA release kinetics from i-CPFs was evaluated for different 
concentrations of drug added to the liquid phase of i-CPFs (50 μM (50-PITA), 75 μM (75-
PITA), 100 μM (100-PITA) and 200 μM (200-PITA)) in PBS for 6 days as shown in Figure 
5-6. The cumulative release of PITA showed two different phases. Initially, a burst release 
was found in the first 5 h, followed by a slow progressive release up to 72 h, later showed 
a tendency of stabilization. The release shows a dose dependent behavior from the initial 
time points as shown in the amplified image (Figure 5-6b).  The maximum release 
obtained was for 200-PITA, 40.93 ± 9.07%, in 72 h after corrected with PITA degradation 
and fitting parameters of KP model to interpret the release kinetics of the i-CPFs are 
reported in Table 5-4.  
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Figure 5-6 Release curves of i-CPFs containing different amounts of PITA for 6 days (a),  
zoom of the initial 5 hours (b) and total amount of PITA released by 72 h is plotted for 
each specimen of PITA loaded i-CPFs such as 50-PITA, 75-PITA, 100-PITA & 200-PITA 
(c) with a proposed scheme of the release of PITA during the setting reaction. 
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Table 5-4 Percentage of total release of PITA in each i-CPF specimen after 72 h and values of R2 
and n with Kosermeyer Peppas model for the release kinetics. 
i-CPFs PITA released (%) 
Korsmeyer-Peppas (KP) 
R2 n 
50-PITA 97.07 ± 10.95 0.9418 0.29 
75-PITA 97.02 ± 17.81 0.8813 0.45 
100-PITA 67.61 ± 13.51 0.8840 0.32 
200-PITA 40.93 ± 9.07 0.9097 0.20 
    
 
Discussion 
Many studies have reported the benefits of statins, specially SIM, in bone formation as 
well as inhibition of bone resorption [23], [27], [29], [35], [36]. Within the family of statins, 
PITA presents some interesting properties, in particular its lower price, hydrophilic 
properties and its comparable efficiency compared to other statins (i.e. SIM) at much 
lower concentrations. Therefore, PITA has potential advantages in views of fostering bone 
regeneration in combination with bone substitutes. However, to the best of our knowledge, 
this potential application of PITA is still unexplored. In this work we addressed some 
aspects that are relevant for this potential application, namely, the stability of PITA under 
different conditions, its biological effects on MSCs and EPCs in vitro, and the feasibility of 
incorporating it i-CPFs, including the effect of the molecule on the properties of the 
calcium phosphate foams and the release kinetics of the drug.  
PITA solutions in PBS were stable both at 5 and 37 ºC for 9 days, which is interesting with 
regard to potential storage of samples, and also in views of the experimental conditions 
during cell cultures and release experiments.  
The setting of calcium phosphate foams involves a dissolution-precipitation reaction, 
which entail a pH fluctuation. The dissolution of α-TCP initially increases the pH of the 
liquid medium, up to pH=9.5, slowly decreasing to pH=8 in 24 h [32]. Therefore, initial 24 h 
of the setting reaction acts as an alkaline environment for PITA. To evaluate whether this 
pH range could affect the stability of PITA, different PITA concentrations were exposed to 
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alkaline pH of either 8 or 9.5 (Figure 5-2). No degradation was found for the 5 and 25 μM 
PITA solution over 9 days of exposure. In contrast, at higher concentrations of 50, 75 and 
100 μM, a significant degradation was recorded which increased with exposure time at 
both pHs. This implies that there will be a partial degradation of PITA due to the pH 
fluctuations during the setting reactions. To estimate the extent of this degradation, we 
can assume that, according to previous studies that assessed the pH evolution during the 
setting reaction [32], [37], when PITA is mixed with an i-CPF, it will be exposed to a pH ≤ 
9.5 for the initial 15h, and to a pH ≤ 8 during the following 9h. With this in mind, the 
degradation associated to the pH fluctuations during the setting reaction for 24 h were 
calculated respectively as shown in section 3.1 and used for correction of final percentage 
of PITA released.  
Apart from other beneficial effects, statins are described to promote in vitro angiogenesis 
and osteogenesis in a dose dependent manner [31], [38]–[41]. However, few studies have 
been conducted with PITA to demonstrate such effects. The present work was originally 
designed for three different concentrations of 0.1, 1 and 10 μM. It was found that 10 μM 
resulted in toxic effects on the cell culture with complete loss of cell viability in rMSCs and 
EPCs. Therefore, the study was continued with PITA concentrations in the cell culture 
medium of 0.1 μM (0.0475 μg/mL) and 1 μM (0.475 μg/mL) (Figure 5-3). The results 
showed an over-expression of genes associated to osteogenesis and vascularization with 
the lowest dosage of PITA (0.1 μM). Our findings of OCN and BMP-2 over-expression are 
in agreement with other studies where the bone anabolic effect of PITA was reported to 
stimulate OCN by inhibition of Rho-associated kinase and BMP-2 in human osteoblasts 
[31] and collagen [30]. It has been observed that present study observed similar results at 
72 h with a concentration of 0.1 μM in rMSCs whereas previous work reported over 
expression at 48h with 1 μM in human osteoblasts. This difference can be explained as 
concentration may depend on type of cells as seen earlier in other studies with 
simvastatin and other statins [42]–[45]. Our results indicate that PITA induces 
mineralization, differentiation and osteogenesis in rMSCs. , 
In the case of EPCs, gene expression values for VEGF, VEGFR1 and VEGFR2 were 
observed for their key role in angiogenesis.  VEGFA plays an important role of key 
regulator to promote growth of vascular endothelial cells and vessel growth, therefore an 
important marker for angiogenesis [46]. While VEGFA binds to two receptors of VEGFR1 
and VEGFR2, it has been seen that role of VEGFR1 is still not well defined as it is known 
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as a `decoy´ receptor which regulate VEGFA in a negative fashion by interfering with 
binding between VEGFA and VEGFR2 [47]. On the other hand, recent studies claimed 
that VEGFR1 plays a role in recruitment of endothelial progenitors [48]. Therefore, role of 
VGEFR1 is still under debate. Whereas, VEGFR2 plays a key role in angiogenesis by 
enhancing effects of VEGFA by binding with it [49]. In present work, a significant increase 
had been observed in VEGFA, VEGFR2 and VEGFR1 at 72 h suggesting stimulation of 
vascularization by PITA. It is important to take into account that increase in VEGFR2 was 
three fold which is really essential for binding with VEGFA and stimulating angiogenesis. 
Similarly, PITA [50] and other statins [39], [51], [52] have been previously described to 
promote angiogenesis. Collectively, our data suggest that PITA has bone anabolic effects 
on both rMSCs and rEPCs, coping well with other studies, where 0.1 μM was also found 
to be the most effective dose [31], [41].  
In addition to the bone anabolic effects just discussed, PITA being a hydrophilic molecule 
allows direct dissolution in the aqueous liquid medium used for i-CPFs synthesis. This is 
an advantage, as SIM  requires an additional step to convert it from hydrophobic to 
hydrophilic by lactone ring opening, if solubility in an aqueous phase is desired [53].  In 
contrast, PITA can be directly incorporated in the aqueous phase of the self-setting foams 
to have a homogenous distribution throughout the foam volume, which can facilitate a 
sustained and a prolonged release. Drug  incorporation in self-setting cements and foams 
can often result in modification of the setting times or alteration of the texture or porosity, 
among other parameters [14], [54], [55]. Therefore, characterization of macroporous i-
CPFs was conducted for 100-PITA samples. As shown in Figure 5-4, it was found that 
PITA did not induce observable changes in the microstructure. Similarly, MIP pore size 
entry distribution was found to be similar for i-CPF as well as PITA loaded i-CPF (Figure 
5-6.). SEM images showed plate like crystallites characteristic of the setting of α-TCP to 
calcium-deficient hydroxyapatite [56]. Also, reconstruction from the μCT scans allowed 
visualization of the interconnected macropores. The interconnected pores were seen 
clearly for control i-CPF as well as PITA (100 μM) loaded i-CPF. The skeletal density, total 
porosity and specific surface area were in accordance with previous results and displayed 
no significant differences among control i-CPF and PITA loaded i-CPF at 100μM. These 
findings were in agreement with other studies for statins, where they showed that SIM did 
not alter phase composition or porosity of cements [57]. 
The concentration of PITA loaded in the i-CPFs was several times above the 0.1 μM 
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found to be fostering expression of angiogenic and mineralization genes. This was done 
with two considerations in mind: 1) the degradation of the drug due to the setting reaction 
that can be assumed to “inactivate” a ~6.5-8 % of the PITA incorporated in i-CPFs (as 
seen for 50, 75 and 100μM) during the period the setting proceeds at basic pHs between 
8 and 9.5; and 2) in our release assays, having a detectable concentration of PITA had to 
be ensured (below 1 μM was undetectable) , and studying the release behavior of i-CPFs 
(Figure 5-5) may allow extrapolating to adjust the concentration in future.  
The behavior of initial burst release was in agreement with other findings showing fresh or 
pre-set for shorter time cements shows burst behavior [57]. The kosermeyer peppas 
model was fitted to analyze the release kinetics but did not allow any conclusion due to 
limiting release mechanism as the parameter (n) was too low for the case of flat surfaces. 
On the other hand, some studies based on matrix tablets have shown that a lower value 
of n < 4.5 reflects  a quasi-fickian diffusion behavior [58], [59].  . The profiles obtained can 
be ascribed to the evolving microstructure of the cement setting, which is responsible for 
the change in the elution regimes. Initially, the paste is just a suspension of α-TCP 
particles in aqueous solutions of PITA. As α-TCP precipitates to CDHA following the 
cement setting reaction, the network of CDHA crystals created progressively increases 
tortuosity, hindering the drug diffusion and reducing the release rate [57].   
It has been observed that with 50-PITA released 0.2 μg/mL which is still very high in 
comparison to findings of in vitro studies at 0.1 μM PITA (0.0475 μg/mL) for significant 
results. It is important to keep in account that release studies were designed with the aim 
of being in the detection range (1 μM) of HPLC technique for PITA. However, with the 
observation of drug loading and release behavior, it is most susceptible that with 
extrapolation of data, a lower loading of PITA (5-10 μM), will be respective to a release of 
0.1 μM similar to in vitro studies. Thereby, it opens a new pathway for future work on PITA 
loaded i-CPFs with cells in vitro.  
When comparing the present findings with our findings of Chapter 3 on simvastatin loaded 
scaffolds [64]: a) PITA shows a much higher loading efficiency due to higher solubility 
than simvastatin, which gives an edge for incorporation of PITA through liquid phase b) 
Percentages released are much higher (~97 - 40 % PITA vs. 16 % Simvastatin in Chapter 
3), and progressive, which can be explained by the fact that i-CPFs are evolving matrices, 
with a high amount of liquid phase where PITA is dissolved, so in the initial release 
timeframe, exchange with the release media is much more favored than with the set 
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macroporous CDHA samples [60]. PITA is efficient at lower dosages [61] so the 
progressive release behavior might allow to maximize the efficiency of the treatment .  
Different release profiles are reported in the literature for SIM with calcium phosphate 
ceramics [62], premixed cement  [63] and comparison of CDHA/ceramic [60], however, it 
is first time that PITA has been loaded with a calcium phosphate. The i-CPFs presented in 
this study exhibit a progressive release profile, corresponding to ~40% of the quantity 
loaded in 200-PITA and almost 97% released for 50-PITA and 75-PITA. The 
interconnected macroporosity (Figure 5-6b) of all these samples is expected to enhance, 
in addition, tissue colonization. The release profile of all samples stabilized after 72 h 
where probably a significant amount of a-TCP had transformed already to CDHA, 
hindering the diffusion of the drug trapped within the crystal structure as reflected in 
Figure 5-6.  Moreover, the macroporosity of the i-CPFs investigated can be assumed to 
foster higher amounts of drug released to the media, in comparison with their non-
macroporous homologues, as fluid exchange is fostered in this kind of samples with 
respect to dense cements [14].  
Conclusions 
First, PITA showed a stable behavior in PBS at different working temperatures of 37 ºC 
(scaffold preparation; release kinetics) and 5 ºC (in vitro studies). On the other hand, pH 8 
and pH 9.5 resulted in progressive degradation of PITA at higher concentrations of 50, 75 
and 100 μM. Second, i-CPFs and PITA loaded i-CPFs both exhibited similar 
interconnected macroporous structure with no significant changes in microstructure (Plate 
like crystallites), SSA, total porosity, pore size distribution and skeletal density. Third, 
PITA application in solution resulted in enhancement of gene expressions of OCN, 
collagen type 1 and BMP-2 in rMSCs indicating towards mineralization and differentiation. 
In case of EPCs, gene expressions of VEGFA, VEGFR2, and VEGFR1 were enhanced by 
72 as verified by RT-PCR as indicators of angiogenesis. Finally, PITA loaded i-CPFs 
followed release kinetics according to the evolving microstructure of the scaffold in the 
initial hours with a burst release which slowly progressed in a dose-dependent manner. 
Design of the i-CPFs as a drug delivery system loaded with PITA, an osteogenic and 
angiogenic promoter, allowing very low dosages, with the fact that it does not alter the 
attractive biomimetic features of the i-CPFs studied here makes them a captivating 
alternative for versatile bone grafts. 
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Chapter 6  
Conclusions 
 
This thesis deals with the development and investigation of novel strategies for improved 
tunable release from calcium phosphates as drug delivery vehicles. Two kinds of drugs 
are investigated: antibiotics, and statins. The main findings are summarized below: 
 
Regarding the use of plasma polymerization to modulate SVA release from Calcium 
phosphate scaffolds  
 
 This work has allowed setting proof of concept of the possibility to fine tune drug 
release of simvastatin acid (SVA) as osteogenic and angiogenic drug, incorporated 
in 3D ceramic scaffolds (CDHA & β-TCP) with a dry plasma polymerization 
process using biocompatible plasma polymers, PCL-co-PEG (1:4).  
 The thickness and structure of the polymer coatings obtained is highly dependent 
on the texture of the materials, in particular on its SSA. Due to its much higher 
SSA, thinner polymer layers were deposited on CDHA, allowing for the diffusion of 
the drug and leading to progressive and controlled drug release with respect to the 
uncoated biomaterial. On the other hand, β-TCP‘s distinct textural features led to 
thicker polymer layers, which acted as a barrier impairing SVA release within the 
timeframe evaluated. 
 On CDHA, long plasma polymerization times implied an initial blocking of the 
release, followed by a slow release pattern, while short treatment times allowed a 
slow, controlled release.  
 The mode of deposition (continuous or pulsed wave) allowed to further control the 
plasma polymer layers produced. Thus, the plasma coatings evaluated were found 
to be suitable for tuning the drug release from bone biomaterials, allowing to 
produce ceramic dosage forms combining delayed release, followed by controlled 
delivery of drugs.  
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Regarding fundamentals of plasma polymerization on -TCP for drug release 
 
 Plasma polymerization of PEG-like polymers on microporous β-Tricalcium 
Phosphate (β-TCP) allowed obtaining coatings with low retention of the PEG 
character (high C/O ratio, grafting of end groups such as C=O and cross-linking of 
the polymer) which allowed avoiding the typical antifouling properties of the 
coating 
 Due to the significant roughness of the surface of β-TCP, following plasma coating 
the bioceramics showed a hydrophobic behavior, despite the wettability of the 
polymer layer produced. This was associated with Wenzel behavior, which allowed 
calculating the apparent surface of the material being around 2.6.  
 The coating thickness was directly dependent on the polymerization time, which in 
turn was related to the total amount of drug released. In general it was observed 
that the coatings produced decreased the amount of drug released, a part of which 
was hypothesized to be due to etching of the most superficial drug adsorbed on 
the surface during plasma processes. Moreover, for certain conditions the release 
profile started to be modified. 
 The two antibiotics evaluated (ampicillin and gentamicin) retained their 
antimicrobial activity intact after being released from the β-TCP substrates, 
confirming the suitability of the technique for coating the drug-loaded ceramic 
matrices.  
 Despite the great modification in wettability due to the PEG-like coating, the good 
cytocompatibility of β-TCP (adhesion and proliferation of SaOS-2) remained 
unaltered. The research undertaken allowed unraveling the characteristics of 
plasma coatings on calcium phosphate ceramics and advancing towards the 
design of drug delivery matrices with suitable biological and microbiological 
behavior. 
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Regarding PITA as osteogenic and angiogenic promoter loaded in i-CPFs as drug delivery 
vehicles 
 
 Pitavastatin (PITA) was incorporated for the first time to calcium phosphate bone 
grafts, in particular in injectable calcium foams (i-CPFs) and no modifications were 
recorded on the physic-chemical properties of the i-CPFs. In particular, i-CPFs 
maintained its injectability, cohesion and interconnected macroporosity with no 
significant changes in microstructure and related parameters (SSA, total porosity 
and skeletal density).  
 PITA exhibited a time-dependent degradation at basic pHs for concentrations 
above 50 μM (between 6.8% and 8.2%), which is important to take into account in 
the preparation of PITA-laden calcium phosphate cements. Conversely, solutions 
of PITA in PBS were shown to be stable at of 5 ºC and 37 ºC. 
 The in vitro effects of PITA on rMSCs and EPCs were clearly dose-dependent, 
with an optimum value found at 0.1mM. The osteogenic properties of PITA were 
investigated with rMSCs and showed enhancement of gene expression for OCN, 
Col type 1 and BMP-2, indicating the promotion of mineralization and 
differentiation.  Moreover, using the same concentration, PITA-treated, EPCs 
showed increased over-expression of VEGFA, VEGFR1, VEGFR2, indicating an 
enhancement of vascularization and angiogenic properties. 
 Finally, PITA-loaded i-CPFs followed a release kinetics that matched to the 
evolving microstructure of the scaffold in the initial hours due to setting, with a 
dose-dependent release which reached between 40% and 97% of the initial 
loaded amount depending on the initial concentration loaded. Therefore, the drug 
loading in the i-CPFs may easily be scaled to the suitable range with optimum 
biological activity. The combination of PITA with the i-CPFs studied in this work is 
a promising alternative for versatile bone grafts, which gather the interesting 
anabolic properties of the drug with the biomimetic features of the CDHA carrier. 
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